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Abstract 
 Medulloblastoma has been identified as an estrogen-responsive tumor that 
expresses estrogen receptor β and whose growth is regulated by 17β-estradiol both in 
vitro and in vivo. However, several clear gaps of knowledge exist with regard to the role 
of 17β-estradiol in medulloblastoma. These include the precise mechanism responsible 
for the growth promoting effect of 17β-estradiol in medulloblastoma as well as the 
potential for estrogen receptor inhibition in medulloblastoma treatment. To address these 
gaps of knowledge and gain a better understanding of the role of 17β-estradiol in 
medulloblastoma, several model systems were utilized.  
Extensive pharmacological studies that utilized the human medulloblastoma cell 
line, D283Med, were performed to characterize the effect of 17β-estradiol on cell death 
and the mechanism responsible for any observed effect. Estrogen protected D283Med 
cells from cell death and this cytoprotection was observed to be due to the activation of 
estrogen receptor β and downstream up-regulation of the insulin-like growth factor 1 
pathway. To characterize the efficacy of estrogen receptor inhibition and clarify the role 
of estrogen receptor β in medulloblastoma, mouse models of medulloblastoma were 
utilized. It was observed that inhibition of estrogen receptors by fulvestrant or loss of 
estrogen receptor β expression decreased tumor growth. This decreased tumor growth 
is likely due to decreased activation of the insulin-like growth factor pathway and 
downstream mediators that increase survival. Lastly, to further support the notion that 
estrogen receptor inhibition may be an effective medulloblastoma treatment, the effect of 
estrogen on the chemosensitivity of D283Med cells was evaluated. These experiments 
were conducted with cisplatin, vincristine and lomustine, which are chemotherapeutics 
that are currently utilized in medulloblastoma treatment. Estrogen decreased the 
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chemosensitivity of D283Med cells while inhibitors of estrogen receptor β blocked this 
effect.  
Taken together, these studies support the notion that medulloblastoma is an 
estrogen-responsive tumor and suggest that therapies that inhibit estrogen receptor β 
may be effective in inhibiting medulloblastoma tumor growth in humans. Furthermore, 
estrogen receptor β inhibition may improve the response rate to current treatments due 
to its sensitizing effect on medulloblastoma with regard to the cytotoxic effects of 
chemotherapeutic compounds. 
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Introduction 
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1    Overview  
 Endogenous estrogens, such as 17β-estradiol (17β-E2), are naturally occurring 
steroid hormones that play an essential role in female reproductive tissues as discussed 
in more detail in sections 1.1 and 1.2 (Allen & Doisy, 1923, 1924; Allen, Pratt, & Doisy, 
1925). Because of this, estrogens are typically thought of as female sex hormones; 
however, 17β-E2 also has a wide array of physiological effects beyond the female 
reproductive system including but not limited to effects on the skeletal, cardiovascular, 
and nervous systems (Gitman & Greenblatt, 1953; Reifenstein & Albright, 1947; Toran-
Allerand, 1976). The activity of 17β-E2 primarily occurs due to binding at estrogen 
receptors (ERs) α and β which act as ligand-activated transcription factors that affect the 
expression of target genes and can rapidly activate intracellular signaling pathways. 
Through these mechanisms, 17β-E2 can affect diverse cellular functions such as 
proliferation, survival and cell migration (Bjornstrom, Sjoberg, Björnström, & Sjöberg, 
2005; R. M. Evans, 1988; Heldring et al., 2007; Ellis R Levin, 2005). 
 In addition to playing a vital role in the development and function of multiple tissues 
and organ systems, 17β-E2 can also affect tumor development and progression. The 
effect of 17β-E2 in breast carcinogenesis and progression has been particularly well-
characterized. In ERα-positive breast cancer, 17β-E2 promotes proliferation and cell 
survival (Russo et al., 2006; Russo et al., 2001; Shull, Spady, Snyder, Johansson, & 
Pennington, 1997; R. X. Song, Fan, Yue, Chen, & Santen, 2006; Soule & McGrath, 1980; 
Surmacz & Bartucci, 2004). Due to its clinical effectiveness, long-term treatment with the 
selective estrogen receptor modulator (SERM) tamoxifen, which inhibits 17β-E2-
mediated growth in ERα-positive breast cancer, is part of the standard of care for breast 
cancer as it prevents both tumor progression and recurrence. The non-selective ER 
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antagonist fulvestrant (Faslodex®) is also used to treat breast cancer as are aromatase 
inhibitors that prevent the conversion of testosterone to 17β-E2 (Bauerschlag, Maass, & 
Schem, 2014; Cleator, Ahamed, Coombes, & Palmieri, 2009; Flemming, Madarnas, & 
Franek, 2009). While breast cancer is certainly the most studied estrogen-responsive 
tumor, cancers arising from several other tissues have also been observed to be 
estrogen-responsive, including those of the nervous system.  
 The most common pediatric malignancy of the central nervous system (CNS) is 
medulloblastoma (MB) which has a peak incidence of five years of age (Frange et al., 
2009; Ries et al., 1999). MB is a primitive neuroectodermal tumor (PNET) that is 
associated with the fourth ventricle and can arise from cerebellar granule cell precursors 
(Hatten & Roussel, 2011; Z. J. Yang et al., 2008). Results from previous studies 
demonstrated that human MB tumors and human MB cell lines express ERβ. Additionally, 
studies utilizing human cell lines of MB demonstrated that 17β-E2 increased proliferation 
and migration of MB cells in vitro and tumor growth in the in vivo MB xenograft model. 
These effects were blocked by the ER antagonist fulvestrant and MB cell proliferation was 
also increased by the ERβ-selective agonist, DPN (S. M. Belcher, X. Ma, & H. H. Le, 
2009). These data suggested that MB tumor growth was modulated by ERβ, but the 
mechanism underlying the effect of ERβ activation was unclear.  
 To further characterize the role of estrogen in MB growth and progression, in vitro 
and in vivo studies were performed in this dissertation. Specifically, while it was known 
that 17β-E2 affected MB tumor growth in vivo, and increased the proliferation of MB cells 
in vitro, it was unclear how 17β-E2 affected tumor growth in vivo. Since tumor growth is 
dependent on the balance of proliferation and cell death, it was of interest to determine if 
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17β-E2 also affected MB cell death in vitro. Viable cell counts and caspase-3 activity 
assays were utilized to determine the effect of 17β-E2 on caspase-dependent cell death. 
Furthermore, the mechanism underlying the effect of 17β-E2 was further investigated by 
assessing protein and messenger ribonucleic acid (mRNA) expression as well as the 
effect of selective pathway inhibitors on 17β-E2-mediated cytoprotection. Since previous 
in vivo studies were performed in a subcutaneous hindlimb xenograft model, it was of 
interest to characterize the clinical efficacy of fulvestrant treatment in an in vivo genetic 
model that better models human MB with regard to microenvironment that the tumor 
grows in (S. M. Belcher et al., 2009). Information regarding the genetic models of MB that 
were utilized is summarized in Table 3. Therefore, the role of estrogen in MB tumor growth 
was also examined in vivo by investigating the effect of fulvestrant treatment on symptom 
onset in the Ptch1+/- Trp53-/- mouse model of MB. The role of ERβ in MB was also 
investigated in vivo by cross-breeding the Ptch1C/C Atoh1-cre mouse model of MB with 
the Esr2-/- model and assessing tumor weight. Due to the results of the in vitro studies 
that demonstrated that both proliferation and cell death were affected by 17β-E2 in MB 
cells, both proliferation and cell death were assessed to determine their potential 
contribution to the tumor suppressing effect of ER inhibition by fulvestrant or genetic loss 
of ERβ function. To further support the in vitro mechanistic findings, 
immunohistochemistry (IHC) was performed to assess protein expression and activation 
of key pathways that were implicated in the mechanism of 17β-E2 cytoprotection in vitro. 
Due to the potentially cytotoxic action of ERβ inhibition in MB and the success of multi-
modal therapies in cancer treatment, the role of estrogen in MB chemosensitivity was also 
examined. These studies examined the effect of 17β-E2 and various ER inhibitors on the 
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sensitivity of MB cells to chemotherapeutic compounds used to treat MB including 
cisplatin, vincristine and lomustine. All together, the studies presented here were 
performed to characterize the role ERβ in the growth and survival of MB.  
1.1 Estrogen  
 According to the Merrium-Webster dictionary, estrogens are “any of various natural 
steroids that are formed from androgen precursors, that are secreted chiefly by the 
ovaries, placenta, adipose tissue, and testes, and that stimulate the development of 
female secondary sex characteristics and promote the growth and maintenance of the 
female reproductive system; also :  any of various synthetic or semisynthetic steroids that 
mimic the physiological effect of natural estrogens” ("Estrogen," 2015). The determination 
of a compound’s binding affinity for the ERs or performance in various in vitro and in vivo 
assays such as the uterotrophic assay is a common method utilized to identify estrogens. 
Estrogens are comprised of endogenous steroid hormones and environmental estrogens, 
which are often referred to as endocrine disrupting chemicals (EDCs, discussed in more 
depth in section 1.9) (Baker, 2001; Blaustein, 2008). Of the endogenous estrogens in 
mammals, 17β-estradiol is the most important and potent. Estrone and estriol are also 
endogenous steroid hormones that possess estrogenic activity; however, neither is as 
potent as 17β-E2 (Coelingh Bennink, 2004). The biological enantiomer of 17β-E2, 17α-
estradiol (17α-E2), was long thought to be inactive. However, 17α-E2 does possess 
estrogenic activity by some measures, such as the uterotrophic assay, at high doses 
(Edwards & McGuire, 1980; Yamasaki et al., 2003; Yamasaki et al., 2002). 
 
 
6 
 
1.1.1 Serum levels of estrogen 
 Total serum levels of 17β-E2 in humans range from 10 to 50 pg/mL in normal adult 
males; whereas, total serum levels of 17β-E2 in normal adult females vary substantially 
during the menstrual cycle (Gardner, 2011). Total serum levels fluctuate from 39-375 
pg/mL during follicular, 96-762 pg/mL during the mid-cycle peak, and 48-440 pg/mL 
during the luteal phase. In post-menopausal women, total serum levels of 17β-estradiol 
decrease to a range of 10 to 20 pg/mL. During pregnancy, total serum levels increase 
substantially due to estrogen production by the placenta reaching 12-15 ng/mL at term 
(Gardner, 2011).  
Murine models are utilized in the studies presented in chapters three through six 
and while female mice also exhibit fluctuating serum levels of 17β-E2 during the estrous 
cycle similar to the fluctuating levels observed in humans during the menstrual cycle, the 
serum levels of 17β-E2 are quite different in mice. The estrous cycle is composed of four 
stages including the diestrus, proestrus, estrus and metestrus stages, and the serum level 
of 17β-E2 peaks prior to ovulation which occurs in estrus (Fata, Chaudhary, & Khokha, 
2001; Walmer, Wrona, Hughes, & Nelson, 1992; Wood, Fata, Watson, & Khokha, 2007). 
The concentration of serum 17β-E2 varies depending on the mouse strain but is fairly 
constant during the estrous cycle and is approximately 50 pg/mL in C57Bl/6 mice. The 
pre-ovulation peak in mice during the estrous cycle ranges from 60 to 70 pg/mL in C57Bl/6 
mice (Fata et al., 2001; Walmer et al., 1992; Wood et al., 2007).  
The majority of serum estrogen is not available to cross the plasma membrane and 
interact with intracellular ERs due to binding to serum proteins. The major serum protein 
that binds 17β-estradiol in humans is the sex hormone-binding globulin (SHBG), but 
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serum albumin also binds to serum estrogens (Dunn, Nisula, & Rodbard, 1981; Gardner, 
2011). Free 17β-estradiol levels are estimated to be approximately two percent of total 
serum levels in humans. During pregnancy, the free fraction of serum estrogen is reduced 
to 0.5% of total serum levels (Pardridge, 1986). 
 The free fraction (~2% of total) of 17β-estradiol is physiologically active since it can 
easily diffuse into tissues and cross plasma membranes in order to bind and activate 
intracellular ERs. This means that serum-binding proteins play an important role in 
regulating the active fraction of 17β-estradiol, and therefore also affect the physiological 
effects of estrogen throughout the body. Steroid-binding proteins may also have direct 
effects on tissue function as evidenced by several studies. A G protein-coupled receptor 
has been identified for SHBG and can mediate diverse physiological effects when bound 
by 17β-E2 bound SHBG (Rosner, Hryb, Kahn, Nakhla, & Romas, 2010). One example of 
this includes the observation that SHBG in a complex with 17β-E2 or dihydrotestosterone 
caused increased cAMP production and increased proliferation in a prostate cancer cell 
line (Rosner, Hryb, Khan, Nakhla, & Romas, 1999). These results demonstrate that the 
bound portion of serum 17β-estradiol should not be assumed to be inactive because it 
may still function at the cell membrane. 
1.1.2 Estrogen biosynthesis in normal and malignant tissue 
 Biosynthesis of 17β-estradiol, similarly to all steroid hormones, begins with the 
conversion of cholesterol by the cholesterol side chain cleavage enzyme (P450scc) to 
pregnenolone. Through a series of enzymatic reactions, pregnenolone is converted to 
androstenedione. Androstenedione is either reduced to testosterone by the enzyme 17β-
hydroxysteroid dehydrogenase (17β-HSD) or aromatized to estrone by the enzyme 
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aromatase. Lastly, either testosterone is converted to 17β-estradiol by the enzyme 
aromatase or estrone is converted to 17β-estradiol by the enzyme 17β-HSD (Gardner, 
2011) (Figure 1). 
The primary site of 17β-estradiol production in human females during the 
reproductive years is the granulosa cells or the ovaries. During pregnancy, however, the 
placenta becomes a significant production center for 17β-estradiol. In males, 17β-
estradiol is produced in the sertoli and leydig cells of the testes (Gardner, 2011). In 
humans, sex steroids are also produced at peripheral sites such as the adrenal gland, 
bone, skin, adipose and brain tissue (Gardner, 2011; Simpson, 2003). Aromatase and 
17β-HSD expression profiles demonstrate that the sites of 17β-E2 synthesis possess 
aromatase and 17β-HSD expression (Labrie, Luu-The, Lin, Simard, & Labrie, 2000; 
Simpson, 2003). 
 Locally synthesized estrogens play an important role in the development and 
function of the CNS. Exposure of CNS tissue to 17β-E2 occurs either due to this locally 
produced 17β-E2 or 17β-E2 that was synthesized in the periphery and transported to the 
brain through the bloodstream. Aromatase is expressed in several areas of the brain and 
is developmentally regulated. Expression is observed is several sexually dimorphic areas 
such as the hypothalamus (Pelletier, 2010; Roselli, Liu, & Hurn, 2009). Aromatase 
expression is, however, not limited to sexually dimorphic areas of the brain as its 
expression is also observed in the cerebellum during development and in adulthood. The 
cerebellum as a site of estrogen synthesis is especially important concerning the studies 
presented here since specific subtypes of MB arise from the cerebellum (Lavaque, Mayen, 
9 
 
Azcoitia, Tena-Sempere, & Garcia-Segura, 2006; Tsutsui, 2012; Tsutsui, Sakamoto, & 
Ukena, 2003). 
Malignant tissue is also potentially a site of 17β-E2 synthesis in estrogen-
responsive tumors such as breast cancer. Local production of 17β-E2 often occurs in 
breast, ovarian and endometrial cancers due to aromatase expression. The intra-tumor 
synthesized 17β-E2 likely acts as an autocrine factor that promotes tumor progression. 
For this reason, aromatase inhibitors are often included in the multi-model treatment of 
breast cancer and have shown efficacy in clinical trials for the treatment of ovarian and 
endometrial tumors (Bulun et al., 2005; Sasano et al., 1999; Simpkins, Garcia-Soto, & 
Slingerland, 2013). Aromatase expression is also observed in tumors that arise from non-
reproductive tissues such as lung cancer. The expression of aromatase in lung cancer 
promotes tumor growth in in vitro and in vivo models and this is likely due to autocrine 
stimulation of ERβ and downstream pro-survival pathways. Aromatase inhibition was also 
demonstrated to decrease lung cancer growth in an in vivo xenograft model (Siegfried & 
Stabile, 2014). It is clear from these studies that intra-tumor synthesis of 17β-E2 by 
aromatase is involved in the progression of several cancers arising from both reproductive 
and non-reproductive tissues. 
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Figure 1 
The biosynthesis of 17β-E2 from cholesterol through the steroidogenesis pathway. 
Updated adaptation of “ovarian steroidgenic pathway” illustration by Rodgers (Rodgers, 
1990). 
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1.2 Estrogen’s effects in normal tissues 
 Estrogen has diverse effects in both males and females in the development and 
function of several tissues. Historically, estrogens such as 17β-E2 have been implicated 
in the development of the female reproductive system and secondary sexual 
characteristics. The function of the female reproductive system is also regulated by 17β-
E2 and it also affects function of the male reproductive system and male reproductive 
behavior despite the historical classification of estrogens as female sex hormones (Allen 
& Doisy, 1924; Colvin & Abdullatif, 2013; J. E. Couse, Mahato, Eddy, & Korach, 2001; 
Gardner, 2011).  
 In addition to the reproductive systems in males and females, 17β-E2 also affects 
the development and function of several other tissues. For example, estrogens promote 
bone health and prevent osteoporosis, and therefore the decrease in serum 17β-E2 
during menopause is likely responsible for the increase in osteoporosis risk in post-
menopausal women (Deroo & Korach, 2006; Reifenstein & Albright, 1947). Metabolism 
and serum levels of lipoproteins are also affected by 17β-E2, and this may partially 
explain why pre-menopausal women enjoy a lower cardiovascular disease risk compared 
to similarly aged males (Barton, 2013; Gitman & Greenblatt, 1953; Harman, 2014). 
Estrogens also play a fundamental role in the development of the CNS and its function 
as described in section 1.2.2 (Brann, Dhandapani, Wakade, Mahesh, & Khan, 2007; 
McCarthy, 2008).  
1.2.1 Reproductive tissues 
 Estrogens have long been associated with the female reproductive system. The 
earliest studies that started to identify and characterize estrogens described it as an 
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estrus associated hormone that was derived from ovarian follicles (Allen & Doisy, 1923, 
1924; Allen et al., 1925). Early observations included the fact that cyclical changes in 
vaginal smears during estrus in rodents could be abolished by double ovariectomy (Allen 
& Doisy, 1923). This suggested that there was an endocrine active hormone produced in 
the ovary that regulated the estrous cycle in rodents. Further experiments demonstrated 
that the hormone was derived from ovarian follicles and could induce estrus associated 
changes in vaginal smears as well as uterine and vaginal histology if injected 
subcutaneously into ovariectomized female rodents (Allen & Doisy, 1923, 1924). This 
work laid the groundwork for the discovery that estrogens and progesterone regulate the 
menstrual cycle in humans (Gardner, 2011). 
 In addition to playing an integral role in the regulation of the menstrual and estrous 
cycles in humans and rodents, respectively, estrogens are also important during puberty. 
Puberty starts when the hypothalamic-pituitary-gonadal (HPG) axis is established, a 
process which is poorly understood (Colvin & Abdullatif, 2013). The HPG axis is a 
negative feedback endocrine loop that controls sex steroid production. This loop begins 
with the release of gonadotropin-releasing hormone (GnRH) from the hypothalamus 
which stimulates the pituitary to release luteinizing hormone (LH) and follicle stimulating 
hormone (FSH). Luteinizing hormone subsequently promotes the production of 
androgens while FSH stimulates the production of estrogens. The increase in serum 
levels of sex steroids then inhibits the release of GnRH from the hypothalamus, 
completing the negative feedback loop (Larsen, Kronenberg, Melmed, & Polonski, 2003). 
The ovaries are one of the first structures to change during puberty, due to hypothalamic-
pituitary activation, and the subsequent development of the ovaries results in increased 
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production of estrogens. The increased serum levels of 17β-E2 then regulate the growth 
of mammary tissue, uterine tissue and changes in vaginal epithelium as well as other 
changes observed during puberty (Colvin & Abdullatif, 2013).  
 While the development of the male reproductive tract is not influenced by 
estrogens, male reproductive behavior and fertility are regulated by estrogens. Studies 
utilizing murine models that lack functional expression of ERα and/or ERβ demonstrate 
that ERα expression is necessary for typical male reproductive behavior and 
spermatogenesis (J. E. Couse et al., 2001). Taken together it is clear that 17β-E2 is 
integral in the development and function of the female reproductive tract, but also extends 
beyond its classical role as a female sex hormone by affecting male fertility.  
1.2.2 Central nervous system 
 Estrogens have been implicated in the development and function of the CNS and 
may even be protective in certain CNS diseases. Perhaps most notable among the 
developmental effects of 17β-E2 in the CNS regards the masculinization of the male brain 
which has been characterized in rodent models. During early post-natal development, the 
testes produce a surge in serum testosterone levels. The testosterone crosses the blood-
brain barrier where is causes structural changes within the hypothalamus and other 
sexually dimorphic regions to a male phenotype (Arnold & Gorski, 1984; Gorski & Wagner, 
1965; McCarthy, 2008). Early studies were conducted with 17β-E2 as a control for the 
known masculinizing effect of testosterone. Surprisingly, 17β-E2 also caused brain 
masculinization, and this observation led to the aromatization hypothesis. This hypothesis, 
which is accepted today, suggested that testosterone was locally converted to 17β-E2 by 
the enzyme aromatase and that the subsequent action of CNS derived 17β-E2 caused 
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the masculinization of the brain (Arnold & Gorski, 1984; Gorski & Wagner, 1965; 
McCarthy, 2008). The aromatization hypothesis was supported by several studies 
including those that demonstrated that masculinization of the brain could be prevented by 
inhibition of ERs or aromatase (Arnold & Gorski, 1984; Dohler et al., 1986; McCarthy, 
2008; McEwen, Lieberburg, Chaptal, & Krey, 1977). This, combined with the observation 
that sexually dimorphic regions of the brain expressed aromatase, suggested that 
testosterone was being converted locally to 17β-E2 to elicit the masculinization of the 
brain (George & Ojeda, 1982; Lauber & Lichtensteiger, 1994; Lephart, 1996). The role, if 
any, for estrogens in the masculinization of the human brain is unclear. It is known, 
however, that increased production of androgens results in the masculinization of the 
brain in females due to studies of females with congenital adrenal hyperplasia. These 
studies suggest that androgens do play a role in the masculinization of the human brain. 
However, studies with the efficacious xenoestrogen, diethylstilbestrol, in humans and in 
primates have failed to suggest that the effect of perinatal androgens on the 
masculinization of the human brain is due to its conversion to 17β-E2 (Cohen-Bendahan, 
van de Beek, & Berenbaum, 2005; Lish et al., 1991; McCarthy, 2008; Newbold, 1993; 
Wallen, 2005).   
 Estrogens also affect the function of the mature brain; one example of this is the 
negative feedback loop of the HPG axis. As described in section 1.2.1, the release of 
GnRH from hypothalamic neurons is inhibited by increased serum levels of 17β-E2 
(Larsen et al., 2003). The exact mechanisms underlying the negative feedback regulation 
of GnRH by 17β-E2 are not clearly understood. It is thought that 17β-E2 acts in ERα 
expressing cells of the hypothalamus that subsequently negatively regulate the release 
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of GnRH in the GnRH releasing neurons that lack ERα expression (Clarke, 2011; Clarke 
& Pompolo, 2005). However, it is now known that GnRH releasing neurons express ERβ 
and that 17β-E2 may also affect GnRH release directly through the activation of ERβ 
(Wolfe & Wu, 2012). 
In addition to the regulation of sexual behavior and reproduction, 17β-E2 also 
affects the development and function of brain areas that are not associated with 
reproduction. The cerebellum is one such area and displays a developmentally regulated 
pattern of estrogen receptor expression and estrogen responsiveness as discussed in 
section 1.6.  
1.3 Estrogen Receptors 
The actions of 17β-E2 in the female reproductive tract and other reproductive 
tissues had been well-characterized by the mid-20th century. However, the mechanism 
by which 17β-E2 exerted its physiological effects was still unknown. It is now accepted 
that the physiological actions of 17β-E2 are mediated through the binding and activation 
of ERα and ERβ (Zhang & Trudeau, 2006). Early evidence for this mechanism came from 
the use of tritiated 17β-E2. Observations from these seminal studies included that tritiated 
17β-E2 was taken up and retained in female reproductive tract tissues (Jensen, 1962; 
Jensen, Suzuki, Numata, Smith, & DeSombre, 1969). Subsequent experiments 
demonstrated that 17β-E2 had a strong affinity for a receptor that translocated to the 
nucleus once bound by 17β-E2 (Jensen, 1962; Jensen, Desombre, Hurst, Kawashima, & 
Jungblut, 1967; Jensen et al., 1969). From these results, it was concluded that 17β-E2 
binding sites were true estrogen receptors that mediated the action of the hormone. The 
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estrogen receptor was, therefore, identified as the first steroid hormone receptor (Jensen, 
2005). 
The first steroid hormone receptor to be identified by molecular cloning, however, 
was the glucocorticoid receptor (GR), but this was followed shortly after by the cloning 
and sequencing of the human ER (Green, Walter, et al., 1986; Hollenberg et al., 1985; 
Miesfeld et al., 1984; Walter et al., 1985; Weinberger, Hollenberg, Rosenfeld, & Evans, 
1985). Sequence homology experiments revealed that these two steroid hormone 
receptors shared common molecular domains with conserved structure and function. 
These similarities are now known to be present in all members of the super-family of 
nuclear hormone receptors including estrogen, androgen, glucocorticoid, progesterone 
receptors and many others (R. M. Evans, 1988; P. Huang, Chandra, & Rastinejad, 2010). 
A pivotal moment in estrogen receptor research came when a second ER was 
discovered through examination of a rat prostate cDNA library (G. G. Kuiper, Enmark, 
Pelto-Huikko, Nilsson, & Gustafsson, 1996). The presence of a second ER suggested 
that apparent physiological effects of 17β-E2 in ER knockout mice and the high affinity 
binding of 17β-E2 that was still present in ER knockout mice may be due to the presence 
of ERβ (Lubahn et al., 1993). However, it is also known that the ERα knockout mice still 
expressed an alternatively spliced variant of ERα which may also be responsible for these 
effects (J. F. Couse et al., 1995; Hamilton, Arao, & Korach, 2014; Lubahn et al., 1993). 
After the discovery of the second ER, the new ER became known as ERβ, while the 
previously known ER was renamed ERα. Since the discovery of ERβ, several splice 
variants of both ERα and ERβ have been described and the function of these splice 
variants is still being investigated (S. E. Taylor, Martin-Hirsch, & Martin, 2010). 
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Additionally, since the discovery of ERα and ERβ, a third ER has been discovered that is 
responsible for many extra-nuclear effects of 17β-E2. This novel ER is a G protein-
coupled receptor and is officially known as G protein-coupled estrogen receptor 1 
(GPER1) (Gigoux & Fourmy, 2013; Lappano, Pisano, & Maggiolini, 2014; Prossnitz & 
Hathaway, 2015). 
1.3.1 Gene and Protein Structure 
Human ERα and ERβ are products of different genes, ESR1 and ESR2 
respectively, that all located on different chromosomes (Enmark et al., 1997; Gosden, 
Middleton, & Rout, 1986). The genes are similar however, each containing eight exons 
and seven introns. The different regions of the ERα and ERβ genes correspond to 
functional domains in the protein. These include region A/B which is encoded by exon 1, 
region C which is encoded by exons 2, 3 and part of 4. Region D is encoded by part of 
exon 4, which also encodes part of region E. The rest of region E is encoded by exons 5, 
6, 7 and part of 8. Exon 8 also encodes all of region F (Enmark et al., 1997; Green, Kumar, 
Krust, Walter, & Chambon, 1986; Green, Walter, et al., 1986; G. G. Kuiper et al., 1996; 
G. G. Kuiper & Gustafsson, 1997; Planey, Kumar, & Arnott, 2014). These regions and 
their corresponding functional protein domains and the homology between ERα and ERβ 
are illustrated in Figure 2. 
Like other members of the nuclear receptor (NR) super-family, ERα and ERβ are 
modular proteins that contain the regions described above. These regions form functional 
domains that can act independently but interact in normal physiological conditions (R. M. 
Evans, 1988; Rastinejad, Huang, Chandra, & Khorasanizadeh, 2013). The modular 
structure of nuclear receptors was first hypothesized due to the observation that limited 
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proteolysis of the GR resulted in the formation of protein fragments that retained the ability 
to bind DNA or bind ligand (Carlstedt-Duke, Okret, Wrange, & Gustafsson, 1982; Wrange 
& Gustafsson, 1978). Following these discoveries, detailed functional analysis of ERα 
were performed which identified and characterized distinct functional domains of ERα 
(Danielian, White, Lees, & Parker, 1992; V. Kumar & Chambon, 1988; V. Kumar et al., 
1987; Lees, Fawell, & Parker, 1989a, 1989b). These domains include the N-terminal 
transactivation domain (NTD), DNA-binding domain (DBD), hinge region and the ligand 
binding domain (LBD). These domains correspond to regions A/B, C, D and E, 
respectively. The role of region F is currently unclear, but studies suggest that it does 
regulate ER function and may play a role in receptor dimerization (Peters & Khan, 1999; 
Skafar & Zhao, 2008; J. Yang, Singleton, Shaughnessy, & Khan, 2008). Homology 
between ERα and ERβ has been determined and varies based on region. Sequence 
alignment and analysis demonstrates that region C, which contains the DBD, is highly 
homologous with 96% similarity between ERα and ERβ. Region E, which contains the 
LBD and thus controls the binding affinity of estrogens for the ERs, is also fairly 
homologous with 59% similarity. The other regions, A/B, D, and F, show fairly low 
similarity with 12, 16 and 9% sequence identity, respectively. Overall, ERα and ERβ 
display 44% amino acid sequence similarity and it is clear that the similarity is highly 
concentrated in regions C and E which contain the DBD and LBD, respectively (Ascenzi, 
Bocedi, & Marino, 2006). 
1.3.2 The N-terminal transactivation and DNA binding domains 
The NTD, which is encoded the A/B region of the gene, contains the activation 
function 1 (AF-1) in addition to phosphorylation sites that are known to regulate ER activity 
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in a ligand independent manner. AF-1 is an important regulator of target gene modulation 
due to its involvement in the recruitment of co-regulators. AF-1 is also known to 
demonstrate constitutive activity as constructs that lack the LBD but contain AF-1 and the 
DBD can still regulate the expression of genes whose enhancer elements in their 
promoters are recognized by the DBD (R. Kumar & Thompson, 1999, 2003; McInerney, 
Tsai, O'Malley, & Katzenellenbogen, 1996; Webb et al., 1998). As mentioned above, the 
DBD is the most homologous domain between ERα and ERβ. It is responsible for binding 
to DNA specifically through interactions with estrogen responsive elements (EREs) in the 
promoters of target genes and receptor dimerization (Ascenzi et al., 2006; R. Kumar & 
Thompson, 1999). The proximal-box (P-Box) sub-domain of the DBD is responsible for 
the recognition of EREs in DNA and the amino acid sequence of the P-Box is identical 
between ERα and ERβ. This explains why both ERs bind to EREs with similar affinity and 
specificity. The distal box (D-Box) sub-domain controls receptor dimerization and is 
functionally and structurally distinct from the P-Box (Claessens & Gewirth, 2004; R. 
Kumar & Thompson, 1999; Ruff, Gangloff, Wurtz, & Moras, 2000). 
1.3.3 The ligand binding domain 
The LBD serves several functions in the regulation of ER activity including ligand 
binding, receptor dimerization, activation function 2 (AF-2), binding to chaperone proteins 
and the recruitment of co-regulators. It also contains a nuclear localization sequence 
(NLS). The LBD is also highly conserved between ERα and ERβ with 59% sequence 
homology, second only to the DBD. The ligand binding pocket is buried in the hydrophobic 
core of the LBD and differs between ERα and ERβ by only two amino acids, potentially 
explaining why both ERs have a similar affinity for 17β-E2 (Ascenzi et al., 2006). In the 
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absence of ligand binding, the ligand binding pocket is exposed due to association of the 
LBD with heat shock proteins. Following the binding of ligand, conformational changes 
result in the disassociation of the heat shock proteins, receptor dimerization and the 
translocation of the ER to the nucleus. The conformational changes also affect AF-2 
activity and the recruitment of co-regulators that can cause the enhancement or 
repression of gene expression at ERE containing genes (Ascenzi et al., 2006; McKenna 
et al., 1999; Pratt, Galigniana, Morishima, & Murphy, 2004). 
 
Figure 2 
ER protein structure and amino acid identity between ERα and ERβ. The NTD is 
composed of regions A/B and shares 12% amino acid identity between ERα and ERβ. 
The DBD is composed of region C and shares the most amino acid identity between the 
two receptors at 96%. The amino acid sequence of the hinge domain (region D) is 16% 
identical between ERα and ERβ while the LBD (region E) shares the second most amino 
acid identity at 59%. Lastly, the F region shares 9% amino acid identity between the 
receptors (Ascenzi et al., 2006; Planey et al., 2014). 
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1.4 Mechanisms of estrogen actions 
Estrogen receptors have long been described as ligand-activated transcription 
factors. This designation is due to the observation in early studies that 17β-E2 treatment 
caused the uptake of radio-labeled nucleotides and the synthesis of specific mRNA and 
protein. From this data, the researchers hypothesized that specific 17β-E2 binding 
initiated a series of molecular events that led to the regulation of specific genes as 
observed by changes in mRNA and protein expression, and this hypothesis has been 
supported throughout the years by additional data (O'Malley, 2005; O'Malley & McGuire, 
1968). For several years, the transcription factor role of ERs was the only mechanism by 
which ERs were known to specifically affect estrogen-responsive tissues. It is now known 
that both ERα and ERβ can also rapidly modulate intracellular signaling cascades to affect 
diverse cellular functions such as proliferation, survival, migration and Ca2+ handling 
(Belcher, 2008; Zhang & Trudeau, 2006). How the different mechanisms of estrogen 
action integrate to cause an overall biological response to 17β-E2 remains an open 
question. 
It is clear that estrogen receptors affect biological processes through four main 
mechanisms including ligand dependent modulation of ERE containing genes, ligand 
dependent modulation of non-ERE genes through interactions with other transcription 
factors, ligand independent transcription via ER phosphorylation and the rapid direct 
modulation of intracellular signaling cascades (Zhang & Trudeau, 2006). The first three 
mechanisms could collectively be referred to as the direct transcriptional effects of ERs 
while the last mechanism could be referred to as the rapid effects. 
1.4.1 Ligand-activated transcription factor 
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Classically, NRs function as inducible transcription factors that modulate specific 
genes following ligand binding. ERs are certainly no exception to this rule as the best 
characterized mechanism of ER action is the modulation of ERE containing genes 
following estrogen binding. In this mechanism, ligand binding causes conformational 
changes that result in the disassociation of heat shock proteins and receptor dimerization. 
The ER dimer then translocates to the nucleus where it binds to specific DNA sequences 
referred to as EREs that are present in the promoters of estrogen-responsive genes. Co-
factors and co-regulators are then recruited to the site in order to form the pre-initiation 
complex (Belcher, 2008; Zhang & Trudeau, 2006) (Figure 3). 
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Figure 3 
Ligand-activated transcription factor pathway of estrogen receptor action. 
Illustrated is the mechanism by which ERs can act as ligand transcription factors. ERs 
exist in the cytoplasm in complexes with HSP chaperones until binding of an estrogen 
such as 17β-E2. Binding of ligand results in conformational changes that release the ER 
from the HSP complex which is followed by the translocation of ERs to the nucleus where 
they dimerize and bind to EREs in estrogen-responsive genes. Once the ER dimer is 
bound to the ERE, co-regulators are recruited that facilitate the recruitment of the basal 
transcription complex and gene expression is subsequently modulated (Belcher, 2008).  
 
 
The DNA sequence that the P-Box in the DBD binds to is referred to as an ERE, 
which was first described in the Xenopus vitellogenin A2 gene. This sequence has since 
been referred to as the consensus ERE and is a palindromic inverted repeat: 5’-
GGTCAnnnTGACC-3’, where n represents any nucleotide (Gruber, Gruber, Gruber, 
Wieser, & Huber, 2004; Klein-Hitpass, Schorpp, Wagner, & Ryffel, 1986; 
Ponglikitmongkol, White, & Chambon, 1990). This consensus sequence is only present 
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in a handful of estrogen-responsive gene promoters and many EREs bear little or no 
similarity to the consensus ERE (Gruber et al., 2004; Klinge, 2001). Regardless of the 
ERE sequence, once bound to DNA through the DBD, the ERs recruit co-regulators 
through protein-protein interactions. These recruited co-activators form a bridge between 
activated ERs and the transcription machinery. This allows ER activation to indirectly 
affect the recruitment of transcriptional machinery to a specific gene and thereby 
modulate the expression of estrogen-responsive genes (Heery, Kalkhoven, Hoare, & 
Parker, 1997; Leers, Treuter, & Gustafsson, 1998; Zhang & Trudeau, 2006). 
1.4.2 Transcription factor co-regulator 
Ligand-activated ERs can also play the role of transcription factor co-regulator in 
order to affect the transcription of target genes. In this role, transcription factors such as 
Sp1 and AP-1 are recruited to genes that do not contain EREs. The ERs can then act as 
a co-regulator by binding to this transcription factor and recruiting additional co-regulators 
that lead to the formation of the pre-initiation complex (O'Lone, Frith, Karlsson, & Hansen, 
2004; Porter, Saville, Hoivik, & Safe, 1997). An example of this is that ERα enhances the 
binding of Sp1 to its target genes and plays a role in co-activator recruitment (O'Lone, 
Frith, Karlsson, & Hansen, 2004; Porter, Saville, Hoivik, & Safe, 1997). Similarly, ERs can 
affect transcription of AP-1 target genes as well without DNA binding, but rather, by acting 
as a co-activator (O'Lone et al., 2004; Webb et al., 1999). These studies demonstrate that 
one additional function of ligand-activated ERs is to modulate gene expression by acting 
as a co-regulator in protein complexes that contain transcription factors (Zhang & Trudeau, 
2006). 
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1.4.3 Ligand independent transcriptional regulation 
Both ERs are capable of being phosphorylated by a variety of pathways, including 
17β-E2-independent pathways (Lannigan, 2003; Nilsson et al., 2001; Tremblay et al., 
1997; Weigel & Zhang, 1998; Zhang & Trudeau, 2006). In response to both 17β-E2 and 
MAPK activation, ERα is phosphorylated at multiple serine residues that are in the AF-1 
domain. While the phosphorylation of ERβ is not as well-characterized, it is known that 
ERβ is also phosphorylated at serine residues within the AF-1 domain following MAPK 
activation. The effect of ER phosphorylation in the AF-1 is generally an enhancement of 
co-activator recruitment and thus an increase in ER-mediated transcription (Dutertre & 
Smith, 2003; Endoh et al., 1999; Lannigan, 2003; Sanchez, Picard, Sauve, & Tremblay, 
2010; Tremblay et al., 1997). 
1.4.4 Rapid activation of intracellular signaling pathways 
Activation of ERs by 17β-E2 or other estrogens can also induce rapid changes in 
the activation of intracellular signaling pathways. This effect of estrogen treatment was 
first described in the 1960s when it was observed that 17β-E2 treatment increased uterine 
cAMP levels rapidly in ovariectomized (OVX) rats. This observation was followed up by 
the demonstration of estrogen binding sites on the surface of cells. These surface 
estrogen binding sites were in reality membrane-associated ERs which are important 
mediators of the rapid effects of estrogens (Pietras & Szego, 1977; Szego & Davis, 1967; 
Zhang & Trudeau, 2006). Despite these early studies, the rapid effects of estrogen did 
not start to be accepted until the 1990s. It was at this time that several groups started to 
report that various intracellular signaling pathways were modulated by 17β-E2 rapidly 
(Graber, Sumida, Vallette, & Nunez, 1993; Kelly, Lagrange, Wagner, & Ronnekleiv, 1999; 
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Le Mellay, Grosse, & Lieberherr, 1997; Migliaccio et al., 1996; Ropero et al., 1999). The 
rapid regulation of growth factor pathways by ligand-activated ERs had diverse effects on 
proliferation, cell survival, migration and other endpoints (Belcher, 2008; Hammes & Levin, 
2011; Kelly & Levin, 2001; Ellis R Levin, 2005; E. R. Levin, 2008; Zhang & Trudeau, 2006). 
Additionally, it was observed that Ca2+ handling could also be affected by ER activation, 
which contributes to functional changes in cardiomyocytes and whole hearts that are 
observed rapidly following the administration of estrogens (E. Murphy, 2011; Parks & 
Howlett, 2013). Many studies have described membrane-associated ERα and ERβ as 
mediating the rapid effects of 17β-E2 and other estrogens. Membrane-associated ERs 
often form complexes with growth factor receptors such as the insulin-like growth factor 
1 receptor (IGF1R) and epidermal growth factor receptor (EGFR) following ligand binding 
that result in the activation of the growth factor pathway. While it is clear that membrane-
associated ERs play an important role in mediating the rapid effects of 17β-E2, it is also 
clear that cytoplasmic ERs can initiate rapid signaling cascades (Belcher, 2008; Fox, 
Andrade, & Shupnik, 2009; Ellis R Levin, 2005; Soltysik & Czekaj, 2013; Zhang & Trudeau, 
2006). In addition to ERα and ERβ, GPER1 is also known to mediate rapid extra-nuclear 
effects of estrogens. Activation of GPER1 can cause the downstream activation of 
mediators such as adenylyl cyclase, ERK 1/2 and phospholipase C. Furthermore, GPER1 
activation is known to increase the proliferation and migration of breast cancer cells 
(Gigoux & Fourmy, 2013; Lappano et al., 2014; Prossnitz & Hathaway, 2015). While 
initially not accepted by the scientific community, it is now clear that the function of ERs 
extends beyond the classical transcriptional pathways and can affect and interact with 
diverse growth factor and other intracellular signaling pathways rapidly. Furthermore, the 
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identification of GPER1 and the characterization of its role in the rapid effects of estrogens 
demonstrate that the classical ERs are not responsible for all of the receptor mediated 
effects of estrogens.  
1.5 The insulin-like growth factor pathway 
 The insulin-like growth factor (IGF) pathway regulates diverse cellular processes 
including proliferation, apoptosis, differentiation and DNA repair. The insulin-like growth 
factor 1 receptor (IGF1R) can be activated by IGF1, IGF2 or insulin and couples to 
downstream mediators of these cellular processes such as PI3K and MEK (Figure 4) 
(Baserga, Sell, Porcu, & Rubini, 1994; Gualco et al., 2009; LeRoith, Baserga, Helman, & 
Roberts, 1995). Transgenic mouse models have demonstrated how important the IGF1R 
is in regulating cell growth and differentiation. Mice that overexpress IGF1 grow to a larger 
size overall and induces brain growth that surpasses the overall increase in body size. 
Conversely, the targeted disruption of the Igf1r gene in mice results in mice that are 
greatly reduced in size. With regard to the brain, Igf1r-/- mice exhibit reduced neuronal 
precursor proliferation and increased apoptosis (Baserga et al., 1994; Gualco et al., 2009; 
LeRoith et al., 1995). 
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Figure 4 
IGF-1 mediated activation of the pro-survival AKT and ERK mediators. Illustrated is 
the mechanism by which IGF-1R activation by IGF-1 can lead to the downstream 
activation of the pro-survival mediators AKT and ERK. First, IGF-1 binds to the IGF-1R 
which leads to receptor dimerization and autophosphorylation of the receptor. The 
activated receptor can then couple to IRS-1 and Ras which begin a kinase cascade that 
leads to the activation of AKT and ERK, respectively. (Baserga et al., 1994; Gualco et al., 
2009; LeRoith et al., 1995).   
 
 The clear effects of the IGF pathway on proliferation and survival have also 
implicated this pathway in cancer development and growth. IGF pathway activity is 
observed in several brain tumors including glioblastomas, astrocytomas, neuroblastomas, 
and meningiomas. Due to the focus of the presented studies, it is especially important to 
note the involvement of the IGF1 pathway in MB (Ajeawung, Wang, Gould, & 
Kamnasaran, 2012; Baserga et al., 1994; Gualco et al., 2009; Guessous, Li, & Abounader, 
2008; LeRoith et al., 1995). As detailed in section 1.7.2.1, the potent IGF1R agonist, IGF1, 
promotes cerebellar granule cell precursor survival. This observation is critically important 
as certain subtypes of MB (discussed in section 1.10.2) arise from cerebellar granule cell 
precursor suggesting that MB cell survival may also be regulated by the IGF pathway 
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(Colvin & Abdullatif, 2013; Gibson et al., 2010; Hatten & Roussel, 2011; Leski, Valentine, 
Baer, & Coyle, 2000; Wechsler-Reya & Scott, 2001). Indeed, it has been observed that 
the IGF pathway regulates both MB carcinogenesis and growth through its effects on 
proliferation and survival (detailed in section 1.10.2.3) (Ajeawung et al., 2012; Gualco et 
al., 2009; Guessous et al., 2008). These data provide the rationale for investigating the 
IGF pathway as a potential mediator of the growth promoting effects of 17β-E2 in MB, as 
discussed in sections 1.10.4 and 1.10.5. 
1.6 The cerebellum as an estrogen-responsive tissue 
 The cerebellum is a region of the brain that plays a role in several aspects of motor 
control including the coordination of voluntary motor movement, muscle tone and balance. 
The importance of the cerebellum in motor control was recognized following observations 
of laboratory animals that displayed abnormal gait and loss of balance following the 
ablation of portions of the cerebellum (Fine, Ionita, & Lohr, 2002). The regulation of motor 
control by the cerebellum depends on the action of several types of neurons located within 
the cerebellum which reside in several different regions of the cerebellum as detailed 
below. Furthermore, while initially described as being unresponsive to estrogen, it is now 
known that neurons within the cerebellum express ERs during development and 
adulthood and that estrogen may regulate the development and synaptic activity of the 
cerebellum as detailed below (Altman, 1997; Hedges, Ebner, Meisel, & Mermelstein, 
2012; Sotelo, 2004). 
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1.6.1 Development and structure of the cerebellum 
 The adult cerebellum is divided into three layers including the molecular layer (ML), 
Purkinje cell layer (PL) and the internal granular layer (IGL). The molecular layer has a 
low cellular density and contains only the stellate and basket cells, which are inhibitory 
interneurons. The ML is primarily composed of the dendritic arbors of Purkinje cells and 
the parallel fibers of the granule cells which form synapses with one another.  The PL 
contains the cell bodies of Purkinje cells, arranged in a monolayer and divides the ML 
from the IGL. The innermost layer of the cerebellum is the IGL, which is composed of 
approximately 80 billion mature granule cells. Granule cells are the most numerous type 
of cell in the brain and comprise more than 95% of the cells present in primary cultures 
of rat cerebella collected during the postnatal development of the cerebellum (Altman, 
1997; Sotelo, 2004). 
 Cerebellar cell progenitors come from two separate regions of the developing 
hindbrain during embryonic and early postnatal development. The ventricular zone gives 
rise to cells that will go on to become Purkinje cells. In the mouse, these progenitors are 
generated between embryonic day 11 and 13 and immediately begin their migration to 
the cerebellar primordium. By birth, the migration of Purkinje cells is complete and the 
cells have formed the monolayer described above as the PL. The rhombic lip also 
generates progenitors, most of which become granule cell precursors (GCPs) that 
migrate and form the external granular layer (EGL). The EGL is a germinal zone that first 
appears at embryonic day 15 and is where the clonal expansion of GCPs occurs until 
approximately post-natal day 15 in the mouse. After the proliferation of GCPs in the EGL 
ceases around post-natal day 15, the GCPs begin to differentiate and migrate through 
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the ML and PL and become mature granule cells in IGL (Altman, 1997; Sotelo, 2004). Of 
particular importance is the fact that in sonic hedgehog MB (detailed in section 1.10.1.2), 
MB likely arises from GCPs that continue proliferating in the EGL and go on to form MB 
tumors because they fail to differentiate as described in more detail in section 1.10.2 
(Northcott et al., 2012; Wechsler-Reya & Scott, 2001). 
1.6.2 Actions of estrogen in the cerebellum 
Expression of both ERα and ERβ mRNA was observed in cerebellar granule cell 
precursors (GCPs) from rat pups and varied during the first 15 days of post-natal 
development (Belcher, 1999). Protein expression of ERβ was also observed to vary 
during the same developmental period in rat GCPs (Jakab, Wong, & Belcher, 2001). 
Furthermore, immunohistochemistry demonstrated that the protein expression of ERβ 
was primarily in the differentiating layer of the external granular layer during post-natal 
development of the cerebellum (Jakab, Wong, & Belcher, 2001). In addition to displaying 
a developmentally-regulated pattern of ERβ expression, CGPs are estrogen-responsive 
both in vitro and in vivo. Specifically, the activation of extracellular signal-regulated kinase 
1/2 (ERK 1/2) in GCPs as well as GCP viability and proliferation are modulated by 17β-
E2 (Belcher, 2008; Belcher, Le, Spurling, & Wong, 2005; J. K. Wong, Le, Zsarnovszky, & 
Belcher, 2003; Zsarnovszky, Le, Wang, & Belcher, 2005). Estrogen action in the 
cerebellum is however not limited to GCPs, 17β-E2 also affects Purkinje cell development 
as well as neurotransmission in the mature cerebellum (Hedges et al., 2012). The role of 
ERβ in the cerebellum, specifically cerebellar GCPs, is especially important since the cell 
of origin of certain MB subtypes is cerebellar GCPs. In fact, the studies that examined the 
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role of ERβ in cerebellar GCPs are what initially prompted the investigation of ERβ in MB 
(S. M. Belcher et al., 2009). 
1.7 Pro-survival signaling by estrogen and insulin-like growth factor 
1.7.1 Cytoprotective effect of estrogen in cancer 
The hypothesis that 17β-E2 affects MB cell death, which is investigated in the 
studies presented here, is paralleled by the well-characterized effects of 17β-E2 in both 
neuroprotection during CNS development and pathogenesis in addition to its 
cytoprotective role during the progression of estrogen-responsive tumors. One example 
of estrogens affecting estrogen-responsive cancer cell death comes from studies of 
breast cancer. While the proliferative effects of 17β-E2 in breast cancer have been 
extensively characterized, the role of estrogen-mediated cytoprotection in breast cancer 
is not entirely clear (Butt, Sutherland, & Musgrove, 2007; Deroo & Korach, 2006; Hah & 
Kraus, 2014; Pearce & Jordan, 2004). What is clear is that 17β-E2 can affect breast 
cancer cell survival through several mechanisms. Early studies revealed that the 
regression of MCF-7 breast cancer xenografts that occurs when 17β-E2 treatment is 
withdrawn is due to increased apoptosis and that tamoxifen, a SERM commonly utilized 
in breast cancer treatment, induced apoptosis. Furthermore, treatment with estrogen 
increases cisplatin resistance in breast cancer cells, in part, through BCL2 mediated 
decreases in apoptosis (Butt et al., 2007; Kyprianou, English, Davidson, & Isaacs, 1991; 
LaPensee & Ben-Jonathan, 2010; Perry, Kang, & Greaves, 1995). It was then determined 
from further studies that ERα activation in breast cancer cells resulted in the up-regulation 
of various pro-survival proteins such as BCL2 and the results from these studies also 
suggested that these effects were, at least in part, due to cross-talk with intracellular 
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signaling pathways such as the insulin-like growth factor 1 (IGF1) pathway (detailed in 
section 1.5) (Bratton et al., 2010; Butt et al., 2007; Gompel et al., 2000; Santen et al., 
2009; Stanculescu et al., 2010; Teixeira, Reed, & Pratt, 1995). Furthermore, the 
regulation of apoptosis by estrogen is not just a feature of breast cancer; it also occurs in 
other estrogen-responsive tumors such as endometrial, prostate, and lung cancer (Abe, 
Watanabe, Tsunoda, Kuramoto, & Okayasu, 2011; Gonzalez-Rodilla et al., 2011; I. Y. 
Kim, Kim, et al., 2002; I. Y. Kim, Seong, et al., 2002; Liang, Xie, Li, Zhong, & Chen, 2015; 
Mariani et al., 2006; Nakajima et al., 2011; J. Song, Rutherford, Naftolin, Brown, & Mor, 
2002; Tang et al., 2012; G. Zhao et al., 2011). In endometrial cancer, ERα plays a similar 
role to that observed in breast cancer. ERα positively correlates with BCL2 expression in 
human endometrial cancer and activation of ERα in endometrial cancer cell lines results 
in decreased apoptosis (Abe et al., 2011; Gonzalez-Rodilla et al., 2011; Mariani et al., 
2006; J. Song et al., 2002). In contrast, the pro-survival effects of estrogen signaling in 
prostate and lung cancer appear to due to an activation of ERβ. Treatment with raloxifene, 
which is a SERM used to prevent osteoporosis, induces apoptosis in several prostate 
cancer cell lines in an androgen receptor independent pathway. The low concentrations 
of raloxifene used in the study suggest that the effect is ER-mediated, rather than off-
target effects. Furthermore, several of the cell lines used express high levels of ERβ and 
do not express ERα, suggesting that the pro-apoptotic effect is due to the inhibition of 
ERβ by raloxifene (I. Y. Kim, Kim, et al., 2002; I. Y. Kim, Seong, et al., 2002). Further 
support for the notion that ERβ activation promotes prostate cancer progression through 
pro-survival signaling comes from a study that demonstrated increased DNA 
fragmentation, which is a hallmark of apoptosis, in a prostate cancer cell line that was 
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exposed to the non-selective ER antagonist fulvestrant, while exposure to 17β-E2 
decreased cell death (Nakajima et al., 2011). It has also been reported that ERβ plays a 
similar pro-survival role in non-small cell lung carcinoma (NSCLC) through several 
mechanisms including the up-regulation of IGF1 signaling and the inhibition of pro-
apoptotic proteins by mitochondrial localized ERβ (Liang et al., 2015; Tang et al., 2012; 
G. Zhao et al., 2011). There is also evidence to suggest that ERβ may increase apoptosis 
in various cancers but the role of ERβ in cancer are discussed in more detail in section 
1.8 (Caiazza, Ryan, Doherty, Winter, & Sheahan, 2015; Haring, Schuler, Lattrich, 
Ortmann, & Treeck, 2012; B. Huang, Warner, & Gustafsson, 2014; Nelson, Tilley, Neal, 
& Carroll, 2014; Siegfried & Stabile, 2014). 
1.7.2 Neuroprotective effect of estrogen and insulin-like growth factor 
Estrogen has long been characterized as a neuroprotective factor that can protect 
various neuronal populations through several mechanisms including the regulation of 
intracellular Ca2+ dynamics, growth factor pathways, nitric oxide synthesis, and BCL2 
expression (Alonso & Gonzalez, 2012; Firozan et al., 2014; L M Garcia-Segura, Arevalo, 
& Azcoitia, 2010; Luis M Garcia-Segura, Sanz, & Mendez, 2006; Liu, Kelley, Herson, & 
Hurn, 2010; Sohrabji, 2015; Wu, Wang, Chen, & Brinton, 2005; L. Zhao & Brinton, 2007; 
L. Zhao, Wu, & Brinton, 2004; Zorrilla Zubilete et al., 2011). It is especially of note that 
the estrogen and IGF1 signaling pathways interact to mediate neuroprotection and that 
IGF1 and 17β-E2 are both neuroprotective in cerebellar GCPs, which is the cell of origin 
for SHH MB tumors. This data forms the rationale for why modulation of IGF1 signaling 
was investigated as a potential downstream mediator of ERβ cytoprotection in MB in the 
studies presented here (Alonso & Gonzalez, 2012; L M Garcia-Segura et al., 2010; Luis 
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M Garcia-Segura et al., 2006; Leski et al., 2000; Villalba, Bockaert, & Journot, 1997; 
Zhong, Deng, Ghetti, & Lee, 2002; Zhong et al., 2005; Zorrilla Zubilete et al., 2011). The 
interactions of 17β-E2 and IGF1, with regard to neuroprotection, have been well-
characterized. For example, it is known that administration of 17β-E2 or IGF-1 can protect 
hippocampal hilar neurons from kainic acid. Inhibition of ERs by fulvestrant can block the 
neuroprotective effect of 17β-E2 and IGF1 in this model. Similarly, inhibition of the IGF1R 
by the IGF1R antagonist JB1 can also block the neuroprotective effect of both 17β-E2 
and IGF1 (Alonso & Gonzalez, 2012; L M Garcia-Segura et al., 2010; Luis M Garcia-
Segura et al., 2006). These results demonstrate that the estrogen and IGF1 pathways 
interact and are dependent on each other to elicit neuroprotection in hippocampal hilar 
neurons. There are several mechanisms by which the estrogen and IGF1 pathways 
interact to protect neurons including protein complex formation between ERα and the 
IGF1R that results in increased IGF1R activity. IGF1R activation also induces the 
phosphorylation and ligand-independent activation of ERs through the activation of 
MAPKs, while activation of both ERα and the IGF1R result in synergistic activation of the 
pro-survival mediator AKT. Lastly, the IGF1 and estrogen pathways increase the activity 
of each other through modulation of gene expression in that ER activation increases IGF1 
and IGF1R expression and IGF1R activation results in increased expression of ERα in 
the brain (Alonso & Gonzalez, 2012; L M Garcia-Segura et al., 2010; Luis M Garcia-
Segura et al., 2006). Interestingly, IGF1R expression is increased by the ER antagonist 
fulvestrant in the cerebellum, which is in contrast to the effect of fulvestrant in other brain 
regions. It was proposed that this may be due to the expression of ERβ in the cerebellum, 
while ERα predominates in other brain regions (Alonso & Gonzalez, 2012; L M Garcia-
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Segura et al., 2010; Luis M Garcia-Segura et al., 2006). This is in contrast to the 
hypothesized role of IGF1 signaling in mediating the cytoprotective role of ERβ in MB. 
However, MB typically arises from cerebellar GCPs that fail to differentiate and would, 
therefore, be unlikely to respond in a similar fashion as mature cerebella which contain 
Purkinje, granule and other neurons (Alonso & Gonzalez, 2012; L M Garcia-Segura et al., 
2010; Wechsler-Reya & Scott, 2001).  
1.7.2.1 Neuroprotective actions of estrogen and insulin-like growth factor in the 
cerebellum 
In addition to the well-characterized interaction of the IGF1 and estrogen pathways 
in neuroprotection, it is also known that these pathways regulate cell death in cerebellar 
GCPs. Cerebellar GCPs can be protected from cell death, both in vitro and in vivo, by 
IGF1 treatment. In culture, the replacement of high potassium levels (25 mM KCl) in 
media with low potassium (5 mM KCl) results in cerebellar GCP cell death, but this can 
be prevented by co-treatment with IGF1, and IGF1 treatment also prevents kainic acid 
toxicity in cultured cerebellar GCPs (Leski et al., 2000; Villalba et al., 1997). Studies 
utilizing the weaver (wv) mouse model, which develops cerebellar ataxia due to 
decreased survival and subsequent maturation of cerebellar GCPs, have also identified 
a pro-survival role of IGF1 in cerebellar GCPs. These studies demonstrated that 
cerebellar GCPs from wv mice exhibit lower levels of IGF1 pathway activation compared 
to those from wild-type mice and that exogenously supplied IGF1 can rescue wv derived 
cerebellar GCPs to an extent (Zhong et al., 2002; Zhong et al., 2005). Furthermore, 
increasing the expression of IGF1 in the cerebella of wv mice resulted in increased 
cerebellar volume due to increased survival of cerebellar GCPs and a decrease in the 
37 
 
cerebellar ataxia that defines the wv mouse model (Zhong et al., 2002; Zhong et al., 2005). 
The estrogen signaling pathway has also been observed to protect cerebellar GCPs from 
cell death both in vitro and in vivo. Chronic exposure of cultured cerebellar GCPs to 17β-
E2 results in decreased proliferation but increased viable cell numbers, suggesting that 
the chronic exposure to 17β-E2 is neuroprotective in cerebellar GCPs (J. K. Wong et al., 
2003). Further evidence for the potential neuroprotective role of 17β-E2 comes from an 
in vivo γ-irradiation model. It was demonstrated using this model that chronic 17β-E2 
treatment prevented the γ-irradiation induced deficits in motor activity and 17β-E2 
exposure protected cultured cerebellar GCPs from the cytotoxic effects of γ-irradiation 
(Zorrilla Zubilete et al., 2011).  
Issues remain with regard to the function of ERs in cancer cytoprotection and the 
interactions between the IGF1 and estrogen pathways. For example, the role of ERβ in 
cancer cytoprotection remains a challenging question as discussed in more detail in 
section 1.8. However, the numerous studies presented above clearly demonstrate that 
17β-E2 can increase survival in several tissues and cancers. Specifically, the results from 
cerebellar GCPs helped build the rationale for investigating the role of ERβ in MB survival. 
This is due to the fact that cerebellar GCPs give rise to certain subtypes of MB as 
discussed in greater detail in section 1.10. 
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1.8 Estrogen receptor signaling in cancer 
In addition to affecting the development and function of several tissues, 17β-E2 
also affects the development and progression of various cancers such as those that arise 
from the breast, female reproductive tract, prostate, lung, and colon to name a few 
(Pearce & Jordan, 2004; Thomas & Gustafsson, 2011). These cancers are, therefore, 
described as estrogen-responsive, and in the case of breast cancer, estrogen 
responsiveness as determined by ERα expression informs clinicians that hormonal 
therapy, such as tamoxifen treatment, would likely be an effective treatment. The success 
of hormone therapy in breast cancer suggests that treatment of other hormone responsive 
cancers may also be improved through the use of hormone based therapies (Bauerschlag 
et al., 2014; Cleator et al., 2009; Flemming et al., 2009; Miller et al., 2014). The effects of 
17β-E2 in malignant tissue, with an emphasis on the role of ERβ in cancer, are discussed 
in the following sections. 
Breast cancer has long been described as an estrogen-dependent tumor. Early 
case reports in the late 19th century even reported that oophorectomy could delay the 
progression of breast cancer in some cases (Cheyne, 1898). Estrogens were not 
discovered until several years later and it took even longer before the mechanisms 
underlying estrogens affects in breast cancer started to be revealed. The first clinical trials 
for tamoxifen treatment of breast cancer were conducted in the 1970s and showed 
promising results (Ward, 1973). It was later determined that the response of breast cancer 
to hormonal treatment, which includes any treatment that affects activation of ERs 
typically through either direct inhibition or a reduction in 17β-E2 synthesis, depends on 
the receptor status of the tumor (Degenshein, Bloom, & Tobin, 1980; Jensen, 1975; Vihko, 
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Alanko, Isomaa, & Kauppila, 1986). Due to the improved response rates observed in ERα-
positive breast cancer to hormonal treatments, the current standard of care for ERα-
positive breast cancer includes long-term treatment with tamoxifen which inhibits tumor 
progression and recurrence. In addition to tamoxifen treatment, aromatase inhibitors are 
often also used in the multi-modal treatment of breast cancer to both inhibit cancer growth 
and recurrence (Cleator et al., 2009; Flemming et al., 2009; Miller et al., 2014; Mohan & 
Ponnusankar, 2013). In post-menopausal women with recurrent breast cancer that no 
longer responds to tamoxifen treatment, hormonal treatment with the ER antagonist 
fulvestrant is often the favored therapy (Cleator et al., 2009; Flemming et al., 2009; Miller 
et al., 2014; Mohan & Ponnusankar, 2013). 
 Despite the widespread use of hormonal therapies in the treatment of breast 
cancer, the underlying mechanisms by which estrogens promote breast tumor growth and 
progression are still being examined. Proliferation, cell death and angiogenesis are all 
affected by estrogen signaling in breast cancer (Bardon, Vignon, Montcourrier, & 
Rochefort, 1987; Bharti, Rani, Kamal, & Agarwal, 2015; Dowsett et al., 1999; Kyprianou 
et al., 1991; Lippman, Bolan, & Huff, 1976). The regulation of these cellular processes 
occurs via multiple mechanisms including rapid and direct transcriptional effects of ERs 
as well as crosstalk with other signaling pathways. Examples include that the proliferation 
of breast cancer cells can be increased by rapid activation of pathway mediators such as 
ERK 1/2 and by direct transcriptional regulation of proliferative genes such as MYC (Dubik 
& Shiu, 1988; Migliaccio et al., 1996; R. X. Song et al., 2006). Estrogens can also regulate 
the expression of IGF1 pathway proteins such as insulin receptor substrate 1 (IRS1), 
which increases the activity of the IGF1 pathway and the subsequent effects on 
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proliferation and cell death (Mauro et al., 2001; R. X. Song et al., 2006; Surmacz & 
Bartucci, 2004). Taken together, it is clear that there are multiple mechanisms by which 
estrogens promote the growth of breast cancer which is likely why hormonal therapy of 
breast cancer is so effective.    
ERα has been implicated in the development and progression of not only breast 
cancer but also other cancers such as those that arise from the female reproductive tract 
and prostate tissue. Estrogen responsiveness has also been observed in non-
reproductive tissues such as the colon, brain and lung (Burns & Korach, 2012; Thomas 
& Gustafsson, 2011). In contrast, the role of ERβ in these cancers is controversial as 
discussed further in section 1.8.1 (L. C. Murphy & Leygue, 2012; Thomas & Gustafsson, 
2011).  
1.8.1 The role of ERβ in cancer 
Since the discovery of the second ER, ERβ, from a rat prostate cDNA library, 
studies have been conducted to elucidate the potential role of ERβ in various cancers 
including those of the breast, prostate, endometrium, ovary, colon and lung (Caiazza et 
al., 2015; Haring, Schuler, et al., 2012; G. G. Kuiper et al., 1996; Leygue & Murphy, 2013; 
L. C. Murphy & Leygue, 2012; Nelson et al., 2014; Siegfried & Stabile, 2014; Thomas & 
Gustafsson, 2011). Despite all these years of research, a definitive answer on the role of 
ERβ in cancer has yet to be determined. Current research supports the notion that ERβ 
can be both a tumor suppressor and an oncogene and the specific role of ERβ depends 
on the context. This context includes, but is likely not limited to, several factors including 
the specific type of cancer, the co-expression of ERα, the localization of ERβ within the 
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cells, and which splice variant of ERβ is expressed (Leygue & Murphy, 2013; L. C. Murphy 
& Leygue, 2012; Nelson et al., 2014; Thomas & Gustafsson, 2011).  
1.8.1.1 Colon Cancer 
Of the cancers known to express ERβ, colon cancer is the only one for which a 
defined and clear role of ERβ in carcinogenesis and tumor progression has been 
determined. In normal colon epithelium and in colon cancer, the expression of ERβ 
predominates and appears to function as a tumor suppressor (Caiazza et al., 2015; Foley, 
Jazaeri, Shupnik, Jazaeri, & Rice, 2000; Rudolph et al., 2012; Rudolph et al., 2013). Initial 
evidence for this potential tumor suppressor function of ERβ came from studies that 
reported decreased ERβ expression in colon cancer, a protective effect of hormone 
replacement therapy in women against colon cancer development and identified ERβ as 
a positive prognostic factor (Caiazza et al., 2015; Foley, Jazaeri, Shupnik, Jazaeri, & Rice, 
2000; Rudolph et al., 2012; Rudolph et al., 2013). Furthermore, in vivo studies utilizing 
the Esr2-/- mouse model determined that while loss of ERβ expression in not sufficient to 
drive colon carcinogenesis, loss of ERβ expression does result in increased tumor size 
in mouse models of colon cancer (Caiazza et al., 2015; Giroux, Lemay, Bernatchez, 
Robitaille, & Carrier, 2008; Wada-Hiraike et al., 2006). In contrast to the decreased 
expression of ERβ in colon cancer, which is suggestive of its tumor suppressor role, the 
expression of the ERβ splice variant, ERβ5, is maintained in colon cancer, suggesting 
that ERβ5 may be involved in colon carcinogenesis and tumor progression (Caiazza et 
al., 2015; N. A. Wong et al., 2005). However, the role of ERβ5 in colon cancer is currently 
unclear due to the lack of studies that directly investigate the effect of ERβ5 expression 
in colon cancer progression (Caiazza et al., 2015; N. A. Wong et al., 2005). These studies, 
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and others, demonstrate that colon cancer is unique among ERβ-positive cancers. In all 
other ERβ-positive tumors, the role of ERβ in carcinogenesis and tumor progression is 
unclear and appears to depend on various factors, as discussed in further detail below. 
In contrast, ERβ is clearly a tumor suppressor in colon cancer, however, the mechanisms 
responsible for this clear and defined role of ERβ in colon cancer, compared to the multi-
faceted role of ERβ in other estrogen-responsive tumors, is unclear. 
1.8.1.2 Ovarian and Endometrial Cancer 
In contrast to the clear role of ERβ as a tumor suppressor in colon cancer, ERβ 
appears to play a multi-faceted role in ovarian, endometrial, breast, prostate and lung 
carcinogenesis and tumor progression. Specifically, the majority of studies suggest that 
ERβ is a tumor suppressor in ovarian cancer (Brandenberger, Tee, & Jaffe, 1998; Chan 
et al., 2008; Haring, Schuler, et al., 2012). Evidence for the potential tumor suppressor 
role of ERβ includes the observation that ERβ expression is decreased in ovarian 
epithelial tumors compared to normal ovary tissue. Furthermore, ERβ expression was 
observed to be a positive prognostic factor in ovarian cancer (Brandenberger, Tee, & 
Jaffe, 1998; Chan et al., 2008; Haring, Schuler, et al., 2012). Despite the apparent tumor 
suppressor role of ERβ suggested by these studies, there is also evidence to suggest 
that various factors influence the role of ERβ in ovarian cancer. For example, while 
several ERβ splice variants undergo decreases in expression during ovary 
carcinogenesis, the splice variant ERβ5 is actually upregulated, suggesting that ERβ5 
may promote ovary carcinogenesis and tumor progression (Ciucci, Zannoni, et al., 2014; 
De Stefano et al., 2011; Haring, Schuler, et al., 2012; Suzuki et al., 2008). Furthermore, 
the subcellular localization of ERβ affects its role in ovarian cancer as it has been 
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demonstrated that cytoplasmic ERβ is associated with reduced disease-free and overall 
survival in ovarian cancer patients (Ciucci, Zannoni, et al., 2014; De Stefano et al., 2011; 
Haring, Schuler, et al., 2012; Suzuki et al., 2008). Together, these studies suggest that 
while ERβ may function as a tumor suppressor in ovarian cancer typically, special 
attention needs to be paid to the specific splice variants of ERβ that are expressed, as 
well as the subcellular localization of ERβ, because these factors likely influence the 
function of ERβ in ovarian cancer. In contrast, the majority of reports suggest that ERβ 
promotes carcinogenesis and tumor progression in endometrial cancer. A few studies 
have reported that ERβ expression is decreased in endometrial cancer when compared 
to normal endometrium. This observation would suggest that ERβ is a tumor suppressor 
in endometrial cancer; however, the majority of reports demonstrate that ERβ expression 
is maintained during endometrial carcinogenesis and tumor progression (Haring, Schuler, 
et al., 2012; Haring, Skrzypczak, et al., 2012; Skrzypczak et al., 2004). Specifically, the 
ERβ splice variant, ERβ5, is consistently observed to be upregulated in endometrial 
cancer and ERβ expression was observed to correlate with the up-regulation of 
oncogenes, suggesting that ERβ promotes endometrial carcinogenesis and tumor 
progression (Collins et al., 2009; Haring, Schuler, et al., 2012; Haring, Skrzypczak, et al., 
2012; Skrzypczak et al., 2004). While ERα is expressed in normal endometrium to a 
greater extent than ERβ, the ERα/ERβ ratio tends to decrease during endometrial 
carcinogenesis and progression (Haring, Schuler, et al., 2012; Jongen et al., 2009; 
Mylonas, 2010; Mylonas et al., 2005; Takama, Kanuma, Wang, Kagami, & Mizunuma, 
2001). Furthermore, a low ERα/ERβ ratio has been associated not only with an invasive 
phenotype in endometrial cancer but is also a negative prognostic factor (Haring, Schuler, 
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et al., 2012; Jongen et al., 2009; Mylonas, 2010; Mylonas et al., 2005; Takama, Kanuma, 
Wang, Kagami, & Mizunuma, 2001). These findings suggest that the absence or at least 
decreased expression of ERα allows ERβ to promote endometrial cancer progression. 
Importantly, the studies reported here investigate the role of ERβ in ERα-negative MB, 
and previous studies have suggested that ERβ may promote MB tumor progression. 
Furthermore, the notion that ERβ promotes tumor growth in the absence of ERα 
expression is also observed in lung and breast cancer, as discussed below (S. M. Belcher 
et al., 2009; Leygue & Murphy, 2013; L. C. Murphy & Leygue, 2012; Siegfried & Stabile, 
2014). 
1.8.1.3 Prostate Cancer 
Yet another ERβ-positive cancer in which the role of ERβ is currently unclear is 
prostate cancer. Epidemiological studies have demonstrated that the consumption of 
diets high in phytoestrogens reduces prostate cancer risk. This protective effect of 
phytoestrogens may be due to the activation of ERβ, as phytoestrogens display selectivity 
for ERβ and ERβ activation by phytoestrogens decreases androgen receptor expression 
in prostate cancer cell lines (Hedelin et al., 2006; Hori, Butler, & McLoughlin, 2011; G. G. 
Kuiper et al., 1998; Nelson et al., 2014). Studies that utilized loss of ER function with ERα 
and ERβ genetic mouse models suggested that ERα promoted prostate carcinogenesis. 
It was observed that the genetic loss of ERα, but not ERβ, prevented the development of 
prostatic intraepithelial neoplasia (PIN), which is a risk factor for prostate cancer 
development. Additionally, treatment with an ERα-selective agonist promoted the 
development of PIN in rats while co-treatment with an ERβ-selective agonist blocked the 
effect of ERα activation on PIN development. The ERβ-selective agonist not only 
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prevented PIN development but also decreased proliferation and increased apoptosis in 
prostate epithelial cells (Attia & Ederveen, 2012; Nelson et al., 2014; Ricke et al., 2008). 
These studies demonstrated that ERα and ERβ had opposing effects in prostate 
carcinogenesis and suggested that ERα was an oncogene while ERβ was a tumor 
suppressor during prostate carcinogenesis (Attia & Ederveen, 2012; Nelson et al., 2014; 
Ricke et al., 2008). Consistent with the proposed roles of oncogene for ERα and tumor 
suppressor for ERβ, the expression of both receptors is regulated during prostate 
carcinogenesis and tumor progression. In general, the expression of ERα is increased in 
prostate cancer while ERβ expression is decreased (Bonkhoff, Fixemer, Hunsicker, & 
Remberger, 1999; Horvath et al., 2001; Nelson et al., 2014). Despite the classical notion 
that ERα is an oncogene while ERβ is a tumor suppressor in prostate cancer, there is 
evidence to suggest that this is not always the case. For example, the expression of the 
ERβ splice variant, ERβ2, is increased in advanced and metastatic prostate cancer. Not 
only is ERβ2 expression increased, but both ERβ2 and ERβ5 expression are prognostic 
factors that correlate with deceased time to relapse and metastasis in prostate cancer 
(Dey et al., 2012; Leung et al., 2010; Nelson et al., 2014). Despite its clear role in 
protecting against prostate carcinogenesis, ERβ expression is a negative prognostic 
factor in hormone-naïve prostate cancer, which is dependent on androgens for growth. 
Furthermore, it has also been suggested that ERβ activation may promote tumor 
progression in castration-resistant prostate cancer. This is supported by the observation 
that ERβ expression increases in castration-resistant prostate cancer. The mechanism 
responsible for the tumor-promoting effect of ERβ in castration-resistant prostate cancer 
involves the formation of a protein complex, which includes ligand-bound ERβ and the 
46 
 
androgen receptor, and regulates the expression of genes that contain androgen 
response elements (Nakamura et al., 2013; Nanni et al., 2009; Nelson et al., 2014; L. 
Yang et al., 2012; Zellweger et al., 2013). These data suggest that while ERβ likely 
functions as a tumor suppressor during prostate carcinogenesis, the role of ERβ likely 
switches once prostate cancer develops and contributes to the progression of the disease. 
1.8.1.4 Lung Cancer 
There have been several studies that have attempted to determine the prognostic 
value of ERβ in lung cancer with conflicting results often reported. Reports are largely 
split, with some demonstrating that ERβ expression is associated with better disease-free 
and/or overall survival while others demonstrate that ERβ is in fact a negative prognostic 
factor (Navaratnam et al., 2012; Raso et al., 2009; Siegfried & Stabile, 2014; Stabile et 
al., 2011). Some issues that may be responsible for this include the lack of ERβ splice 
variant specific antibody use in several studies, as well as the need to evaluate the 
subcellular localization of ERβ and disease stage. Specifically, cytoplasmic localization 
of ERβ is associated with worse overall survival and while ERβ expression associates 
with better overall survival in early stages of lung cancer, expression of ERβ in later stages 
is a negative prognostic factor (Navaratnam et al., 2012; Raso et al., 2009; Siegfried & 
Stabile, 2014; Stabile et al., 2011). Studies that have examined the effect of hormone 
replacement and anti-estrogen therapy on lung cancer survival are consistent with the 
idea that ERβ activation promotes lung cancer progression. Specifically, women that 
receive hormone replacement therapy and develop NSCLC have worse overall survival. 
In contrast, women that are receiving anti-estrogen therapy, which included tamoxifen 
and/or aromatase inhibitors, as part of breast cancer treatment and develop lung cancer, 
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had better overall survival  (Bouchardy et al., 2011; Chlebowski et al., 2009; Lother, 
Harding, Musto, Navaratnam, & Pitz, 2013; Siegfried & Stabile, 2014). These data 
suggest that estrogen signaling, presumably through ERβ activation which is the 
predominant ER expressed in lung cancer, promotes lung cancer progression. Direct pre-
clinical evidence for the tumor-promoting role of ERβ is also available from studies that 
utilized both in vitro and in vivo model systems. Several in vitro studies utilizing NSCLC 
cell lines have demonstrated a proliferative and cytoprotective effect of ERβ activation 
that can be blocked by the non-selective ER antagonist fulvestrant. Mechanisms 
responsible for these effects include the direct transcriptional regulation of the proliferative 
MYC and CCND1 genes as well as pro-survival signaling through up-regulation of the 
IGF1 pathway and the direct inhibition of BAD, which is a pro-apoptotic BCL2 family 
member, by mitochondrial localized ERβ (Hershberger et al., 2009; Hershberger et al., 
2005; Liang et al., 2015; Siegfried & Stabile, 2014; Stabile et al., 2002; Stabile et al., 2005; 
Tang et al., 2012; G. Zhao et al., 2011). Consistent with the results from in vitro studies, 
in vivo studies utilizing murine models of lung cancer have also defined a tumor-promoting 
role of ERβ in lung cancer. Specifically, treatment with 17β-E2 increased tumor incidence 
and size in a murine genetic model of lung cancer that displayed ERβ, but not ERα, 
expression in the tumor tissue, suggesting that ERβ activation was responsible for the 
effect of 17β-E2. In a tobacco-carcinogen induced murine model of lung cancer, treatment 
with the aromatase inhibitor anastrozole or the non-selective ER antagonist fulvestrant 
decreased lung carcinogenesis and tumor progression and it was observed that co-
treatment with anastrozole and fulvestrant was more effective than either treatment alone 
(Hammoud, Tan, Badve, & Bigsby, 2008; Siegfried & Stabile, 2014; Stabile et al., 2011; 
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Stabile et al., 2012). Expression of ERα was not assessed, however, ERβ was observed 
to be expressed in these tumors and due to the rarity of ERα expression in lung cancer, 
as well as the fairly well-defined role of ERβ in promoting lung cancer progression, it is 
likely that the effects of anastrozole and fulvestrant were due to decreased ERβ activation 
(Hammoud, Tan, Badve, & Bigsby, 2008; Siegfried & Stabile, 2014; Stabile et al., 2011; 
Stabile et al., 2012). Despite the consistent evidence from in vitro and in vivo pre-clinical 
studies that suggest ERβ promotes lung carcinogenesis and tumor progression, there is 
currently no clear prognostic significance of ERβ expression in lung cancer. The reasons 
for the conflicting reports regarding associations between ERβ expression and both better 
and worse overall survival are currently unclear, and further research that utilizes 
validated antibodies for specific ERβ splice variants and evaluate subcellular localization 
of ERβ splice variants are needed to resolve this question. However, it is clear that ER 
activation promotes lung cancer progression as evidenced by retrospective analysis of 
female lung cancer patients that were undergoing hormone replacement or anti-estrogen 
therapy (Siegfried & Stabile, 2014). Of particular interest, is the fact that lung cancer 
typically does not express ERα, which supports the notion that ERβ activation promotes 
tumor progression when ERα expression is absent. This idea is investigated in the studies 
presented here that were performed in ERα-negative, ERβ-positive MB (S. M. Belcher et 
al., 2009; Leygue & Murphy, 2013). 
1.8.1.5 Breast Cancer 
 Breast cancer is perhaps the best characterized estrogen-responsive tumor with 
both breast carcinogenesis and breast tumor growth being promoted by ERα activation. 
However, the role of ERβ in breast cancer, despite many years of research, remains 
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unclear. It has been proposed that ERβ functions as a tumor suppressor in breast cancer 
and this notion is supported by several lines of evidence. These observations include 
results from retrospective biomarker analysis which revealed a consistent decrease of 
ERβ expression during breast carcinogenesis, and a positive correlation between overall 
survival and ERβ expression in breast cancer patients  (Dhimolea et al., 2015; Esslimani-
Sahla et al., 2004; Fleming, Hill, McDermott, O'Higgins, & Young, 2004; Leygue & Murphy, 
2013; Mandusic et al., 2012; L. C. Murphy & Leygue, 2012; Novelli et al., 2008). 
Furthermore, there are several in vitro studies utilizing breast cancer cell lines that support 
the notion that ERβ is a tumor suppressor in breast cancer. These studies have 
consistently reported that ERβ overexpression suppresses 17β-E2-induced growth 
through anti-proliferative and pro-apoptotic mechanisms (Hodges-Gallagher, Valentine, 
El Bader, & Kushner, 2008; Leygue & Murphy, 2013; Lindberg, Helguero, Omoto, 
Gustafsson, & Haldosen, 2011; L. C. Murphy & Leygue, 2012; L. C. Murphy et al., 2005; 
Paruthiyil et al., 2011; Paruthiyil et al., 2004; Secreto, Monroe, Dutta, Ingle, & Spelsberg, 
2007; Shanle, Hawse, & Xu, 2011; Strom et al., 2004). 
 Despite the expansive evidence that suggests that ERβ is a tumor suppressor in 
breast cancer, several studies also demonstrate that ERβ promotes breast cancer growth 
and progression under certain circumstances (Leygue & Murphy, 2013). The major 
factors that appear to affect the function of ERβ in breast cancer include the relative 
expression of ERβ splice variants, the subcellular localization of ERβ and the expression 
status of ERα (Leygue & Murphy, 2013). Of particular interest is the role of ERβ in ERα-
negative breast cancer since MB typically only expresses ERβ. (S. M. Belcher et al., 2009; 
Chantzi et al., 2013; Dhimolea et al., 2015; Leygue, Dotzlaw, Watson, & Murphy, 1999; 
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Leygue & Murphy, 2013; Mandusic et al., 2012; L. C. Murphy & Leygue, 2012; Rosin et 
al., 2014; Saji, Omoto, Shimizu, Horiguchi, et al., 2002; Saji, Omoto, Shimizu, Warner, et 
al., 2002; Wimberly et al., 2014). There are several lines of evidence that suggest that in 
the absence of ERα, ERβ functions as an oncogene in breast cancer. However, these 
studies typically rely on ERβ overexpression which may impact the function of ERβ 
compared to physiological expression levels of ERβ in breast cancer that is positive for 
ERβ (Cailleau, Olive, & Cruciger, 1978; Engel & Young, 1978; Fuqua et al., 1999; Leygue 
& Murphy, 2013; Tonetti et al., 2003; Vladusic, Hornby, Guerra-Vladusic, Lakins, & Lupu, 
2000). There are a limited number of studies that address ERβ function in breast cancer 
cell lines that possess endogenous ERβ expression (Leygue & Murphy, 2013). One such 
study was performed using the MC4-L2 breast cancer cell line which expresses both ERβ 
and ERα. Cultured MC4-L2 cells treated with the ERβ-selective agonist, DPN, displayed 
increased apoptosis while the ERα-selective agonist and 17β-E2 increased proliferation, 
supporting the notion that ERβ is a tumor suppressor in ERα/ERβ-positive breast cancer 
(Cotrim et al., 2013). In contrast to the effect of ERβ activation in the ERα-positive MC4-
L2 breast cancer cell line, in vitro proliferation is increased by 17β-E2 through the 
activation of ERβ in the ERα-negative/ERβ-positive MDA-MB-468 breast cancer cell line. 
The chemosensitivity of MDA-MB-468 cells is decreased by ERβ activation, suggesting 
that ERβ activation promotes survival in ERα-negative breast cancer cells. Lastly, the 
proliferative and pro-survival effects of ERβ activation in MDA-MB-468 cells were blocked 
by co-treatment with the SERM tamoxifen (W. Li et al., 2013). These examples of in vitro 
studies that examine the role of ERβ in breast cancer suggest that in the absence of ERα, 
ERβ can promote breast tumor growth. Furthermore, ERβ expression has been identified 
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as a predictor of tamoxifen response in ERα-negative breast cancer in humans. In 
addition to predicting the response to tamoxifen, high ERβ expression was positively 
correlated with Ki-67, which is a marker of proliferation, as well as breast cancer 
resistance protein (BCRP), in human ERα-negative breast cancer samples. (Gruvberger-
Saal et al., 2007; Honma et al., 2008; Leygue & Murphy, 2013; W. Li et al., 2013; Novelli 
et al., 2008; O'Neill et al., 2004; Yan et al., 2013). These data suggest that, as in in vitro 
models, ERβ expression promotes tumor growth in ERα-negative breast cancer. The 
general notion that ERβ promotes tumor growth in the absence of ERα is further 
supported by studies of ERα-negative lung and endometrial cancer as discussed above.  
Taken together, the review of literature concerning the role of ERβ in cancer clearly 
suggests that in the absence of ERα, ERβ can promote tumor growth. Therefore, it was 
of interest to characterize the role of ERβ in MB, which do not express ERα (S. M. Belcher 
et al., 2009; Mancuso et al., 2011). 
1.9 Estrogenic Endocrine Disrupting Chemicals 
 The Environmental Protection Agency of the United States of America defines 
endocrine disrupting chemicals (EDCs) as “an exogenous agent that interferes with the 
production, release, transport, metabolism, binding, action, or elimination of natural 
hormones in the body responsible for the maintenance of homeostasis and the regulation 
of developmental processes” (Kavlock et al., 1996). Estrogenic EDCs are capable of 
binding specifically to ERs and display varying affinities for both ERα and ERβ. It is likely 
that the estrogenic effect of these EDCs is due to the specific binding to ERs and 
subsequent modulation of ER activity (G. G. Kuiper et al., 1998). In general, there are two 
main groups of estrogenic EDCs, the xenoestrogens and the phytoestrogens. 
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Xenoestrogens are synthetic compounds present in a wide variety of industrial and 
consumer products, while phytoestrogens are compounds produced in various plant 
species as well as the metabolites of such compounds (Yoon, Kwack, Kim, & Lee, 2014). 
In both cases, these estrogenic EDCs vary greatly in their structure and may or may not 
bear any obvious structural similarities to 17β-E2 (Yoon, Kwack, Kim, & Lee, 2014).    
1.9.1 Phytoestrogens 
 As stated above, phytoestrogens are a structurally diverse set of compounds that 
are produced by plants directly or are produced by fungal or bacterial metabolism of plant 
derived substrate compounds. Phytoestrogens are comprised of three main groups 
including the isoflavones, coumestans and lignans (Vitale, Piazza, Melilli, Drago, & 
Salomone, 2013). Of these, the isoflavones are the best studied group due to the 
extensive characterization of the actions of genistein and daidzein (Vitale, Piazza, Melilli, 
Drago, & Salomone, 2013). These phytoestrogens are found in soybeans and consumed 
in a wide variety of soy containing foods. The mechanisms that are responsible for the 
effects of phytoestrogens are not completely understood but developmental effects have 
been observed in animal models and epidemiological studies in humans (Bar-El & Reifen, 
2010; Jefferson & Williams, 2011; Vitale et al., 2013). The developmental effects of 
phytoestrogens are not surprising given the important role of estrogen signaling in 
development and it suggests that the elevated serum levels of genistein observed in 
infants given soy-based formula should be a concern (Bar-El & Reifen, 2010; Jefferson & 
Williams, 2011; Setchell, Zimmer-Nechemias, Cai, & Heubi, 1998). Additionally, 
phytoestrogens are increasingly consumed as dietary supplements due to the protective 
effects they may confer for cardiovascular disease and osteoporosis. These supplements 
53 
 
are also believed by the public to be a safe and natural alternative to hormone 
replacement therapy (HRT) for the management of menopausal symptoms (Bingham, 
Atkinson, Liggins, Bluck, & Coward, 1998; Moreira, Silva, Santos, & Sardao, 2014; 
Poluzzi et al., 2014). However, given the risks associated with traditional HRT and the 
fact that phytoestrogens also act through activation of ERs, the conclusion that 
phytoestrogens are safe and natural may be unwarranted. Regardless, it is clear that 
further investigation into the safety of phytoestrogens is needed. (Bingham, Atkinson, 
Liggins, Bluck, & Coward, 1998; Moreira, Silva, Santos, & Sardao, 2014; Poluzzi et al., 
2014).  
1.9.2 Xenoestrogens 
 Xenoestrogens are a structurally diverse set of compounds that are present in a 
wide variety of industrial and consumer products such as organic solvents, pesticides, 
phenols, phthalates, plastics, polychlorinated biphenyls and drugs. Extensive research 
has characterized the effect of developmental and adult exposure to xenoestrogens on 
the reproductive system in animal models (Degen & Bolt, 2000; Jeng, 2014; Maffini, Rubin, 
Sonnenschein, & Soto, 2006; Rosselli, Reinhart, Imthurn, Keller, & Dubey, 2000). The 
results of these studies indicate that xenoestrogens can affect many reproductive 
endpoints such as spermatogenesis, ovulation, secondary sex characteristics, sexual 
behavior, fertility, fecundity, offspring sex ratio and gonad development (Degen & Bolt, 
2000; Jeng, 2014; Maffini, Rubin, Sonnenschein, & Soto, 2006; Rosselli, Reinhart, 
Imthurn, Keller, & Dubey, 2000). Of concern, is the fact that humans are exposed to a 
wide variety of xenoestrogens as environmental pollutants and epidemiological studies 
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have indicated that exposure to these compounds may cause adverse effects, especially 
in children (Rochester, 2013; Welshons et al., 2003).   
 Due to the fact that MB is a pediatric cancer, it is of particular interest that exposure 
to both phytoestrogens and xenoestrogens tends to be greater in young children. This 
suggests that estrogenic EDCs could impact estrogen-responsive MB progression and is 
the rationale for why the effects of phytoestrogens in MB are examined in chapters 3 and 
6 (Bar-El & Reifen, 2010; Belcher, 2009; Jefferson & Williams, 2011; Setchell et al., 1998; 
vom Saal et al., 2007).    
1.10 Medulloblastoma 
 Malignancies of the CNS are among the most common childhood cancers, second 
only to leukemia (Ries et al., 1999). Among childhood CNS malignancies, 
medulloblastoma is the most common and has a peak incidence around 5 years of age 
(Ries et al., 1999). Medulloblastoma are primitive neuroectodermal tumors that are 
associated with the 4th ventricle. Histological staining of MB demonstrates that they are 
typically composed of monomorphic sheets of cells that have a high nuclear to 
cytoplasmic ratio (Wechsler-Reya & Scott, 2001). Due to both their morphology and 
location, it was long hypothesized that MB arose from cerebellar granule cell precursors 
that failed to differentiate (Wechsler-Reya & Scott, 2001). This hypothesis has been 
supported by studies that utilized neural precursor-specific gene knock-out mouse models 
but additional neural precursor populations are also now known to give rise to MB (Gibson 
et al., 2010; Wang & Wechsler-Reya, 2014; Z. J. Yang et al., 2008). It appears from these 
studies that the different molecular subgroups of MB likely arise from different neural 
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precursor populations (Gibson et al., 2010; Wang & Wechsler-Reya, 2014; Z. J. Yang et 
al., 2008). 
 Due to the development and implementation of effective multimodal therapies that 
include chemotherapy, radiation and surgery, the survival rates for MB patients have 
improved over the years. Overall 5-year survival rates are approximately 70%; however, 
the 5-year survival rate varies greatly primarily due to the age at diagnosis with infants 
and small children fairing the worst (Lee et al., 2014; Smoll, 2012). Additionally, even 
those lucky enough to survive often experience debilitating life-long side effects of the 
treatments due to the developmentally sensitive time period during which the treatments 
are administered (Frange et al., 2009; Hoang et al., 2014; Mulhern et al., 2005; Uday et 
al., 2015).  
 To address some of the limitations of the treatments, such as the life-long side 
effects, there have been attempts to develop new targeted treatments. These targeted 
treatments would ideally be given based on the tumor expression of specific receptors or 
other proteins that are known to affect MB growth and progression. Examples include the 
sonic hedgehog (SHH) and wingless (WNT) signaling pathways which have both been 
demonstrated to be important in MB growth and are up-regulated in human MB (DeSouza, 
Jones, Lowis, & Kurian, 2014; Kieran, 2014; Samkari, White, & Packer, 2015). Only a few 
clinical trials have been conducted using inhibitors of the SHH pathway in MB; however, 
the results of these clinical trials suggest that inhibition of the SHH pathway may be 
effective in treating MB in a subset of the patient population (DeSouza, Jones, Lowis, & 
Kurian, 2014; Kieran, 2014; Samkari, White, & Packer, 2015). 
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 Another potential targeted therapy for MB may be the blockade of ERβ activity. 
Initial findings that suggested an involvement of ERβ in MB came from studies utilizing 
cerebellar granule cell precursors (Belcher, 1999, 2008; Belcher et al., 2005; J. K. Wong 
et al., 2003; Zsarnovszky et al., 2005). GCPs were observed to express ERβ at the mRNA 
and protein level as well as respond to physiological concentrations of 17β-E2 and ERβ-
selective agonists (Belcher, 1999, 2008; Belcher et al., 2005; J. K. Wong et al., 2003; 
Zsarnovszky et al., 2005). Due to the fact that some, if not most, MB likely arise from 
GCPs that fail to differentiate, it was hypothesized that MB may also express ERβ and be 
estrogen-responsive. Indeed, subsequent studies indicated that ERβ was expressed in 
human MB cell lines and primary human MB samples and that MB growth was increased 
by 17β-E2 both in vitro and in vivo, likely through the activation of ERβ (Belcher, 2009; S. 
M. Belcher et al., 2009). It remained unclear, however, exactly how 17β-E2 affected tumor 
growth and whether blockade of ERβ activity could be used in MB treatment.  
Therefore, the studies presented here were performed to investigate the 
mechanisms underlying 17β-E2-mediated growth of MB and the potential for ER inhibition 
in MB treatment through the use of pre-clinical models of MB. 
1.10.1 Medulloblastoma Classification 
 As stated above, MB tumors are primitive neuroectodermal tumors that are 
associated with the 4th ventricle. Histologically, MB tumors are typically composed of 
monomorphic sheets of cells that have a high nuclear to cytoplasmic ratio. While this 
histological appearance is typical, the world health organization (WHO) classifies MB, 
currently based on histological analysis, into five subtypes (Louis et al., 2007). These 
subtypes include classic MB, desmoplastic/nodular MB, MB with extensive nodularity, 
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anaplastic MB, and large-cell MB which are discussed further in section 1.10.1.1 and 
summarized in Table 1 (Louis et al., 2007).  
 Due to heterogeneity observed in MB subgroups when classified based on 
histology, a new approach to classify MB has emerged that relies on the sequencing of 
individual tumor transcriptomes and whole genomes (M. D. Taylor et al., 2012). These 
molecular subgroups tend to have distinct patterns of gene expression that appear to 
drive tumor progression, predict prognosis and may allow for personalized treatment that 
will improve outcomes. These molecular subgroups have yet to be incorporated into the 
WHO classification scheme for MB, but will likely be incorporated when WHO guidelines 
for the classification of CNS tumors is updated. The molecular subgroups include 
wingless (WNT), sonic hedgehog (SHH), group 3 and group 4 and are discussed in detail 
in section 1.10.1.2 and summarized in Table 1 (DeSouza et al., 2014; Li, Lau, & Ng, 2013; 
Samkari et al., 2015; M. D. Taylor et al., 2012). The emerging classification of MB by 
molecular subgroups holds the potential to improve therapies by personalizing treatment 
for individuals based on the subgroup that the patients MB tumor belongs to.  
1.10.1.1 Histological Classification 
 Classification of MB by histological analysis is the classical way that MB tumors 
have been grouped into separate subgroups that differ with regard to prognosis and 
biomarker expression. As stated above, these groups include classic MB, desmoplastic 
MB, MB with excessive nodularity (MBEN), large cell MB and anaplastic MB. However, 
due to the fact that large cell and anaplastic variants share similar histology that varies 
on a continuum and both have a poor prognosis, they are often combined into a single 
group referred to as large cell/anaplastic (LCA) MB (Ellison, 2002; Gulino, Arcella, & 
58 
 
Giangaspero, 2008; Louis et al., 2007). Approximately 10 to 22% of MB are of the LCA 
variant, and the typical histological features of LCA tumors include nuclear pleomorphism 
and nuclear molding in a purely anaplastic tumor, while purely large cell MB are 
composed of spherical cells with large round nuclei and prominent nucleoli (Gulino et al., 
2008; Louis et al., 2007). However, since large cell and anaplastic MB exist on a 
continuum, many tumors of the LCA variant contain varying amounts of large cell and 
anaplastic tissue and all tend to be highly mitotic. The LCA variant is also associated with 
poor prognosis as the overall 5-year survival rate for LCA MB patients is approximately 
57% compared to 73% for classic MB (Gulino et al., 2008; Louis et al., 2007). MBEN is 
related to desmoplastic MB with the main difference being that MBEN has a significantly 
reduced amount of the internodular reticulin-rich component compared to desmoplastic 
MB. Desmoplastic MB and MBEN are generally composed of nodules, which are 
characterized by neuronal differentiation, monomorphic spherical cells that have a low 
mitotic index, and varying amounts of internodular region which is reticulin-rich and 
contains pleomorphic cells with a high mitotic index. Desmoplastic MB and MBEN 
comprise approximately 7 and   3% of MB cases, respectively. Additionally, desmoplastic 
MB is likely a favorable prognostic factor as infants diagnosed with desmoplastic MB had 
a 5-year survival of 95% compared to 41% for infants diagnosed with classic MB (Ellison, 
2002; Gulino et al., 2008; Louis et al., 2007). Further studies have also suggested that 
desmoplastic MB may have a better prognosis in older children as well (Ellison, 2002; 
Gulino et al., 2008; Louis et al., 2007). Classic MB is the most common histological 
classification for MB tumors, comprising approximately 68 to 80% of MB and is composed 
of monomorphic sheets of cells with a high nuclear to cytoplasmic ratio (Gulino et al., 
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2008). Classic MB can also possess neuroblastic rosettes, which appear as circular 
arrangements of nuclei that surround neuropil, that often have high mitotic activity (Gulino 
et al., 2008). Lastly, all histological subtypes of MB can possess characteristics of 
myogenic or melanotic differentiation. MB tumors with myogenic differentiation display 
characteristics of rhabdomyoblastic differentiation, immunoreactivity to desmin, 
myoglobin and fast myosin and may contain crude myofibrils (Ellison, 2002; Louis et al., 
2007). MB tumors with melanotic differentiation contain clusters of cells that produce 
melanin (Ellison, 2002; Louis et al., 2007). Despite the fact that the current WHO 
classification guidelines for MB rely on morphological differences, the current trend is to 
re-evaluate this classification scheme. The new molecular classification scheme is based 
on transcriptome and whole genome sequencing of individual MB tumors. The molecular 
subtypes that have been defined through this method and the utility of classifying MB 
through this method are discussed in section 1.10.1.2 below. 
1.10.1.2 Molecular Classification 
 As stated above, MB has also been classified into 4 molecular subgroups including 
SHH, WNT, Group 3 and Group 4. This molecular classification is based on transcriptome 
and whole genome sequencing and allows classification based in part on chromosomal 
alterations and gene amplifications (Samkari et al., 2015; M. D. Taylor et al., 2012). This 
classification scheme is seen by many as an improvement over the histological sub-
grouping and it is expected that the WHO will update the classification of MB based on 
the new molecular sub-grouping (Samkari et al., 2015; M. D. Taylor et al., 2012). The 
most common molecular subgroup is Group 4, which make of approximately 35% of MB 
cases. Group 4 tumors typically have histology consistent with classic MB but will rarely 
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have LCA variant histology. Overall 5-year survival is approximately 75% and this 
subgroup typically affects older children and young adults. Because group 4 tumors are 
not well understood, identifying them reliably has been a challenge, but currently, 
identification is typically based on the amplification of MYCN and expression of KCNA, 
which are common features of group 4 MB tumors (Northcott et al., 2012; Samkari et al., 
2015; Schroeder & Gururangan, 2014; M. D. Taylor et al., 2012). Duplication of 
chromosome 17q and deletion of chromosome 17p also commonly occur in group 4 
tumors, and while these chromosomal events also occur in group 3 tumors, they are more 
common in group 4 tumors and therefore may be of use in classifying group 4 MB tumors 
(Northcott et al., 2012; Samkari et al., 2015; Schroeder & Gururangan, 2014; M. D. Taylor 
et al., 2012). Similarly to group 4 MB tumors, group 3 tumors are also poorly understood 
with regard to the specific aberrations in gene expression that drive them. Approximately 
25% of MB cases are group 3 and one of the key features that differentiate group 4 and 
group 3 MB tumors is that group 3 tumors have a significantly worse prognosis. Five year 
overall survival for patients with group 3 MB tumors is approximately 50% and most cases 
occur in infants. Histologically, group 3 MB tumors are typically classic MB but a 
significant portion of group 3 tumors display the histological features of the LCA variant 
(Samkari et al., 2015; Schroeder & Gururangan, 2014; M. D. Taylor et al., 2012). The 
most common mutation in group 3 tumors is MYC amplification, and additional hallmarks 
of group 3 tumors are amplification of chromosome 1q and deletion of chromosome 16q 
(Samkari et al., 2015; Schroeder & Gururangan, 2014; M. D. Taylor et al., 2012). In 
contrast to group 3 and 4 MB tumors, MB tumors from the WNT and SHH subgroups have 
well-defined genomic and transcriptome features including the presence of gene 
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mutations that clearly drive MB carcinogenesis and progression in these subgroups. 
Approximately 30% of MB cases are of the SHH subgroup, making this subgroup the 
second most common. While SHH MB tumors can occur at all ages, they are far more 
common in infants and adults, and overall 5-year survival stands at approximately 75%. 
Histologically, nearly all desmoplastic MB and MBEN cases are SHH MB tumors but 
classic MB histology is also common, while LCA histology is rare with SHH MB tumors 
(Northcott et al., 2012; Samkari et al., 2015; Schroeder & Gururangan, 2014; M. D. Taylor 
et al., 2012). SHH MB tumors, as the subgroup name suggests, are driven by mutations 
in the SHH pathway including deletion of PTCH1 or SUFU and amplification of SMO or 
GLI2 (Northcott et al., 2012; Samkari et al., 2015; Schroeder & Gururangan, 2014; M. D. 
Taylor et al., 2012). As a group, WNT MB tumors are the rarest with only 10% of MB 
cases belonging to this group. These tumors typically occur in older children and have an 
excellent prognosis with an overall 5-year survival of 95%. Histologically, WNT MB tumors 
are almost always classic MB, but WNT MB tumors are also very rarely the LCA variant. 
WNT MB tumors are easily identified by deletion of chromosome 6 and mutations that 
increase WNT signaling such as amplification of CTNNB1 (Gibson et al., 2010; Northcott 
et al., 2012; Samkari et al., 2015; Schroeder & Gururangan, 2014; M. D. Taylor et al., 
2012). These tumors are clearly driven by increased WNT signaling as disruption of WNT 
signaling in genetic mouse models result in the formation of WNT MB tumors with classic 
morphology (Gibson et al., 2010; Northcott et al., 2012; Samkari et al., 2015; Schroeder 
& Gururangan, 2014; M. D. Taylor et al., 2012). The molecular classification of MB holds 
the promise of developing better personalized treatments for MB patients with regard 
given to molecular subgroup and specific mutations that are driving tumor progression. 
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However, the drivers of carcinogenesis and MB tumor progression in group 3 and 4 
tumors needs to be unraveled before the full benefit of molecular sub-grouping of MB can 
be realized. Emerging treatments based on the molecular classification of MB are 
discussed in more detail in section 1.10.3.1.
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Table 1: Classification of Medulloblastoma 
 Subgroups Incidence 5-year 
Survival 
Key Features 
H
is
to
lo
g
ic
a
l 
Classic 68-80% 73% Neuroblastic rossettes 
Desmoplastic 7% 95% 
(infants) 
Internodular reticulin rich regions 
MBEN 3%  Extensive nodules with neuronal 
differentiation 
LC/A 10-22% 57% Large round nuclei/ Nuclear 
Pleomorphism 
M
o
le
c
u
la
r 
WNT 10% 95% CTNNB1 amplification 
SHH 30% 75% PTCH1/SUFU deletion, SMO/GLI2 
amplification 
Group 3 25% 50% MYC amplication 
Group 4 35% 75% MYCN amplification, KCNA 
expression 
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1.10.2 Medulloblastoma etiology 
 Typically, cancer development is discussed with regard to oncogenes and tumor 
suppressors. Oncogenes are genes whose increased expression drives carcinogenesis 
and tumor progression and are commonly up-regulated during carcinogenesis. In contrast, 
tumor suppressors, as the name suggests, suppress carcinogenesis and tumor 
progression and are commonly down-regulated during carcinogenesis. The regulation of 
oncogenes and tumor suppressors and selection of favorable phenotypes often depends 
on characteristics that have been described as the “hallmarks of cancer” (Hanahan & 
Weinberg, 2000, 2011). These “hallmarks of cancer” include mechanisms that allow the 
tumor to enhance proliferation through autocrine stimulation, evade cell death, maintain 
telomeres, sustain angiogenesis, become insensitive to anti-growth signals, and invade 
surrounding tissues or metastasize. In addition to these six hallmarks of cancer, there are 
two more that may be generalizable enough to be added to list which include the alteration 
of cell metabolism and the evasion of the immune system (Hanahan & Weinberg, 2000, 
2011).  
1.10.2.1 Sonic Hedgehog pathway in Medulloblastoma 
Several pathways have been observed to be up-regulated in human MB and are 
implicated in the development of the disease by affecting these “hallmarks of cancer”. Of 
these, the sonic hedgehog pathway is likely the most notable and well-characterized. The 
SHH pathway is an integral pathway that is best known for its regulation of growth and 
patterning during embryogenesis but remains important in adulthood during which it likely 
regulates adult stem cell populations (Guessous et al., 2008; Ryan & Chiang, 2012). 
Importantly, mutations in the SHH signaling pathway are involved in several human 
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diseases including cancer. Specifically, nevoid basal cell carcinoma syndrome (NBCCS) 
is caused by loss of function mutations in the PTCH1 gene. NBCCS patients have a 
higher incidence of both basal cell carcinomas and medulloblastoma, and this observation 
suggested that the SHH pathway was important in MB carcinogenesis and progression 
(D. G. Evans et al., 1993; Guessous et al., 2008; Lo Muzio, 2008). Activating mutations 
in the SHH pathway which include loss of patched (PTCH) function and gain of 
smoothened (SMO) function among others are the most common group of mutations in 
MB. Approximately 30% of MB exhibit mutations that increase the activity of the SHH 
pathway (Samkari et al., 2015; Schroeder & Gururangan, 2014; M. D. Taylor et al., 2012). 
Additionally, it is known from several studies that the disruption of the SHH pathway in 
genetic mouse models causes MB carcinogenesis with incidences varying depending on 
how the SHH pathway is up-regulated and if additional mutations are present (Briggs et 
al., 2008; Goodrich, Milenkovic, Higgins, & Scott, 1997; Lau et al., 2012; Pazzaglia et al., 
2002; Pazzaglia et al., 2006; Rao et al., 2004; Svard, Rozell, Toftgard, & Teglund, 2009; 
Wetmore, Eberhart, & Curran, 2001; Z. J. Yang et al., 2008). The most notable example 
of a SHH MB model is the first model to generate MB through increased SHH signaling, 
the Ptch1+/- mouse model of MB. This murine model lacks expression of one allele of the 
Ptch1 gene in all tissues and develops MB with an incidence of approximately 10% 
(Goodrich et al., 1997). This seminal study was the first direct evidence that disruption of 
SHH signaling can cause MB and prompted the investigation of SHH pathway inhibitors 
as a potential MB treatment as discussed in section 1.10.3 (Goodrich et al., 1997).  
Additional murine models of MB that are dependent on the activation of the SHH 
pathway have been developed with varying levels of success. Several of these models 
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cross mice that harbor SHH activating mutations with mice that either up-regulate 
oncogenes or knock-out tumor suppressors (Briggs et al., 2008; Rao et al., 2004; Svard 
et al., 2009; Wetmore et al., 2001). One such model is the Ptch1+/- Trp53-/- murine model 
of MB which has 100% incidence of MB. One drawback to this model, however, is that 
Trp53-/- female mice on the C57Bl/6 background die during embryogenesis due to 
overgrowth of the neural tube and subsequent failure of the neural tube to close during 
development (T. Jacks et al., 1994; Wetmore et al., 2001). This limitation results in the 
inability to examine differences in MB tumor growth and progression that arise due to 
gender that may be due to the hormonal milieu. Another murine MB model utilizes the 
floxed system to specifically delete the Ptch1 gene in Atoh1 expressing neural precursors, 
which are mostly cerebellar GCPs. A complementary model utilizes the tamoxifen 
inducible system so that Ptch1 can be knocked out in Atoh1 expressing cells at a 
controlled time-point when it is known that only cerebellar GCPs are expressing Atoh1 (Z. 
J. Yang et al., 2008). Extensive experiments using both of these Atoh1 specific Ptch1 
knock-out mouse models clearly demonstrated that the loss of Ptch1 in cerebellar GCPs 
caused rapid MB formation that resulted in the death of the animal by 8 to 12 weeks of 
age (Z. J. Yang et al., 2008). These experiments were the first to clearly demonstrate 
directly that the cell of origin for MB in this model, and likely the cell of origin for all MB 
mouse models that rely on increased SHH pathway activity, are cerebellar granule cell 
precursors. These studies, therefore, suggested that human MB that harbor SHH 
activating mutations likely arise from GCPs as hypothesized for years based on the 
morphology and location of MB tumors (Gibson et al., 2010; Samkari et al., 2015; 
Schroeder & Gururangan, 2014; M. D. Taylor et al., 2012; Z. J. Yang et al., 2008). While 
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other MB subtypes may also arise from cerebellar GCPs, it is now known that other neural 
precursor populations can give rise to MB and so the exact contribution of cerebellar 
GCPs as the origin cell for MB is unclear (Gibson et al., 2010; Samkari et al., 2015; 
Schroeder & Gururangan, 2014; M. D. Taylor et al., 2012; Z. J. Yang et al., 2008). 
1.10.2.2 The wingless (WNT) pathway in Medulloblastoma 
As indicated in section 1.10.1.2, there is another pathway that has been 
extensively studied due to its role in medulloblastoma. The WNT pathway has been 
implicated in MB development and as stated above, WNT MB tumors form an 
independent subgroup due to their consistent genomic and transcriptome features that 
result in the up-regulation of WNT signaling (Samkari et al., 2015; Schroeder & 
Gururangan, 2014; M. D. Taylor et al., 2012). There is a mouse model that recapitulates 
WNT MB tumors that relies on specific amplification of Ctnnb1 in neuronal precursors of 
the dorsal brainstem combined with loss of Trp53. These mice develop MB tumors after 
approximately 10 months with an incidence of about 15%. Interestingly, examination of 
WNT MB tumors in humans revealed that they infiltrated the dorsal brainstem in contrast 
to the cerebellar location of SHH MB tumors and other MB tumors (Gibson et al., 2010; 
Northcott et al., 2012; Samkari et al., 2015; Schroeder & Gururangan, 2014; M. D. Taylor 
et al., 2012). These results demonstrate that at least WNT MB tumors arise from a 
separate neuronal precursor population that go on to form the dorsal brainstem (Gibson 
et al., 2010; Northcott et al., 2012; Samkari et al., 2015; Schroeder & Gururangan, 2014; 
M. D. Taylor et al., 2012). This is in sharp contrast to the cerebellar GCP origin for SHH 
MB tumors that has been confirmed and the suggestion that other MB tumors may also 
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arise from cerebellar GCPs (Northcott et al., 2012; Samkari et al., 2015; Schroeder & 
Gururangan, 2014; M. D. Taylor et al., 2012; Z. J. Yang et al., 2008). 
1.10.2.3 The insulin-like growth factor pathway and additional regulators of 
Medulloblastoma carcinogenesis and growth  
There are also a couple less-defined pathways that have been implicated in MB 
development including signaling through the IGF pathway, and the function of the 
transcription factors MYC and MYCN (Hatten & Roussel, 2011; Lau et al., 2012; Samkari 
et al., 2015; Schroeder & Gururangan, 2014; M. D. Taylor et al., 2012). The amplification 
of MYC and MYCN are known to be important features of group 3 and group 4 MB tumors, 
respectively, but it is also now clear from mouse models that these amplifications can 
drive MB formation. Amplification of Mycn expression in the developing cerebellum of 
mice can cause MB formation that typically have classic MB histological features but also 
form LCA variant histology. Additionally, amplification of Myc in murine cerebellar GCPs 
with concurrent loss of Trp53 caused the GCPs to form aggressive tumors upon 
transplantation into the cerebella of immunocompromised mice (Lau et al., 2012; Pei et 
al., 2012; Swartling et al., 2010). In both cases, MB formed without concurrent mutations 
in the SHH pathway which demonstrated that amplification of MYCN or MYC can drive 
MB carcinogenesis on their own (Lau et al., 2012; Pei et al., 2012; Swartling et al., 2010).  
The IGF1 pathway has been observed to be up-regulated in human 
medulloblastoma, and this early observation suggested its importance in MB 
development and growth (Ajeawung et al., 2012; Del Valle et al., 2002; Gualco et al., 
2009; Guessous et al., 2008). In fact, amplification of Igf2 can increase the incidence of 
MB in the Ptch1+/- mouse model of MB, suggesting that the IGF1 pathway is an important 
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regulator of MB carcinogenesis, but mutations that increase IGF1 pathway activity are not 
sufficient to cause MB without additional activating mutations in the SHH pathway 
(Guessous et al., 2008; Hatten & Roussel, 2011; Lau et al., 2012; Rao et al., 2004). The 
IGF1 pathway also appears to regulate medulloblastoma progression in addition to being 
important during MB carcinogenesis. Stimulation of the IGF-1 pathway promotes cell 
survival and proliferation in cell lines of MB. Furthermore, small molecule inhibitors of the 
IGF1R have been observed to block MB growth in the Ptch+/- mouse model of MB 
(Ajeawung et al., 2012; Guessous et al., 2008; Hartmann et al., 2005; Ohshima-
Hosoyama, Hosoyama, Nelon, & Keller, 2010; Patti et al., 2000; Urbanska et al., 2007). 
Substantial progress has been made over the years in the understanding of MB 
carcinogenesis and progression. It is now clear that several pathways can independently 
drive MB development and progression including activating mutations in the SHH and 
WNT pathways in addition to the amplification of transcription factor genes such as MYC 
and MYCN. These advancements in the understanding of the etiology of MB suggest that 
specific targeting of these drivers of tumor progression may be beneficial in the treatment 
of MB as discussed in more detail in section 1.10.3.1 (Guessous et al., 2008; Hatten & 
Roussel, 2011; Lau et al., 2012; Northcott et al., 2012; Samkari et al., 2015; Schroeder & 
Gururangan, 2014; M. D. Taylor et al., 2012).  
1.10.3 Current Medulloblastoma treatment 
 The outcomes of MB have gradually improved over the years due to improvements 
in multi-modal treatment that includes surgery, radiation and chemotherapy. These 
improvements were noted in one study in particular that demonstrated that MB patients 
treated from 1992-1999 had an overall 5-year survival rate of 61.5% while those treated 
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from 2000-2009 had an overall 5-year survival rate of 73.6% (Lee et al., 2014). This study 
also noted a benefit of combined chemotherapy using multiple chemotherapeutic agents 
versus single chemotherapeutic agent therapy. This result was similar to earlier studies 
that investigated the benefits of multi-modal therapy utilizing chemotherapy in addition to 
radiation therapy in MB patients and the well-characterized benefit of combined 
chemotherapy in other tumors (Aapro, 2001; Davis & Carbone, 1978; Lee et al., 2014; 
Mueller & Chang, 2009; Packer et al., 1999; R. E. Taylor et al., 2003). These studies have 
established the standard of care for MB which includes surgical resection of tumor, 
followed by irradiation of the craniospinal axis and combination chemotherapy (De 
Braganca & Packer, 2013; Martin, Raabe, Eberhart, & Cohen, 2014; Mueller & Chang, 
2009).   
 Surgery is the first step of MB treatment in the current standard of care. Complete 
resection of the tumor is preferable and is typically achieved unless the tumor is infiltrating 
surrounding tissue (De Braganca & Packer, 2013; Lee et al., 2014; Martin et al., 2014). 
Achieving complete resection is important because patients with complete or near 
complete resection have better outcomes compared to those with significant tumor mass 
left behind (De Braganca & Packer, 2013; Lee et al., 2014; Martin et al., 2014). Following 
surgical recovery, radiation therapy is administered over the course of several days. The 
entire craniospinal axis is irradiated, as this type of treatment improves outcomes 
regardless of the extent of the disease at time of diagnosis. Even though the entire 
craniospinal axis is irradiated, the primary tumor site receives additional irradiation in 
order to obtain the best outcomes (De Braganca & Packer, 2013; Martin et al., 2014). 
Since radiation therapy causes significant side effects in survivors, there have been 
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attempts to decrease the dose of radiation given. Whenever radiation dose has been 
decreased, outcomes have gotten worse unless chemotherapy is added to the treatment 
regimen (De Braganca & Packer, 2013; Lee et al., 2014; Martin et al., 2014; Mueller & 
Chang, 2009). This has prompted the inclusion of chemotherapy into the standard of care 
for MB. Chemotherapy treatment regimens for MB vary but typically include some 
combination of vincristine, cisplatin, lomustine and cyclophosphamide. One common 
chemotherapy treatment regimen for MB includes vincristine during and after radiation 
therapy, followed by combination chemotherapy that is administered every 4 to 6 weeks 
and alternates between cisplatin-lomustine-vincristine and cyclophosphamide-vincristine 
combination treatments (De Braganca & Packer, 2013; Martin et al., 2014; Mueller & 
Chang, 2009). As stated above, it is clear that improvements in MB treatments ranging 
from better surgical resection, to the inclusion of complete craniospinal axis irradiation 
and to the inclusion of chemotherapy have improved outcomes for MB patients. However, 
improvements are still needed in MB management, especially with regard to the reduction 
of life-long side-effects (Frange et al., 2009; Hoang et al., 2014; Lee et al., 2014; Mueller 
& Chang, 2009; Mulhern et al., 2005; Uday et al., 2015).  
1.10.3.1 Emerging Medulloblastoma treatments 
 The current standard of care includes radiation therapy and chemotherapy which 
are known to induce life-long neurocognitive and endocrine side effects (Frange et al., 
2009; Hoang et al., 2014; Mulhern et al., 2005; Uday et al., 2015). These side effects can 
include neurocognitive deficits such as impairments of attention, memory, executive 
function and intelligence quotient scores. Endocrine side effects are also common due in 
part to a disruption of hypothalamic-pituitary function and commonly include growth 
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hormone deficiency, hypothyroidism, and adrenocorticotrophic hormone deficiency 
(Hoang et al., 2014; Uday et al., 2015). Due to the high incidence and debilitating nature 
of these side-effects, the development of adjuvant MB treatments that would allow 
decreased doses of the side-effect inducing radiation treatments are being actively 
pursued. As stated above, the molecular classification of MB holds the promise of 
allowing the development of targeted therapies based on what signaling pathways are 
driving the disease (Samkari et al., 2015; Schroeder & Gururangan, 2014; M. D. Taylor 
et al., 2012).  
 Several pre-clinical studies have demonstrated that inhibition of SHH pathway 
activity, typically through the inhibition of SMO, inhibits MB growth both in vitro and in vivo 
(Berman et al., 2002; J. Kim et al., 2010; Robarge et al., 2009; Rohner et al., 2012; 
Samkari et al., 2015; Taipale et al., 2000; M. D. Taylor et al., 2012). This result should not 
be surprising given the fact that activation of the SHH pathway clearly drives MB formation 
and progression as evidenced by the increased incidence of MB in NBCCS patients and 
the fact that up-regulation of SHH pathway activity is utilized in murine genetic models to 
induce MB formation (D. G. Evans et al., 1993; Goodrich et al., 1997; Guessous et al., 
2008; Lau et al., 2012; Lo Muzio, 2008; Z. J. Yang et al., 2008). Due to the clear 
implication of SHH signaling in MB carcinogenesis and progression and the effectiveness 
of SMO inhibition in pre-clinical trials, the use of SMO inhibitors in human MB has been 
pursued in clinical trials. A proof of concept case study has been presented in which a 
MB patient had a substantial, although transient, response to treatment with the SMO 
inhibitor vismodegib (Rudin et al., 2009; Samkari et al., 2015; M. D. Taylor et al., 2012). 
This encouraging result has prompted the further study of SHH pathway inhibition as an 
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adjuvant treatment in MB and clinical trials are currently ongoing (Rudin et al., 2009; 
Samkari et al., 2015; M. D. Taylor et al., 2012).  
The WNT subgroup of MB is clearly driven by an up-regulation of WNT signaling 
and therefore may be effectively treated through the specific targeting of the WNT 
pathway. While no human studies have been conducted, there is evidence from a pre-
clinical study that inhibition of the WNT pathway can impair the growth of MB cells both 
in vitro and in vivo (Cimmino et al., 2012; Samkari et al., 2015; M. D. Taylor et al., 2012). 
Group 3 and group 4 MB tumors do not have clear mechanisms that are driving 
carcinogenesis and progression in contrast to the WNT and SHH MB tumors. Therefore, 
the development of specific treatments for these molecular subgroups is more challenging. 
However, one promising area is the regulation of MYC and MYCN which are common in 
group 3 and group 4 MB tumors and have been demonstrated to drive MB carcinogenesis 
in murine models (Lau et al., 2012; Pei et al., 2012; Samkari et al., 2015; Schroeder & 
Gururangan, 2014; Swartling et al., 2010; M. D. Taylor et al., 2012). The potential 
effectiveness of MYC gene inhibition in group 3 MB treatment was demonstrated by the 
effectiveness of pemetrexed and gemcitabine combination treatment. This combination 
inhibited the growth of MYC amplified group 3 MB tumors both in vitro and in vivo, but did 
not affect the growth of SHH MB tumors. This suggested that MYC amplification may 
sensitize group 3 tumors to the effects of pemetrexed and gemcitabine (Morfouace et al., 
2014; Samkari et al., 2015; M. D. Taylor et al., 2012).  
All of these studies make it clear that MB can be treated based on molecular 
subgroup through the utilization of specific inhibitors that target the pathways that are 
driving progression in the individual subgroups. Further research is needed, however, not 
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only to determine the molecular drivers of tumor progression in group 3 and 4 MB tumors 
but also to determine the effectiveness of these targeted treatments in humans. Once 
effectiveness of these targeted therapies is proven, it may be possible to reduce the doses 
used in radiation therapy in the current standard of care in order to maintain disease 
management but reduce the debilitating life-long side-effects (Hoang et al., 2014; Samkari 
et al., 2015; Schroeder & Gururangan, 2014; M. D. Taylor et al., 2012; Uday et al., 2015). 
Lastly, another emerging treatment for MB may be the inhibition of ERβ which may be 
effective in treating all ERβ-positive MB tumors as discussed in the following sections and 
helps build the rationale for the studies presented in chapters 3 through 6 (Belcher, 2009; 
S. M. Belcher et al., 2009; Hatten & Roussel, 2011).  
1.10.4 Expression of ERs in medulloblastoma 
 The discovery that MB expressed ERβ actually began with studies in cerebellar 
GCPs. It was demonstrated that cerebellar GCPs expressed ERβ at the mRNA and 
protein level and that this expression was developmentally regulated (Belcher, 1999; 
Jakab et al., 2001). In addition to expressing ERβ, cerebellar GCPs were demonstrated 
to respond to physiological concentrations of 17β-E2 and various environmental 
estrogens with significant activity at ERβ. Activation of ERβ in cerebellar GCPs was 
observed to rapidly activate the ERK signaling pathway. Additionally, chronic treatment 
of cerebellar GCPs with 17β-E2 caused decreased mitotic activity and increased survival 
(Belcher, 2008; Belcher et al., 2005; H. H. Le & Belcher, 2010; J. K. Wong et al., 2003; 
Zsarnovszky et al., 2005). 
 At the time of these studies, it was believed that MB developed from cerebellar 
GCPs that escaped terminal differentiation. This idea was initially hypothesized due to 
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the location and cellular morphology of MB tumors and was supported by the crucial 
involvement of the SHH pathway, both in developing cerebellar GCPs and MB tumors 
(Goodrich et al., 1997; Hatten & Roussel, 2011; Wechsler-Reya & Scott, 2001). Due to 
the likelihood that MB developed from cerebellar GCPs and the observed estrogen 
responsiveness in cerebellar GCPs, it was hypothesized that MB may express ERβ and 
be responsive to estrogen treatment. Initial studies characterized the expression of both 
ERα and ERβ in both human MB and human MB cell lines. It was observed that all human 
MB samples expressed ERβ while many did not express ERα and those MB tumors that 
did express ERα expressed it to a lesser extent than ERβ. As for the human MB cell lines, 
both the D283Med and DAOY cell lines of MB expressed high levels of ERβ and very low 
levels of ERα (S. M. Belcher et al., 2009; Kirby, Zsarnovszky, & Belcher, 2004). Similarly, 
the PNET cell line, PFSK1, also expressed high levels of ERβ and virtually no ERα protein, 
suggesting that high ERβ expression may be characteristic of PNETs in general rather 
than MB tumors alone (S. M. Belcher et al., 2009; Kirby, Zsarnovszky, & Belcher, 2004). 
The high protein expression of ERβ, along with the fact that ERβ was expressed in every 
human MB sample and cell line examined, opened up the possibility that ERβ activation 
may affect MB tumor growth and progression. 
1.10.5 Effect of 17β-E2 in medulloblastoma 
 Due to the observation that ERβ was expressed in MB, the effect of estrogen 
treatment in MB was investigated. The D283Med cell line, which is a human MB cell line, 
was utilized to determine if 17β-E2 affected MB cell proliferation. It was observed that 
17β-E2 increased viable cell counts in a concentration-dependent manner. Additionally, 
17β-E2 increased BrdU incorporation, suggesting that the observed changes in viable 
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cell counts were due to increased proliferation (S. M. Belcher et al., 2009; Kirby et al., 
2004). The effects of 17β-E2 were blocked by co-treatment with the non-selective ER 
antagonist, fulvestrant, suggesting that 17β-E2 effects were mediated by an ER. Similar 
results were observed utilizing the ERβ-selective agonist, DPN, while the ERα-selective 
agonist, PPT, had no effect (S. M. Belcher et al., 2009; Kirby et al., 2004). Migration of 
the D283Med and DAOY MB cell lines and the PFSK1 PNET cell line was increased by 
17β-E2 in a concentration-dependent manner and this effect of 17β-E2 was also blocked 
by co-treatment with fulvestrant (S. M. Belcher et al., 2009; Kirby et al., 2004). To 
determine if 17β-E2 also affected MB tumor growth in vivo, a D283Med xenograft model 
was utilized. It was observed that fulvestrant treatment inhibited D283Med xenograft 
growth in intact males and females, while 17β-E2 treatment increased MB tumor growth 
in gonadectomized males and females (S. M. Belcher et al., 2009; Kirby et al., 2004). The 
effect of 17β-E2 could be blocked by co-treatment with fulvestrant, suggesting that 17β-
E2 affected MB tumor growth through the activation of an ER. Lastly, MB tumor growth 
was increased in intact males versus females and it was hypothesized that this may be 
due to intratumor conversion of testosterone to 17β-E2 by aromatase (S. M. Belcher et 
al., 2009; Kirby et al., 2004). These studies established MB as an estrogen-responsive 
tumor and have prompted further investigation into the mechanism of estrogen action in 
MB, the results of which are presented in chapters 3 through 6.  
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1.11 Rationale, Hypothesis and Goals 
1.11.1 Overall Rationale 
 The current body of literature regarding the role of ERβ in cancer is unclear. 
Although far from confirmed, it has been suggested that ERβ may promote tumor growth 
and progression, but only in the absence of ERα expression, as discussed in section 1.8. 
Therefore, the identification of MB as an ERβ-positive, ERα-negative estrogen-
responsive tumor represents an excellent opportunity to investigate the role of ERβ in 
cancer and lend support to the notion that ERβ can promote tumor growth and 
progression in the absence of ERα expression. To this end, the role of ERβ in MB was 
investigated thoroughly through the use of both in vitro and in vivo models. Furthermore, 
the extensive body of literature regarding the effect of 17β-E2 on pro-survival signaling 
(discussed briefly in sections 1.6 and 1.7), and in particular the effect of 17β-E2 on the 
viability of cerebellar GCPs, which give rise to MB, suggested that ERβ may impact MB 
growth by affecting tumor survival. Therefore, the effect of ERβ activation on tumor 
survival was examined in both in vitro and in vivo models. The studies presented here 
were also guided by potential clinical significance as it is well-established that anti-
estrogen therapies are effective in ERα-driven cancer such as breast cancer (discussed 
briefly in section 1.8). Therefore, the determination of the mechanism of estrogen action 
in MB may allow the development of targeted adjuvant therapies for MB. To this end, the 
efficacy of fulvestrant treatment in a murine pre-clinical model of MB was evaluated. 
Lastly, due to the success of multi-modal therapies in MB and other cancers (discussed 
in section 1.10.3), the effect of estrogen blockade treatment on the sensitivity of MB cells 
to chemotherapeutic compounds that are currently used in the MB standard of care was 
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evaluated. These studies would inform on the potential efficacy of ERβ blockade as an 
adjuvant treatment in MB.  
1.11.2 Hypothesis 
Activation of ERβ promotes increased MB tumor growth and resistance to 
chemotherapy through pro-survival up-regulation of the IGF1 signaling pathway. 
1.11.3 Specific Goals 
The first goal of these studies was to determine the effect of estrogen signaling on 
the survival of MB cells. The investigation of the effect of estrogen signaling on MB cell 
death was prompted by several facts. First, there is a large body of literature (discussed 
in sections 1.6, 1.7 and 1.8) which demonstrates that 17β-E2 affects cell survival in a 
wide variety of tissues and cells, including cancer. Second, the viability of cerebellar 
GCPs, which give rise to MB, is increased by 17β-E2 treatment. Third, it had previously 
been demonstrated that MB growth was estrogen-responsive in vivo. Since tumor growth 
is largely determined by the balance between proliferation and cell death, and the effect 
of 17β-E2 on MB proliferation in vitro had already been evaluated, it was of interest to 
investigate the potential involvement of cell death regulation by 17β-E2 in the 17β-E2-
mediated growth of MB. Lastly, these studies were also performed to determine the 
potential of ER inhibition as an adjuvant treatment in MB since the goal of adjuvant 
treatments is to decrease proliferation, increase cell death and/or sensitize tumors to 
treatments currently used in the standard of care in order to improve outcomes. 
The second goal of these studies was to determine the role of ERβ in mediating 
the pro-survival effect of estrogen in MB. The rationale for investigating the role of ERβ 
in MB is largely based on the observation that ERβ is the dominant ER expressed in MB. 
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Additional evidence for the potential involvement of ERβ is based on the results from 
cerebellar GCPs, that predominantly express ERβ and whose viability is increased by 
17β-E2. It was of particular interest to investigate the role of ERβ in MB in order to help 
determine what the role of ERβ is in cancer since it is currently unclear based on the 
current body of literature, as discussed in section 1.8. Lastly, the determination of the role 
of ERβ in MB could also have important clinical implications that may inform on the 
potential efficacy of ERβ inhibition as an adjuvant treatment in MB.   
The final goal of these studies was to determine what mechanisms were 
responsible for the pro-survival effect of 17β-E2 in MB downstream of ERβ activation. 
This was of interest because pro-survival signaling by ERβ is not particularly well-
characterized. The majority of research into the pro-survival effects of 17β-E2 either does 
not investigate which ER is responsible or often attributes effects to ERα activation. 
Therefore, it was unclear how ERβ may affect survival in MB, and in order to better 
understand the role of ERβ in cancer, the mechanisms responsible for its effect on MB 
survival needed to be determined.  
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Chapter 2 
Materials and Methods 
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2.1 Steroids and Pharmacological Agents 
 Dimethylsulfoxide (DMSO), 17α-estradiol (17α-E2), 17β-estradiol (17β-E2), 4-
hydroxytamoxifen (4-OHT) and methylthiazolyldiphenyl-tetrazolium bromide (MTT) were 
from Sigma-Aldrich (St. Louis, MO). Fulvestrant (ICI 182, 780; Faslodex®), 4,4',4''-(4-
Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT), 2,3-bis(4-Hydroxyphenyl)-propionitrile 
(DPN), G-1, 4-[2-Phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol 
(PHTPP), 1,3-Bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-
pyrazole dihydrochloride (MPP) and LY294002 were from Tocris Bioscience (R&D 
Systems, Inc., Minneapolis, MN). U0126 was from Promega (Madison, WI), wortmannin 
was from Calbiochem (San Diego, CA) and NVP-AEW541 was from Cayman Chemical 
(Ann Arbor, MI). Cisplatin, vincristine and lomustine were from Selleck Chemical (Houston, 
TX).  
2.2 Cell Culture Conditions 
 The D283Med cell line, which was established from the peritoneal implant and 
ascetic fluid of a 5 year old boy with metastatic medulloblastoma, was acquired from the 
American Type Culture Collection and propagated in minimum essential media (MEM) 
with Earle’s Balanced Salt Solution (EBSS) (Thermo Fisher Scientific, Waltham, MA) 
(Friedman et al., 1985). Media was supplemented with 10% fetal bovine serum (FBS), 
100 U/ml penicillin (Thermo Fisher Scientific, Waltham, MA) and 100 μg/ml streptomycin 
(Thermo Fisher Scientific, Waltham, MA) and had a final L-glutamine concentration of 4 
mM (Thermo Fisher Scientific, Waltham, MA). Media was renewed every two to four days 
and cells were passaged when a density of 1 x 106 cells/mL was observed. To passage 
cells, viable cell numbers were first determined by counting trypan blue (0.04%, Invitrogen 
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Inc., Carlsbad, CA) excluding cells using a Neubauer hemocytometer and light 
microscopy. Then, the cell suspension was centrifuged at 1120 x g until the cells had 
formed a pellet (approximately one minute), and the supernatant was aspirated. The cell 
pellet was then resuspended in fresh 37⁰C MEM with EBSS at a density of 5 x 105 
cells/mL and transferred to a sterile tissue culture flask with 0.2 micron filter cap. The 
PFSK1 cell line, which was established from a PNET in the cerebral hemisphere of a 22 
month old boy, was acquired from the American Type Culture Collection and propagated 
in RPMI 1640 media (Thermo Fisher Scientific, Waltham, MA) (Fults, Pedone, Morse, 
Rose, & McKay, 1992). Media was supplemented with 10% FBS, 100 U/ml penicillin and 
100 μg/ml streptomycin. PFSK1 cells were maintained at a confluence of 20% to 80% 
with media renewal every 2 to 3 days. Cells were passaged by detaching the cells with 
0.05% trypsin and 0.53 mM ethylenediaminetetraacetic acid (EDTA) in Hank’s buffered 
salt solution with sodium bicarbonate but without calcium or magnesium (Mediatech, Inc., 
Manassas VA). Trypsin was inactivated by adding 10% FBS to the solution, then the cells 
were diluted appropriately in fresh RPMI 1640 media and pipetted into a fresh tissue 
culture flask to obtain a confluence of approximately 20%. Both cell lines were acquired 
from the American Type Culture Collection (ATCC, Manassas VA) and cells used for 
experiments were passaged no more than twenty times after being received from the 
ATCC. 
2.3 Treatment of PNET cell lines 
2.3.1 Analysis of viability and proliferation 
 D283Med cells were counted as described above and then seeded in 6-well or 96-
well tissue culture plates at a density of 1.25 x 105 cells/mL in MEM/EBSS without L-
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glutamine supplemented with 10% charcoal stripped serum (CSS), 100 U/ml penicillin 
and 100 μg/ml streptomycin. To prepare CSS, 2 g of activated charcoal (Fisher Scientific, 
Pittsburg, PA) was added per 100 mL of FBS and was stirred for 2 hours at 4⁰C, the 
charcoal was then cleared by centrifugation at 3220 x g and the supernatant (CSS) was 
removed. Similarly, PFSK1 cells were seeded at a density of 10000 cells per well in a 6-
well plate in 5.4 mL of L-glutamine free RPMI 1649 media supplemented with 10% CSS, 
100 U/mL penicillin and 100 μg/mL streptomycin. Stocks of the drugs were prepared in 
cell culture media and then diluted 1/10 in the wells of the 6-well or 96-well plates to obtain 
the desired final drug concentration. In inhibitor studies, the cells were pre-treated with 
the inhibitor for 30 minutes before agonist exposure began. The vehicle for all drugs was 
DMSO and the final concentration of DMSO was 0.01%. Cell viability was determined by 
counting viable cells as described below and proliferation was assessed by 
bromodeoxyuridine incorporation after 24, 48, 72, and 96 hours of drug exposure. 
2.3.2 Analysis of caspase-3 activity 
 D283Med cells were seeded in 96-well tissue culture microplates at a density of 1 
x 106 cells/mL in 270 µL of MEM/EBSS without L-glutamine supplemented with 10% CSS, 
100 U/mL penicillin and 100 μg/mL streptomycin. Similarly, PFSK1 cells were seeded at 
a density of 10000 cells per well in a 6-well plate in 5.4 mL of L-glutamine free RPMI 1649 
media supplemented with 10% CSS, 100 U/mL penicillin and 100 μg/mL streptomycin. 
Stocks of drugs were prepared in cell culture media so that a 1/10 dilution could then be 
performed in the wells of the 96-well or 6-well microplates to obtain the desired final drug 
concentration. In inhibitor studies, the cells were pre-treated with the inhibitor for 30 
minutes before agonist exposure began. The vehicle for all drugs was DMSO and the 
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final concentration of DMSO was 0.01%. Following 48 hours of drug exposure, the 
D283Med cell suspensions were transferred to microcentrifuge tubes and the PFSK1 
cells were detached as described above with trypsin/EDTA and also transferred to 
microcentrifuge tubes. The cells were then centrifuged at 9300 x g for one minute to pellet 
the cells and the supernatant was removed by aspiration. The cell pellet was resuspended 
in lysis buffer [20 mM Tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl; 
Promega, Madison, WI), 150 mM sodium chloride (NaCl; Fisher Scientific, Pittsburg, PA), 
1 mM EDTA (Fisher Scientific, Pittsburg, PA), 1 mM Ethylene glycol-bis(2-
aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA; Fisher Scientific, Pittsburg, PA), 1% 
Triton (Bio-Rad, Hercules, CA), pH 7.5]. The cell lysates were cleared by centrifugation 
at 9300 x g for 1 minute and then immediately assayed for total protein concentration 
using a modified Lowry assay (DC protein assay; Bio-Rad, Hercules, CA). Caspase-3 
activity of the cell lysates was then determined as described below.  
2.4 Proliferation and viability studies 
2.4.1 Viable cell counts 
 Viability of D283Med cells exposed to drugs for 24, 48, 72, and 96 hours was 
determined by counting viable cells. D283Med cells grow in suspension and adhere to 
each other, therefore, to get accurate viable cell counts the groups of cells are dissociated 
by gentle trituration using a sterile serological pipette. If several clumps of cells are still 
present, then the dissociation procedure is repeated. The dissociated cell suspension is 
then mixed in a 1:1 ratio with 0.04% trypan blue and pipetted into a hemocytometer 
chamber. Viable cell numbers are determined by counting trypan blue excluding cells 
under a light microscope. Each drug exposure was represented by at least 3 wells. Viable 
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cell counts were also obtained for PFSK1 following treatment for 96 hours. To count 
PFSK1 cells, the media was aspirated and the cells were detached as described above 
with a trypsin/EDTA solution. The PFSK1 cells were then mixed 1:1 with 0.04% trypan 
blue as described above and counted using a hemocytometer. 
2.4.2 Caspase-3 activity assay 
 Following treatment, cell lysis, and total protein quantification as described above, 
cell lysates were diluted to a concentration of 1 µg/µL. The 2x buffer solution for the 
caspase-3 assay was composed of 200 mM 4-(2-Hydroxyethyl)piperazine-1-
ethanesulfonic acid, N-(2-Hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) (HEPES; 
Fisher Scientific, Pittsburg, PA), 1 mM EDTA, and 40% glycerol (Fisher Scientific, 
Pittsburg, PA) with 2-mercaptoethanol (Bio-Rad, Hercules, CA) added right before use to 
a concentration of 100 mM to make the complete 2x buffer solution. The 10 mM stock N-
Acetyl-Asp-Glu-Val-Asp p-nitroanilide (Ac-DEVD-pNA; Cayman Chemical, Ann Arbor, MI) 
solution was diluted 1 to 40 in water immediately before use. The reactions were set up 
in a 96-well microplate by adding 10 µL of 1 µg/µL protein lysate, then 50 µL of the 
complete 2x buffer solution followed by addition of 40 µL of 0.25 mM Ac-DEVD-pNA 
solution to give a final volume of 100 µL per well. The final concentrations in the reaction 
mixture are 100 mM HEPES, 0.5 mM EDTA, 20% glycerol, 50 mM 2-mercaptoethanol, 
and 0.1 mM Ac-DEVD-pNA. After a 48 hour incubation in a humidified 37⁰C incubator, 
the 4-nitroaniline (pNA; Acros Organics, Beel, Belgium) standards were prepared and 
added to the plate. The 100 mM pNA DMSO stock was serially diluted in DMSO to make 
4, 3, 2, 1, 0.4, and 0.2 mM dilutions. Each of these dilutions were further diluted by adding 
5 µL of the appropriate dilution to 95 µL of 1x caspase-3 assay buffer to make the 200, 
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150, 100, 50, 20, and 10 µM pNA standards on the 96-well microplate. The absorbance 
of all experimental samples and pNA standards at 405 nm was then measured using a 
multifunctional plate reader (TECAN Spectra Fluor Plus, Tecan Systems, Inc., San Jose, 
CA). The amount of pNA released by cleavage of the caspase-3 substrate Ac-DEVD-pNA 
was then determined by interpolating the pNA concentrations in the experimental samples 
using the pNA standard curve. Each drug exposure was represented by at least 6 
biological replicates and each protein lysate was assayed for caspase-3 activity using the 
average of three replicates. 
2.4.3 Bromodeoxyuridine Incorporation Assay 
 Incorporation of bromodeoxyuridine (BrdU) into the DNA of proliferating D283Med 
cells was assessed as an indicator of proliferation through the use of a BrdU labeling and 
detection kit III (Roche, Nutley, NJ). The assay was performed according to the 
manufacturer’s instructions after 24, 48, 72, or 96 hours of treatment as described above. 
Following treatment, the BrdU labeling solution was added to each well so that the final 
concentration of BrdU was 10 µM and the cells were then cultured in a 37⁰C 5% CO2 
humidified incubator for 18 hours. Following incubation with the BrdU labeling solution, 
the 96-well plate was centrifuged for 10 minutes at 3220 x g and the media was carefully 
aspirated to ensure no cells were lost. The plate was then dried at 60⁰C for 2 hours and 
the cells were subsequently fixed in -20⁰C 0.5 M HCl (Fisher Scientific, Pittsburg, PA) in 
70% ethanol (Fisher Scientific, Pittsburg, PA) for 30 minutes at -20⁰C. After fixation, the 
cells were washed three times with 200 µL of MEM/EBSS containing 10% CSS followed 
by the addition of 100 µL of the nuclease solution. The plate was incubated at 37⁰C for 
30 minutes, then the nuclease solution was aspirated and the wells were washed three 
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times with 200 µL of MEM/EBSS containing 10% CSS. After the washes, 100 µL of anti-
BrdU-POD Fab fragment solution was added to each well and the plate was incubated at 
37⁰C for 30 minutes. Following aspiration of the Fab fragment solution, the wells were 
washed three times with 200 µL of the supplied washing buffer followed by the addition 
of 100 µL of the peroxidase substrate solution to each well. Once a discernable green 
color had developed in the wells, the absorbance was measured at a wavelength of 405 
nm for each well using a multifuctional microplate reader (TECAN Spectra Fluor Plus, 
Tecan Systems, Inc., San Jose, CA) with a reference wavelength 490 nm. 
2.4.4 MTT Assay  
D283Med cells were seeded in a 24-well tissue culture plate in 1 mL of 10% CSS 
supplemented phenol red free MEM/EBSS at a density of 0.5 x 106 cells/mL. Media was 
supplemented with the desired concentration of 17β-E2 or the vehicle control (0.01% 
DMSO) prior to suspending the cells in the media. The cells were then cultured in a 37⁰C 
5% CO2 humidified incubator for 24 hours prior to cisplatin treatment. Following 96 hours 
of treatment with the chemotherapeutic agent, 100 µL of 5 mg/mL MTT was added to 
each well and the cells were allowed to incubate at 37⁰C for 4 hours. After removing the 
media, the formazan product was solubilized using 0.1 N HCl in absolute isopropanol 
(Fisher Scientific, Pittsburg, PA) and the absorbance was read at a wavelength of 570 
nm. Relative MTT viability was determined by normalizing the absorbance readings to the 
vehicle control (van Meerloo, Kaspers, & Cloos, 2011). 
 
 
 
88 
 
2.4.5 Clonogenic Assay 
 Clonogenic assays were performed to assess chemosensitivity in MB and PNET 
cells as described previously (Guda, Natale, & Markowitz, 2007; Sumantran, 2011). For 
clonogenic assays, D283Med cells were triturated with a sterile serological pipette and 
then filtered through a 40 µm cell strainer to ensure that only single cells and not clumps 
of cells would be plated. The adherent PFSK1 cells were detached as described above 
and triturated with a sterile serological pipette to ensure a single cell suspension prior to 
counting and plating. Viable cell numbers were determined by combining 10 µL of cell 
suspension with 10 µL of 0.04% trypan blue, loading the mixture into a hemocytometer 
chamber and counting trypan blue excluding cells under a light microscope. Since 
D283Med cells grow in suspension, the 6-well cell culture plates were coated with poly-
L-lysine (PLL; Sigma Aldrich, St. Louis, MO) so the D283Med cells would attach and form 
colonies. The PLL coating was applied by adding 1 mL of 0.1 mg/mL PLL in water to each 
well, rocking the plate gently for 5 minutes to ensure even coating of the culture surface, 
aspirating the PLL solution out of the wells and then rinsing the wells with 3 mL of sterile 
water 2x. The plates were then allowed to dry for 2 or more hours before plating cells. 
Plates to be used for the adherent PFSK1 cells were not coated with PLL. Once the plates 
were prepared and the viable cell numbers had been determined, the cell suspension 
was diluted appropriately in the appropriate media supplemented with 10% CSS, 100 
U/ml penicillin, 100 μg/ml streptomycin, and 4 mM L-glutamine so the cell concentration 
was 500 cells/mL. For 17β-E2, Fulvestrant (Ful), Ful/17β-E2, DPN, PPT, PHTPP, and 
PHTPP/17β-E2 exposure groups, the compound was diluted to the final desired 
concentration in the cell culture media prior to diluting the cells in the media. The diluted 
89 
 
cell suspension was then added to each well to a volume of 2 mL in order to have 1000 
cells per well. The D283Med or PFSK1 cells were then cultured in a humidified 37⁰C 5% 
CO2 incubator; after 24 hours of treatment with vehicle (0.01% DMSO), 17β-E2, Ful, 
Ful/17β-E2, DPN, PPT PHTPP, or PHTPP/17β-E2 the cells were exposed to cisplatin, 
vincristine, or lomustine. Cisplatin was dissolved in DMSO for all experiments, a solvent 
that is known to affect the potency of cisplatin in cell culture applications. Since the effect 
of DMSO on cisplatin potency varies based on cell line, the effect of DMSO on cisplatin 
potency in D283Med cells was assessed as detailed in Figure 5 (Hall et al., 2014). The 
results from this control experiment demonstrate that DMSO reduces the potency of 
cisplatin by approximately 25-fold, suggesting that the concentrations of cisplatin used in 
the presented studies are likely 25-fold higher than what would be observed if water had 
been used as the solvent. The chemotherapeutic drugs were diluted in cell culture media 
to a 5x concentration and then 0.5 mL were added to each well so that the final volume 
was 2.5 mL in order to obtain the desired final concentration. Following a 6 hour exposure 
to cisplatin or a 24 hour exposure to vincristine or lomustine, the cell culture media was 
aspirated, wells were rinsed 2x with fresh cell culture media and then 2.5 mL of cell culture 
media was added to each well. Cells were then allowed to grow and form colonies in a 
humidified 37⁰C 5% CO2 incubator and the media was renewed every 2 to 3 days. Once 
several colonies of 50 or more cells were observed, the colonies were visualized and 
counted. To visualize the colonies, the cell culture media was aspirated and the cells were 
stained by adding approximately 2 mL of 1% methylene blue (Fisher Scientific, Pittsburg, 
PA) in 50% ethanol. The cells were incubated while gently rocking for 5 minutes in the 1% 
methylene blue solution. The methylene blue solution was then aspirated and the cells 
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were rinsed with tap water several times until the water ran clear. An alternate method of 
colony visualization was also utilized at times in which the cell culture media was 
aspirated and the cells were fixed with 5 mL of methanol (Fisher Scientific, Pittsburg, PA) 
per well for 5 minutes. After aspirating the methanol, 5 mL of 0.1% coomassie brilliant 
blue (Bio-Rad, Hercules, CA) in methanol was added to each well and the plates were 
gently rocked for 1 hour to stain the colonies. The 0.1% coomassie brilliant blue solution 
was aspirated and the wells were rinsed with water 2x before counting the stained 
colonies. Following staining, the 6-well plates were imaged using the Alpha Innotech 
FluorChem FC2 imager (ProteinSimple, Santa Clara, CA). Images were then analyzed 
and colonies were counted using Adobe Photoshop CS8 (Adobe Systems Inc., San Jose, 
CA). In order to calculate the surviving fraction, the plating efficiency of D283Med and 
PFSK1 cells was first calculated (Figure 6). The plating efficiency is calculated by dividing 
the number of colonies formed by the number of cells plated and was observed to be 
approximately 10% for the D283Med cell line and 1.5% for the PFSK1 cell line. The plating 
efficiency for the PFSK1 cell line was based on preliminary data that was not replicated. 
The plating efficiency was assumed to be a constant and was not assessed every time 
an experiment was performed. All drug exposures are represented by 4 or more biological 
replicates.   
91 
 
 
Figure 5 
The effect of solvents on the cytotoxic potency of cisplatin in D283Med cells. MTT 
viability of D283Med cells following treatment with increasing concentrations of cisplatin 
from stocks of cisplatin prepared in either water or DMSO. (n=4 per data point) 
 
 
 
Figure 6 
The plating efficiency of D283Med and PFSK1 cells in a colony forming assay. 
Number of colonies formed after plating 1000 cells of both of the D283Med and PFSK1 
cell lines in a colony forming assay with no treatment (n=2). Plating efficiency was 
calculated based on these results by dividing the number of colonies formed by the 
number of cells plated. 
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2.5 mRNA expression studies 
2.5.1 mRNA isolation and purification 
 D283Med cells were counted and treated as described above for the proliferation 
and viability studies. Cells were cultured in a humidified 37⁰C 5% CO2 during the 48 hour 
exposure period. After the 48 hour drug exposure period, the cell suspensions were 
transferred to RNase/DNase free 0.5 mL microcentrifuge tubes and centrifuged at 9300 
x g for 1 minute to pellet the cells. The supernatant was removed by aspiration and the 
cell pellet was rapidly frozen in liquid nitrogen and then stored in a -80⁰C freezer. RNA 
isolation was then performed using the RNeasy kit (Qiagen, Valencia, CA) according the 
manufacturer’s protocols. The cells were lysed in 350 µL of buffer RLT and then 
centrifuged at 9300 x g for 3 minutes. The supernatant was then removed and placed in 
a new RNase/DNase free 1.5 mL microcentrifuge tube and 350 µL of 70% ethanol was 
added. This mixture was added to a RNeasy spin column with supplied collection tube 
and centrifuged at 9300 x g for 15 seconds, the flow through was then discarded. The 
column was then rinsed by adding 700 µL of buffer RW1, centrifuging at 9300 x g for 15 
seconds, and discarding the flow through. The column was also rinsed 2x with 500 µL of 
buffer RPE using the same procedure. The RNA was then eluted by adding 50 µL RNase 
free water to the column, centrifuging at 9300 x g for 1 minute and collecting the flow-
through in a new RNase/DNase free 1.5 mL microcentrifuge tube. The concentration and 
purity of the isolated RNA was then determined by measuring the absorbance of the 
sample at 230, 260 and 280 nm using the NanoDrop 2000 spectrophotometer (Thermo 
Fisher Scientific, Waltham, MA). 
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2.5.2 Quantitative real-time PCR analysis 
 To perform quantitative real-time polymerase chain reaction (PCR) analysis, the 
purified RNA was first reverse transcribed into cDNA using a high capacity cDNA reverse 
transcription kit according to manufacturer’s instructions (Life Technologies Corporation, 
Carlsbad, CA). To prepare cDNA the 2x reverse transcriptase master mix was prepared 
according to manufacturer’s instructions and 30 µL of the 2x master mix was then added 
to 30 µL of the isolated and purified RNA. The tubes were closed and centrifuged to 
ensure the absence of air bubbles and were then placed in a thermal cycler. The reactions 
were heated to 25⁰ C for 10 minutes, then 37⁰ C for 120 minutes and finally 85⁰ C for 5 
minutes. The cDNA was then stored at -20⁰ C until needed for quantitative real-time PCR. 
Quantitative real-time PCR reactions were set up using specific Taqman® probe and 
primer sets for LTF, IGF1R, IGF1, and BCL2 (Life Technologies Corporation, Carlsbad, 
CA) and TaqMan® Fast Universal PCR Master Mix (2✕) according to the manufacturer’s 
instructions (Life Technologies Corporation, Carlsbad, CA). To set up reactions, 10 ng of 
cDNA, 10 µL of the TaqMan® Fast Universal PCR Master Mix (2✕), 1 µL of the Taqman® 
probe/primer set and enough RNase free water to bring the volume to 20 µL were 
combined in a single well of a 96-well PCR plate. All reactions were set up in triplicate 
and then the plate was covered with optical film and centrifuged at 3220 x g for 1 minute. 
The plate was then loaded into the Applied Biosystems StepOnePlus Real-Time PCR 
System (Life Technologies Corporation, Carlsbad, CA) and the plate was run using the 
standard setting for fast real-time PCR. The conditions for the run were a 20 second 
holding stage at 95⁰ C, followed by 50 cycles of 1 second at 95⁰ C followed by 20 seconds 
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at 60⁰ C. The relative expression of genes was then calculated using the ΔΔCT method 
with normalization to 18s rRNA expression. 
2.6 Protein expression and activation studies 
2.6.1 Protein isolation and quantification 
 D283Med cells were counted and treated as described above for the proliferation 
and viability studies for 24 or 48 hours. Cells were cultured in a humidified 37⁰C 5% CO2 
incubator during the drug exposure period. For rapid E2 exposure studies the D283Med 
cells were counted and treated very similarly as described above for the proliferation and 
viability studies. The only differences were that the D283Med cells were serum starved 
for 24 hours prior to drug exposure and the drug exposure was performed in serum free 
media. Drug exposure was performed for 5, 15, 30, or 60 minutes and the positive control 
of 5 minutes of 10% FBS exposure was used.  After the drug exposure period, the cell 
suspensions were transferred to 15 mL conical tubes and centrifuged at 1120 x g until the 
cells had formed a pellet. The supernatant was aspirated and the cell pellet was 
resuspended in lysis buffer supplemented with a protease inhibitor tablet (Roche, Nutley, 
NJ) and phosphatase inhibitor cocktails two and three (Sigma-Aldrich, St. Louis, MO). 
Cell lysates were cleared by centrifugation at 9300 x g for 3 minutes and the supernatant 
was transferred to a fresh tube. Total protein concentration of cell lysates was quantified 
using a modified Lowry assay (DC protein assay; Bio-Rad, Hercules, CA) and cell lysates 
were then stored at -80⁰ C until used for western blot studies.  
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2.6.2 Western Blot analysis 
 To prepare the cell lysates for sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE), 20 to 60 µg of protein lysate was combined 3:1 with 4x 
sample buffer [240 mM Tris-HCl, pH 6.8, 8% sodium dodecyl sulfate (SDS; Bio-Rad, 
Hercules, CA), 40% (w/v) glycerol, 0.02% bromophenol blue (Fisher Scientific, Pittsburg, 
PA)] with 4% beta-mercaptoethanol added right before use. Samples were mixed with the 
sample buffer and incubated for 15 minutes at room temperature or were boiled for 10 
minutes depending on what proteins were to be immunoblotted. Next, 10 to 40 µg of 
protein lysate and a molecular weight marker (Li-Cor inc., Lincoln, NE) were loaded onto 
polyacrylamide gels according to what was needed for a specific protein of interest. The 
polyacrylamide gels were comprised of a stacking gel [3.9% acrylamide (Fisher Scientific, 
Pittsburg, PA), 0.1% bisacrylamide (Fisher Scientific, Pittsburg, PA), 125 mM 
tris(hydroxymethyl)aminomethane (Tris base; Fisher Scientific, Pittsburg, PA), 0.1% SDS, 
0.1% ammonium persulfate (APS, Fisher Scientific, Pittsburg, PA), 0.08% 
tetramethylethylenediamine (TEMED; Bio-Rad, Hercules, CA), pH 6.8] and a resolving 
gel [11.6% acrylamide, 0.4% bisacrylamide, 375 mM Tris base, 0.1% SDS, 0.05% APS, 
0.04% TEMED, pH 8.8]. SDS-PAGE was used to resolve the proteins according to 
molecular weight using a running buffer that was comprised of 190 mM glycine (Fisher 
Scientific, Pittsburg, PA), 25 mM Tris base, and 0.1% SDS. A constant voltage of 80 mV 
was applied for 30 minutes followed by a constant voltage of 150 mV until the 
bromophenol blue dye front ran off the gel. The gel was then removed and placed into ice 
cold transfer buffer [48 mM Tris base, 39 mM glycine, 0.0375% SDS, and 20% v/v 
methanol] for 30 minutes. This incubation, and all that follow, were performed with gentle 
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rocking. To set up the electrotransfer, the components were assembled in the following 
order starting on the anode plate: sponge, paper, gel, nitrocellulose membrane (Li-Cor, 
Lincoln, NE), paper, sponge. When placing the next layer, transfer buffer was layered on 
top and bubbles were removed by rolling a glass rod over the layer. The electrotransfer 
was performed by completely submerging the gel-membrane assembly into a chamber 
filled with transfer buffer and then constant amperage of 70 mA was applied for 16 hours 
at 4⁰ C. Following electrotransfer, the transfer efficiency was checked by visualizing the 
transferred proteins with Ponceau S staining solution (0.1% Ponceau S (Fisher Scientific, 
Pittsburg, PA) in 1% acetic acid (Fisher Scientific, Pittsburg, PA)). The nitrocellulose 
membrane was then blocked with 5% non-fat dry milk (Bio-Rad, Hercules, CA) in tris-
buffered saline with tween [TBST; 20 mM Tris base, 137 NaCl, 0.1% v/v Tween-20 (Fisher 
Scientific, Pittsburg, PA), pH 7.6]. Primary antibodies (Table 2) were diluted in 5% non-
fat dry milk in TBST and the membrane was incubated with the diluted primary antibody 
overnight at 4⁰ C. Following primary antibody incubation, the membrane was washed 
three times in TBST and then incubated in 0.1 µg/mL Goat anti-rabbit 800CW or 0.1 
µg/mL of Goat anti-mouse 680RD secondary antibodies (Li-Cor inc., Lincoln, NE) for one 
hour. Following incubation with the secondary antibody, the membrane was washed three 
times with TBST and then placed in tris-buffered saline [TBS; 20 mM Tris base, 137 NaCl, 
pH 7.6] prior to visualization. Visualization of protein bands was performed using the 
Odyssey Clx (Li-Cor, Lincoln, NE) system and band densitometry analysis was performed 
using ImageStudio Lite Ver. 4.0 software (Li-Cor, Lincoln, NE). 
 
 
97 
 
 
Table 2 - Primary Antibodies  
Antigen 
Recognized 
Source 
Catalog 
# 
Conc. IHC 
(μg/ml) 
Conc. 
WB 
(μg/ml)  
Species/Type 
beta-actin Cell Signaling 
Technology 
8457 N/A 0.02 Rabbit 
Monoclonal 
Bcl-2 (Human) Thermo Fisher 
Scientific 
MS-597-
P1 
8.0 0.2 Mouse 
Monoclonal 
Bcl-2 (Mouse) Abcam 7973 2.0 N/A Rabbit 
Polyclonal 
Cleaved 
Caspase 3 
Cell Signaling 
Technology 
9661 0.2 N/A Rabbit 
Polyclonal 
ERβ Affinity BioReagents PA1-
310B 
1.0 N/A Rabbit 
Polyclonal 
IGF1R Cell Signaling 
Technology 
9750 2.0 0.2 Rabbit 
Monoclonal 
Phospho-
IGF1R 
Cell Signaling 
Technology 
3024 N/A 0.089 Rabbit 
Monoclonal 
Ki67 Abcam 15580 2.5 N/A Rabbit 
Polyclonal 
AKT Cell Signaling 
Technology 
9272 N/A 0.025 Rabbit 
Polyclonal 
Phospho-AKT Cell Signaling 
Technology 
4060 N/A 0.071 Rabbit 
Monoclonal 
Phospho-AKT Cell Signaling 
Technology 
3787 1.0 N/A Rabbit 
Monoclonal 
ERK Cell Signaling 
Technology 
9102 N/A 0.008 Rabbit 
Polyclonal 
Phospho-ERK Cell Signaling 
Technology 
9101 0.9 0.045 Rabbit 
Polyclonal 
Phospho-JNK Cell Signaling 
Technology 
9251 0.5 N/A Rabbit 
Polyclonal 
Phospho-p38 Cell Signaling 
Technology 
9211 1.0 N/A Rabbit 
Polyclonal 
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 2.7 Animal procedures, necropsy and tissue preparation 
Mouse strains B6.129S2-Trp53tm1Tyj/J; STOCK Ptch1tm1Mps/J; B6.Cg-Tg(Atoh1-
cre)1Bfri/J, B6.129P2-Esr2tm1Unc/J; B6N.129-Ptch1tm1Hahn/J were obtained from The 
Jackson Laboratory (Bar Harbor, ME) at 3-4 weeks of age. Mice were housed under 
controlled laboratory conditions in a pathogen-free animal care facility accredited by the 
Association of Assessment and Accreditation of Laboratory Animal Care. All animal 
procedures were done in accordance with approved Institutional Animal Care and Use 
Committee protocols. All mice were maintained ad libitum on a reduced phytoestrogen 
diet (2019S Teklad Global 19% Protein Extruded Rodent Diet; Teklad Diets, Madison WI). 
Selective breeding was performed in house to obtain the desired Ptch1+/- Trp53-/-, 
Ptch1C/C Atoh1-cre, and Esr2-/- Ptch1C/C Atoh1-cre mice (Figure 7). A summary of the 
mouse models utilized in these studies can be found in Table 3. Genomic DNA was 
prepared from tail biopsies that were digested using DirectPCR reagent (Viagen Biotech 
Inc., Los Angeles, CA) supplemented with a final concentration of 0.5 mg/mL proteinase 
K (Viagen Biotech Inc., Los Angeles, CA) and was used to genotype pups as previously 
reported using the primers listed in Table 4 (T Jacks et al., 1994; Krege et al., 1998; Lisa 
V. Goodrich Kay M. Higgns, Goodrich, Milenkovic, Higgins, & Scott, 1997; Z J Yang et al., 
2008).  
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Table 3 – Mouse Models of Medulloblastoma 
Mouse Model Gender Incidence Esr2 Symptom 
Onset 
Location 
D283Med Xenograft Males and Females N/A Wildtype N/A Hindlimb 
Ptch1+/- Trp53-/- Males only 100% Wildtype 4 to 6 weeks 
of age 
Cerebellum 
Ptch1C/C Atoh1-cre Males and Females 100% Wildtype 2 to 3 weeks 
of age 
Cerebellum 
Esr2-/- Ptch1C/C 
Atoh1-cre 
Males and Females 100% Null 2 to 3 weeks 
of age 
Cerebellum 
 
 
 
 
 Table 4 – Genotyping PCR Primers  
Target Gene 
Product 
Size 
Forward primer 5’  3’ Reverse Primer 5’  3’ 
Trp53 – mutant 650 bp CTA TCA GGA CAT AGC GTT GG TAT ACT CAG AGC CGG CCT 
Trp53 – 
wildtype 
450 bp ACA GCG TGG TGG TAC CTT AT TAT ACT CAG AGC CGG CCT 
Ptch1 – mutant 479 bp GCC CTG AAT GAA CTG CAG GAC G CAC GGG TAG CCA ACG CTA TGT C 
Ptch1 – 
wildtype 
200 bp AGG GCT TCT CGT TGG CTA CAA G CTG CGG CAA GTT TTT GGT TG 
LacZ 315 bp ATC CTC TGC ATG GTC AGG TC CGT GGC CTG ATT CAT TCC 
Positive control 
for LacZ 
210 bp CAA ATG TTG CTT GTC TGG TG GTC AGT CGA GTG CAC AGT TT 
Atoh1-cre 450 bp CCG GCA GAG TTT ACA GAA GC ATG TTT AGC TGG CCC AAA TG 
Positive control 
for Atoh1-cre 
324 bp 
CTA GGC CAC AGA ATT GAA AGA 
TCT 
GTA GGT GGA AAT TCT AGC ATC ATC 
C 
Ptch1 
conditional 
269 bp 
(mutant) 
216 bp 
(WT) 
TTC ATT GAA CCT TGG GGA AC AGT GCG TGA CAC AGA TCA GC 
Esr2 – mutant 160 bp GCA GCC TCT GTT CCA CAT ACA C TCA CAG GAC CAG ACA CCG TA 
Esr2 – wildtype 106 bp GTT GTG CCA GCC CTG TTA CT TCA CAG GAC CAG ACA CCG TA 
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Figure 7 
Selective breeding scheme utilized to produce Esr2-/- Ptch1C/C Atoh1-cre and Esr2+/+ 
Ptch1C/C Atoh1-cre mice. 
 
Pups genotyped as Ptch1+/- Trp53-/- were randomly assigned to either the control 
or fulvestrant treatment groups. The clinical drug preparation Faslodex (fulvestrant) 
injection (AstraZeneca, Willington, DE) was administered as a weekly 20 μL (1 mg) 
intramuscular injection beginning on postnatal day (PND) 21. Mice in the control group 
received weekly 20 μL IM injections of the castor oil vehicle. Mice were observed daily for 
presentation of MB symptoms including abnormal gait, ataxia, or signs of intracranial 
pressure and cranial doming. Following symptom onset, Ptch1+/- Trp53-/- mice were 
euthanized by CO2 asphyxiation and perfused with 4% paraformaldehyde (Fisher 
Scientific, Pittsburg, PA). The brain was removed and placed in 4% paraformaldehyde 
which was renewed 24 hours later. Wild-type (WT) and Esr2-/- Ptch1C/C Atoh1-cre mice 
were euthanized by CO2 asphyxiation on PND45 due to the rapid and severe onset of 
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symptoms and sudden death that was typically observed after PND45. Following 
euthanasia, the tumor was removed, weighed, and then drop fixed in 4% 
paraformaldehyde, which was renewed 24 hours later. Fixed tissue was washed several 
times in 70% ethanol prior to automated tissue processing and embedding in paraffin 
(Histocenter 3; Themo-Shandon Kalamazoo, MI). Microtome sections were cut at 5 μm 
thickness from blocks at 4°C and placed on Fisherbrand Excell slides (Fisher Scientific, 
Pittsburg, PA) for immunohistochemistry (IHC). Xenograft MB tumors generated 
previously were fixed, processed and sectioned by the same procedure as the MB tumors 
from Ptch1C/C Atoh1-cre mice (Scott M Belcher, Xiaolan Ma, & Hoa H Le, 2009).  
2.8 Immunohistochemical staining and analysis 
Microscope slides with 5 µM paraffin embedded tissue sections were heated at 
60⁰C for 30 minutes and then deparaffinized by washing the slides in xylene (Fisher 
Scientific, Pittsburg, PA) 3 times for 5 minutes each time. The tissue was rehydrated by 
washing the slides in 100% ethanol two times for 5 minutes each, 95% ethanol once for 
5 minutes, and then 70% ethanol two times for 5 minutes each. Rehydration was 
completed by washing the slides with running tap water for 5 minutes and then 
endogenous peroxidase activity was blocked by incubating the slides in in 3% hydrogen 
peroxide (H2O2; Fisher Scientific, Pittsburg, PA) in phosphate buffered saline (PBS) [137 
mM NaCl, 2.7 mM potassium chloride (KCl; Fisher Scientific, Pittsburg, PA), 10 mM 
dibasic sodium phosphate (Na2HPO4; Fisher Scientific, Pittsburg, PA), 2 mM monobasic 
potassium phosphate (KH2PO4; Fisher Scientific, Pittsburg, PA), pH 7.4] for 10 minutes. 
This was followed by another 5 minute wash with running tap water. Heat-mediated 
epitope retrieval was performed at 97 °C in Tris-EDTA buffer (10mM Tris-HCl, 1mM EDTA, 
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pH 9.0) and 0.05% Tween-20 for 10 minutes followed by a 20 minute cool down at room 
temperature. Sections were incubated at room temperature for one hour with 3% normal 
goat or horse serum in PBS, and then incubated overnight at 4 °C with the primary 
antibody. The primary antibodies used and their concentrations are listed in Table 2. 
Following primary antibody incubation, slides were washed 3 times in IHC-specific tris 
buffered saline with tween (IHC-TBST, 20 mM Tris base, 300 mM NaCl, 0.1% Tween-20, 
pH 7.6) for 5 minutes each time. The slides were then incubated at room temperature 
with biotinylated goat anti-rabbit (BA1000, 7.5 μg/mL, Vector Laboratories, Burlingame, 
CA) or biotinylated horse anti-mouse (BA2000, 7.5 μg/mL, Vector Laboratories, 
Burlingame, CA) for one hour in a humidified chamber. Slides were washed three times 
in IHC-TBST for five minutes and then incubated at room temperature with the avidin 
biotin complex solution (Vector Laboratories, Burlingame, CA) for one hour. After three 
washes in IHC-TBST, visualization was performed with 0.05% 3’3-diaminobenzidine as 
per manufacturer instructions (Vector Laboratories, Burlingame, CA). The slides were 
washed in running tap water three times, for five minutes each time, deionized water for 
one minute, and were lightly counterstained in hematoxylin for 10 s (Richard Allan; 
Kalamazoo, MI). The slides were washed in running tap water until the water ran clear 
and then placed in clarifier (Richard Allan; Kalamazoo, MI) for 30 seconds. Following a 
wash in tap water, the slides were placed in bluing reagent (Richard Allan; Kalamazoo, 
MI) for one minute. Following one last wash in running water for one minute the slides 
were dehydrated by placing them in 95% ethanol for one minute, 100% ethanol for one 
minute three times; and lastly xylene (Fisher Scientific, Pittsburg, PA) for one minute 3 
times. The slides were then mounted in Permount (Fisher Scientific, Pittsburg, PA).  
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Internal controls for specificity of immunostaining included replacement of primary 
antibody with non-specific serum, and preincubation of the cleaved caspase 3 antibody 
with blocking peptide (1050; Cell Signaling Technology, Danvers, MA). Spleen sections 
were used as the positive control for cleaved caspase 3 staining. Microscopic examination 
and collection of digital photomicrographs of immunostained tumors was carried out using 
a Nikon Eclipse 55i microscope and a DS-Fi1 CCD camera controlled with Digital Sight 
software (Nikon Instruments, Inc., Melville, NY).  Immunopositive cell numbers and mitotic 
figures were scored by an investigator blinded to the treatment from 10 random 40x fields 
from a single section of the tumor outside the necrotic core. Apoptotic and mitotic indexes 
for each sample are expressed as number of positive cells divided by the total cell count 
multiplied by 100. Final photomicrograph graphics were generated and labeled using 
Adobe Photoshop CS8 (Adobe Systems, Inc., San Jose, CA). 
2.9 Statistical Analysis 
 Differences between control and treatment groups were analyzed with a student’s 
t-test, Dunnett’s multiple comparison test, or one-way ANOVA and Tukey-Kramer post-
test as appropriate. Percentage data was arcsine transformed (arcsine of the square root 
of the value) prior to statistical analysis. A two-way ANOVA was used to analyze 
experiments with two variables to determine if either or both of the variables affected the 
endpoint. To calculate the effective concentration that induces 50% of an effect (EC50), 
the doses used were log transformed and the data was subjected to a sigmoidal dose 
response nonlinear fit model.  Differences in symptom-free survival were analyzed using 
the Kaplan-Meier survival test and statistical significance determined using Mantel–Cox 
log-rank test. Differences in IGF1R immunostaining was assessed using the 
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immunohistochemical score (HSCORE) approach (36). The HSCORE was calculated 
according to the equation, HSCORE = ∑Pi(I + 1), where I represents the intensity of 
staining (0 = no staining, 1 = mild, 2= moderate, 3 = intense) and Pi represents the 
percentage of cells within each staining intensity category. A minimal level of statistical 
significance for differences was defined as p < 0.05 and is indicated in figures with an 
asterisk. Analysis was performed using Prism v5 software (GraphPad Software, Inc., La 
Jolla, CA). 
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CHAPTER 3 
CHARACTERIZATION OF ESTRADIOL-MEDIATED PROTECTION OF PNET CELLS 
FROM METABOLIC STRESS-INDUCED APOPTOSIS 
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3.1 Characterization of L-glutamine Withdrawal in Medulloblastoma 
 To establish a model of cell death in D283Med cells, the effect of L-glutamine 
withdrawal on D283Med viability and caspase-dependent cell death was examined. L-
glutamine withdrawal was chosen because it had been observed that v-myc avian 
myelocytomatosis viral oncogene homolog (MYC) overexpressing cell lines are sensitive 
to L-glutamine withdrawal and the D283Med cell line is known to overexpress MYC 
(Bruggers et al., 1998; A. Le et al., 2012; Qing et al., 2012; Siu, Lal, Blankenship, Aldosari, 
& Riggins, 2003; Wise et al., 2008; Yuneva, Zamboni, Oefner, Sachidanandam, & 
Lazebnik, 2007). Analysis of D283Med viable cell counts following L-glutamine withdrawal 
by 2-way ANOVA revealed both a significant main effect of time [F (4, 10) = 14.26, p = 
0.0004] and a significant main effect of L-glutamine withdrawal [F (1, 10) = 92.62, p < 
0.0001] (Figure 8A). Further analysis of D283Med viability by the percent of cells negative 
for trypan blue revealed both a significant main effect of time [F (4, 10) = 11.59, p = 0.0009] 
and a significant main effect of L-glutamine withdrawal [F (1, 10) = 94.71, p < 0.0001] 
(Figure 8B). The effect of caspase-3 inhibition by Z-DEVD-fmk was also investigated to 
determine if the decreases in viable cell numbers was due to a caspase-dependent 
mechanism. A significant main effect of both time [F (4, 10) = 13.80, p = 0.0004] and Z-
DEVD-fmk treatment [F (1, 10) = 192.14, p < 0.0001] on viable cell numbers was observed 
in D283Med cells subjected to L-glutamine withdrawal (Figure 8A). Analysis of D283Med 
cell viability, as measured by the percent of trypan blue excluding cells, also revealed a 
both a significant main effect of time [F (4, 10) = 18.37, p = 0.0001] and a significant main 
effect of Z-DEVD-fmk treatment [F (1, 10) = 68.27, p < 0.0001] (Figure 8B). Furthermore, 
caspase-3 activity was significantly [t(21) = 2.75, p = 0.012] (Figure 8C) increased by L-
glutamine withdrawal and treatment with Z-DEVD-fmk prevented this increase [t(22) = 
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3.64, p = 0.0015] (Figure 8D). The effect of the caspase-3 inhibitor Z-DEVD-fmk on the 
L-glutamine withdrawal-induced decrease in viable cell numbers as well as the effect of 
L-glutamine withdrawal on caspase-3 activity; both establish L-glutamine withdrawal as a 
model of caspase-dependent cell death in D283Med cells. 
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Figure 8 
Characterization of L-glutamine withdrawal in D283Med cells. A,B. Viable cell counts and 
viability, respectively, of D283Med cultured in MEM supplemented with 10% CSS either with 
L-glutamine (5 mM L-glutamine), without L-glutamine (Vehicle) or without L-glutamine and 
treated with a caspase-3 inhibitor (10 µM Z-DEVD-fmk). C. Caspase-3 activity, as determined 
by the liberation of pNA from the caspase-3 substrate Ac-DEVD-pNA, following 48 hours of 
D283Med culture in MEM supplemented with 10% CSS either with or without 5 mM L-
glutamine. D. Caspase-3 activity following 48 hours of L-glutamine withdrawal both with and 
without Z-DEVD-fmk treatment. Results are expressed as mean ± SEM. Data was analyzed 
by either two-way ANOVA or t-test as appropriate and significance from the control is 
indicated above the error bars; *. p ≤ 0.05. Groups are composed of three or more replicates. 
The experiment was repeated three times (n=3) on separate days with similar results. 
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3.2 The effect of 17β-E2 and selective ER agonists on proliferation and viability of 
medulloblastoma cells following L-glutamine withdrawal 
 The effect of 17β-E2 on viable cell counts was investigated using D283Med cells 
subjected to L-glutamine withdrawal. Analysis of the data by 2-way ANOVA revealed a 
significant main effect of time [F (4, 10) = 24.60, p < 0.0001] and a significant main effect 
of 17β-E2 treatment [F (1, 10) = 67.48, p < 0.0001] (Figure 9A). Furthermore, analysis of 
viability, as measured by the percent of trypan blue excluding cells, revealed both a 
significant main effect of time [F (4, 10) = 36.88, p < 0.0001] and a significant main effect 
of 17β-E2 treatment [F (1, 10) = 34.55, p = 0.0002] (Figure 9B). While these data 
suggested that 17β-E2 protects D283Med cells from L-glutamine-induced cell death, it 
was still unclear how 17β-E2 was affecting cell death and whether alterations in D283Med 
proliferation by 17β-E2 were involved in the effect of 17β-E2 on viable cell numbers. To 
address whether the 17β-E2-induced changes in D283Med viable cell numbers were due 
in part to a proliferative effect of 17β-E2, a BrdU incorporation assay was utilized with a 
positive control of 10% FBS treatment. Analysis of BrdU incorporation revealed that 17β-
E2 significantly increased D283Med proliferation at the 24 hour timepoint [t(14) = 7.41, p 
< 0.0001] but not at the 48 [t(14) = 0.36, p = 0.7241], 72 [t(14) = 0.20, p = 0.8472] or 96 
[t(14) = 0.11, p = 0.9177] hour timepoints (Figure 9C). Due to the acute nature of the 
proliferative effect of 17β-E2, it seemed unlikely that the pro-proliferative effect of 17β-E2 
was responsible for the long-term changes in viable cell numbers. To address to 
possibility that 17β-E2 may inhibit caspase-dependent cell death, the caspase-3 inhibitor, 
Z-DEVD-fmk, was utilized and caspase-3 activity was measured. Analysis of the viable 
cell count data revealed that while there was a  
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Figure 9 
Characterization of the effect of 17β-E2 exposure on viability and proliferation in 
D283Med cells. A,B. Viable cell counts and viability, respectively, of D283Med cultured 
in MEM supplemented with 10% CSS subjected to L-glutamine withdrawal either with or 
without 10 nM E2. C. BrdU incorporation in D283Med cells subjected to L-glutamine 
withdrawal either with or without 10 nM E2 in 10% CSS supplemented MEM or 10% FBS 
supplemented media as a positive control. Results are expressed as mean ± SEM. Data 
was analyzed by two-way ANOVA, significance from the control was determined by 
Bonferroni post-test and is indicated above the error bars; *. p ≤ 0.05. Groups are 
composed of three or more replicates. The experiment was repeated three times (n=3) 
on separate days with similar results. 
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significant main effect of time [F (4, 10) = 14.68, p = 0.0003], 17β-E2 treatment had no 
effect [F (1, 10) = 0.24, p = 0.6315] in the presence of Z-DEVD-fmk (Figure 10A). Similarly, 
analysis of cell viability also revealed a significant main effect of time [F (4, 10) = 9.75, p 
= 0.0018] and no effect [F (1, 10) = 2.36, p = 0.1555] of 17β-E2 treatment in the presence 
of Z-DEVD-fmk (Figure 10B). Furthermore, analysis of caspase-3 activity demonstrated 
that 17β-E2 treatment significantly [t(21) = 4.46, p = 0.0002] decreases caspase-3 activity, 
but has no effect [t(21) = 1.48, p = 0.1546] in the presence of Z-DEVD-fmk (Figure 10C). 
Blocking ER activation with the non-selective ER antagonist fulvestrant significantly [t(4) 
= 9.35, p = 0.0007] blocked the effect of 17β-E2 on viable cell numbers after 96 hours of 
treatment (Figure 10D). The effect of 17β-E2 on caspase-3 activity 48 hours after 
treatment was also significantly [t(22) = 3.49, p = 0.0021] blocked by fulvestrant co-
treatment (Figure 10E). These data demonstrated that 17β-E2 protects D283Med cells 
from L-glutamine withdrawal-induced cell death and suggest that this protection is 
dependent on ER activation causing reduced caspase-3 activity. To further investigate 
the cytoprotective effect of 17β-E2, selective ER agonists were utilized to determine which 
receptor was responsible for the effect of 17β-E2. Analysis of viable cell count data 
revealed that the ERβ-selective agonist, DPN, significantly [t(4) = 10.48, p = 0.0005] 
increased viable cell numbers but the ERα-selective agonist, PPT, had no effect [t(4) = 
0.21, p = 0.8442] (Figure 11A). Similar to the effect of 17β-E2, DPN also significantly [t(22) 
= 4.68, p = 0.0001] decreased caspase-3 activity while PPT had no effect [t(22) = 0.38, p 
= 0.7112] (Figure 11B). These data demonstrate that 17β-E2 protects D283Med cells 
from L-glutamine-induced caspase-dependent cell death likely through the activation of 
ERβ and a subsequent decrease in caspase-3 activity.  
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Figure 10 
Effect of caspase-3 or ER inhibition on cytoprotective effect of 17β-E2. A,B. Viable 
cell counts and viability, respectively, of D283Med cells cultured in MEM supplemented 
with 10% CSS subjected to L-glutamine withdrawal while exposed to 10 µM Z-DEVD-fmk 
both with and without 10 nM E2. C,E. Relative caspase-3 activity in D283Med cells 
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subjected to 48 hours of L-glutamine withdrawal while exposed to the indicated 
compounds (Z-DEVD-fmk, fmk; Fulvestrant, Ful). in 10% CSS supplemented MEM. D. 
Viable cell counts of D283Med cells cultured in MEM supplemented with 10% CSS 
subjected to L-glutamine withdrawal for 96 hours while exposed to the indicated 
compounds. Results are expressed as mean ± SEM. Data was analyzed by two-way 
ANOVA, one-way ANOVA or Student’s t-test as appropriate. Significance between 
treatment groups was determined by either Dunnett’s multiple comparisons test or 
Student’s t-test and is indicated above the error bars; *. p ≤ 0.05. Groups are composed 
of three or more replicates. The experiment was repeated three times (n=3) on separate 
days with similar results. 
 
 
 
Figure 11 
Characterization of the effect of selective ER agonists on D283Med cytoprotection. 
A. Viable cell counts of D283Med cells cultured in MEM supplemented with 10% CSS 
subjected to 96 hours of L-glutamine withdrawal while exposed to the indicated selective 
ER agonists. B. Relative caspase-3 activity in D283Med cells subjected to 48 hours of L-
glutamine withdrawal while exposed to the indicated selective ER agonists in 10% CSS 
supplemented MEM. Results are expressed as mean ± SEM. Data was analyzed by one-
way ANOVA or Student’s t-test as appropriate. Significance between treatment groups 
was determined by Student’s t-test and is indicated above the error bars; *. p ≤ 0.05. 
Groups are composed of three or more replicates. The experiment was repeated three 
times (n=3) on separate days with similar results. 
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3.3 Concentration response analysis of the effect of 17β-E2 on caspase-3 activity 
in medulloblastoma cells subjected to L-glutamine withdrawal 
 To further examine the effect of 17β-E2, D283Med cells were exposed to a range 
of 17β-E2 doses to characterize the concentration dependency of the effect of 17β-E2 on 
caspase-3 activity. Analysis by ANOVA revealed that 17β-E2 significantly decreased 
caspase-3 activity [F (7, 83) = 4.36, p = 0.0004] in a concentration-dependent manner. 
Furthermore, Dunnett’s multiple comparisons test revealed that 17β-E2 significantly 
decreased caspase-3 activity at 10 (p < 0.01), 100 (p < 0.01) and 1000 (p < 0.001) nM 
(Figure 12A). Nonlinear regression analysis utilizing the variable slope sigmoidal dose-
response model calculated the EC50 for the effect of 17β-E2 to be 0.5488 nM, which is 
consistent with reported data concerning the potency of 17β-E2 and its binding affinity for 
the ERs (Bertini et al., 2011; Brian G Chrzan & Peter G Bradford, 2007; Evers et al., 2014; 
G G Kuiper et al., 1997; Van Den Belt, Berckmans, Vangenechten, Verheyen, & Witters, 
2004). To rule out the potential for an ER-independent effect, the effect of 17α-E2 on 
caspase-3 activity was also assessed. Analysis by ANOVA revealed that 17α-E2 had no 
effect on caspase-3 activity at any of the tested concentrations [F (7, 78) = 0.95, p = 
0.4715] (Figure 12B). These data demonstrate that increasing concentrations of 17β-E2 
decreases caspase-3 activity. Since the inactive enantiomer, 17α-E2, has no effect, these 
data also demonstrate that the effect of 17β-E2 is a specific effect likely due to the 
activation of ER-mediated signaling. 
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Figure 12 
Concentration response analysis of the effect of 17β-E2 and 17α-E2 on caspase-3 
activity in D283Med cells. A,B. Relative caspase-3 activity in D283Med cells subjected 
to 48 hours of L-glutamine withdrawal while exposed to increasing concentrations of 
either 17β-E2 or 17α-E2, respectively. Results are expressed as mean ± SEM. Data was 
analyzed by one-way ANOVA and significance between treatment groups and vehicle 
was determined by Dunnett’s multiple comparisons test and is indicated above the error 
bars; *. p ≤ 0.05. Groups are composed of three or more replicates. The experiment was 
repeated three times (n=3) on separate days with similar results. 
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3.4 Concentration response analysis of the effect of selective estrogen receptor 
agonists on caspase-3 activity in medulloblastoma cells subjected to L-glutamine 
withdrawal 
 To determine which ER was responsible for the effect of 17β-E2 on caspase-3 
activity, concentration response analysis was performed using selective ER agonists 
(Table 5). Increasing concentrations of the selective ERβ agonist DPN significantly [F (7, 
84) = 8.78, p < 0.0001] (Figure 13A) reduced caspase-3 activity but the ERα-selective 
agonist, PPT, [F (7, 85) = 1.81, p = 0.0965] (Figure 13B) and G-protein coupled estrogen 
receptor (GPER) agonist, G-1, [F (6, 67) = 0.90, p = 0.4990] (Figure 13C) had no effect. 
Further examination using Dunnett’s multiple comparisons test revealed that the 10 nM, 
100 nM, and 1000 nM concentrations of DPN significantly (p < 0.001) decreased caspase-
3 activity while no concentration of PPT or G-1 displayed a significant effect. Nonlinear 
regression analysis utilizing the variable slope sigmoidal dose-response model calculated 
the EC50 for the effect of DPN to be 0.8590 nM. While the effect of PPT was not significant, 
it did trend towards significance at high concentrations and nonlinear regression analysis 
calculated the EC50 of PPT to be 1.968 µM. The high concentrations of PPT required to 
cause a modest decrease in capase-3 activity is consistent with the loss of ERα selectivity 
at high concentrations (Stauffer et al., 2000). These data, therefore, demonstrate that 
activation of ERβ decreases caspase-3 activity and is likely responsible for the protective 
effect of 17β-E2. 
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Figure 13 
Concentration response analysis of the effect of selective ER agonists on caspase-
3 activity in D283Med cells. A-C. Relative caspase-3 activity in D283Med cells subjected 
to 48 hours of L-glutamine withdrawal while exposed to increasing concentrations of the 
selective ER agonists DPN, PPT and G-1, respectively. Results are expressed as mean 
± SEM. Data was analyzed by one-way ANOVA and significance between treatment 
groups and vehicle was determined by Dunnett’s multiple comparisons test and is 
indicated above the error bars; *. p ≤ 0.05. Groups are composed of three or more 
replicates. The experiment was repeated three times (n=3) on separate days with similar 
results. 
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3.5 Concentration response analysis of the effect of phytoestrogens on caspase-3 
activity in medulloblastoma cells subjected to L-glutamine withdrawal 
 D283Med cells were also exposed to several ERβ-selective phytoestrogens (Table 
5) to determine their effects on caspase-3 activity following L-glutamine withdrawal. 
Analysis by ANOVA revealed that caspase-3 activity was significantly decreased by 
genistein [F (7, 84) = 5.19, p < 0.0001] (Figure 14A), daidzein [F (7, 86) = 3.43, p = 0.0028] 
(Figure 14B), and (S)-equol [F (7, 86) = 8.65, p < 0.0001] (Figure 14C). Both genistein 
and daidzein displayed lower efficacy than (S)-equol and the calculated EC50 values were 
0.4269 nM, 3.570 nM and 0.4727 nM for genistein, daidzein and (S)-equol, respectively. 
These findings are consistent with previous reports of efficacy and potency for these 
phytoestrogens at ERβ (Brian G Chrzan & Peter G Bradford, 2007; Muthyala et al., 2004). 
These data further support the notion that ERβ activation protects D283Med cells from L-
glutamine withdrawal-induced cell death. 
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Figure 14 
Concentration response analysis of the effect of phytoestrogens on caspase-3 
activity in D283Med cells. A-C. Relative caspase-3 activity in D283Med cells subjected 
to 48 hours of L-glutamine withdrawal while exposed to increasing concentrations of the 
phytoestrogens genistein, daidzein, and (S)-equol, respectively. Results are expressed 
as mean ± SEM. Data was analyzed by one-way ANOVA and significance between 
treatment groups and vehicle was determined by Dunnett’s multiple comparisons test and 
is indicated above the error bars; *. p ≤ 0.05. Groups are composed of three or more 
replicates. The experiment was repeated three times (n=3) on separate days with similar 
results. 
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3.6 The effect of non-selective and selective estrogen receptor inhibitors on the 
protective effect of 17β-E2 in medulloblastoma cells subjected to L-glutamine 
withdrawal 
 To further characterize the 17β-E2-mediated protection of D283Med cells from L-
glutamine withdrawal-induced cell death, selective and non-selective ER inhibitors were 
used (Table 5). Increasing concentrations of the non-selective ER inhibitor fulvestrant 
appeared to block [F (3, 44) = 2.74, p = 0.0546] (Figure 15A) the protective effect of 17β-
E2. Further examination using Dunnett’s multiple comparisons test confirmed that the 10 
nM concentration of fulvestrant significantly (p < 0.05) blocked the protective effect of 
17β-E2. Similarly, increasing concentrations of the ERβ-selective inhibitor, PHTPP, 
appeared to block [F (3, 39) = 2.66, p = 0.0614] (Figure 15B) the protective effect of 17β-
E2. Further examination using Dunnett’s multiple comparisons test confirmed that the 5 
µM concentration of PHTPP significantly (p < 0.05) blocked the protective effect of 17β-
E2. In contrast, increasing concentrations of the ERα-selective inhibitor, MPP, had no 
effect [F (3, 41) = 0.88, p = 0.4590] (Figure 15C) on 17β-E2-mediated protection of 
D283Med cells from L-glutamine withdrawal-induced cell death. These results 
demonstrate that blockade of ERβ activation prevents the protective effect of 17β-E2, 
further supporting the notion that activation of ERβ is responsible for the protective effect 
of 17β-E2. 
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Figure 15 
Characterization of the effect of selective and non-selective ER antagonists on the 
cytoprotective effect of 17β-E2. A-C. Relative caspase-3 activity in D283Med cells 
subjected to 48 hours of L-glutamine withdrawal while exposed to 10 nM 17β=E2 and co-
exposed to increasing concentrations of the non-selective ER inhibitor fulvestrant or the 
selective ER inhibitors PHTPP or MPP, respectively. Results are expressed as mean ± 
SEM. Data was analyzed by one-way ANOVA and significance between treatment groups 
was determined by Dunnett’s multiple comparisons test and is indicated above the error 
bars; *. p ≤ 0.05. Groups are composed of three or more replicates. The experiment was 
repeated three times (n=3) on separate days with similar results. 
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Table 5: Estrogen Receptor Ligand Selectivity 
Compound ERα ERβ 
17β-E2 0.5-1.0 nM (EC50) 0.06-0.25 nM (EC50) 
DPN 66 nM (EC50) 0.85 nM (EC50) 
PPT 0.2 nM (EC50) 82 nM (EC50) 
Genistein 80 nM (EC50) 6.6 nM (EC50) 
Daidzein 250 nM (EC50) 100 nM (EC50) 
(s)-Equol 85 nM (EC50) 65 nM (EC50) 
Fulvestrant 1.04 nM (Ki) 1.39 nM (Ki) 
PHTPP 2220 nM (Ki) 139 nM (Ki) 
MPP 2.7 nM (Ki) 1800 nM (Ki) 
17β-estradiol (17β-E2), Fulvestrant (ICI 182, 780; Faslodex®), 4,4',4''-(4-Propyl-[1H]-
pyrazole-1,3,5-triyl)trisphenol (PPT), 2,3-bis(4-Hydroxyphenyl)-propionitrile (DPN), 4-[2-
Phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol (PHTPP), 1,3-Bis(4-
hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride 
(MPP) (Bovee, Helsdingen, Rietjens, Keijer, & Hoogenboom, 2004; B. G. Chrzan & P. G. 
Bradford, 2007; Meyers et al., 2001; Muthyala et al., 2004; Stauffer et al., 2000) 
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3.7 The effect of 17β-E2 and the ERβ agonist DPN on the expression and activity of 
IGF-1 pathway mediators 
 In order to gain a better understanding of how ERβ protects D283Med cells from 
L-glutamine withdrawal, the potential involvement of the IGF1 pathway downstream of 
ERβ activation in this effect was investigated. The IGF1 pathway was investigated due to 
its well-characterized role in the protective effect of 17β-E2 as discussed in detail in 
section 1.7. To this end, the expression and activation of proteins involved in the IGF1 
pathway were investigated. Real-time qPCR was utilized to determine the mRNA 
expression of key members of the IGF1 pathway including IGF1, IGF1R and BCL2. As a 
positive control, the mRNA expression of the estrogen-responsive gene LTF was also 
determined. Analysis by ANOVA revealed that treatment significantly [F (3, 8) = 54.98, p 
< 0.0001] affected LTF mRNA expression and Dunnett’s multiple comparisons test 
demonstrated that both 17β-E2 (10 nM) and DPN (10 nM) significantly (p < 0.001) 
increased LTF mRNA expression while co-treatment with PHTPP (5 µM) significantly [t(4) 
= 9.42, p = 0.0007] blocked the effect of 17β-E2 (Figure 16A). These data demonstrated 
that LTF mRNA expression was an appropriate positive control and that the chosen 
concentrations of compounds were effective. After establishing the positive control, the 
mRNA expression of IGF1, IGF1R and BCL2 were assessed. Analysis by ANOVA 
revealed that treatment significantly [F (3, 8) = 9.35, p = 0.0054] affected IGF1 mRNA 
expression and Dunnett’s multiple comparisons test demonstrated that both 17β-E2 (p < 
0.05) and DPN (p < 0.01) significantly increased IGF1 mRNA expression. While co-
treatment with PHTPP (5 µM) appeared [t(4) = 2.48, p = 0.0684] to block the effect of 
17β-E2, the effect was not significant (Figure 16B). Similarly, treatment significantly [F (3, 
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8) = 12.69, p = 0.0021] affected IGF1R mRNA expression and Dunnett’s multiple 
comparisons test demonstrated that both 17β-E2 (p < 0.05) and DPN (p < 0.01) 
significantly increased IGF1R mRNA expression while the PHTPP co-treatment group 
was not significantly different from the vehicle control. However, the decreased 
expression in the PHTPP co-treatment group compared to 17β-E2 alone was not 
significant [t(4) = 1.74, p = 0.1573] (Figure 16C). The mRNA expression of the pro-survival 
protein BCL2 was also significantly [F (3, 8) = 26.96, p = 0.0002] affected by treatment 
and Dunnett’s multiple comparisons test demonstrated that both 17β-E2 (p < 0.01) and 
DPN (p < 0.001) significantly increased BCL2 mRNA expression. Furthermore, PHTPP 
co-treatment significantly blocked the effect of 17β-E2 on BCL2 mRNA expression [t(4) = 
6.81, p = 0.0024] (Figure 16D). Together, these data demonstrate that ERβ activation is 
responsible for 17β-E2-mediated increases in mRNA expression of key members of the 
IGF1 pathway and suggests that increased IGF1 pathway activity is responsible for the 
protective effect of 17β-E2 in D283Med cells subjected to L-glutamine withdrawal. 
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Figure 16 
Relative mRNA expression of genes involved in the IGF1 pathway following ERβ 
activation or blockade in D283Med cells. A-D. Relative mRNA expression of the 
indicated genes in D283Med cells subjected to 48 hours of L-glutamine withdrawal while 
exposed to 10 nM 17β-E2, 10 nM DPN or co-exposed to E2 and 5 µM PHTPP. Results 
are expressed as mean ± SEM. Data was analyzed by one-way ANOVA and significance 
between treatment groups was determined by Dunnett’s multiple comparisons test or 
Student’s t-test as appropriate and is indicated above the error bars; *. p ≤ 0.05. Groups 
are composed of three or more replicates. The experiment was repeated three times (n=3) 
on separate days with similar results. 
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 Further investigation into the expression and activation of IGF1 pathway proteins 
was performed using an immunoblot approach. The protein expression of IGF1R and 
BCL2 were assessed to confirm the changes observed at the mRNA level. Furthermore, 
the activation of key mediators of the IGF1 pathway including IGF1R, AKT, and ERK were 
assessed by specifically immunolabeling the phosphorylated (active) form of each protein. 
The effect of 17β-E2 on the phosphorylation of ERK, AKT and IGF1R was assessed at 
timepoints ranging from 5 to 60 minutes (Figure 17A). IGF1R phosphorylation was not 
observed in the treatment groups but was observed in the positive control (10% FBS). 
Treatment with 17β-E2 appeared to rapidly and transiently increase ERK phosphorylation 
(Figure 17B) while not affecting AKT (Figure 17C) phosphorylation when the duration of 
treatment ranged from 5 to 60 minutes. While the role of this rapid and transient effect of 
of 17β-E2 on ERK phosphorylation was not investigated directly, it seems plausible that 
it may be responsible for the effect of 17β-E2 on D283Med proliferation, which is also 
transient (see Figure 9). Further investigation into the effect of 17β-E2 or DPN on protein 
expression and activation was performed using protein isolated from D283Med cells 
exposed to the compound for 24 or 48 hours. These timepoints were chosen because the 
effects of 17β-E2 on caspase-3 activity and mRNA expression were observed in cells 
exposed to compounds for 48 hours. Protein expression of IGF1R and BCL2 and 
activation of IGF1R, ERK and AKT were assessed after 24 (Figure 18A) or 48 (Figure 
18B) hours of compound exposure. Protein expression of IGF1R was increased by both 
17β-E2 and DPN at both timepoints (Figure 19A). Phosphorylation of IGF1R was also 
increased by both compounds at both timepoints (Figure 19B). The downstream 
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mediators of IGF1R activation, ERK and AKT, were also investigated. Phosphorylation of 
ERK was increased by both 17β-E2 and DPN at both 24 (Figure 16C) and 48 (Figure 19D) 
hour timepoints. In contrast, phosphorylation of AKT was only slightly increased by 17β-
E2 or DPN after 24 hours of exposure but was dramatically increased after 48 hours of 
exposure to the compounds (Figure 19E). Lastly, the protein expression of the pro-
survival protein BCL2 was increased by both compounds at both timepoints (Figure 19F). 
Taken together with the findings from the real-time qPCR studies, these data further 
support the notion that ERβ activation in D283Med cells causes increased activity of the 
IGF1 pathway and suggest that increased IGF1 pathway activity may mediate the 
protective effect of 17β-E2.  
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Figure 17 
Assessment of rapid growth factor pathway mediator activation following 17β-E2 
exposure in D283Med cells.  A. Representative immunoblots from serum starved 
D283Med cells exposed to 17β-E2 for the indicated timepoints. B,C. Quantification of 
ERK and AKT phosphorylation, respectively, normalized to total ERK or AKT protein 
expression. These measurements were performed by a semi-quantitative method and 
were not subjected to statistical analysis. (n=1) 
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Figure 18 
Assessment of IGF1 pathway protein expression and activation following exposure 
to 17β-E2 or DPN in D283Med cells. A,B. Representative immunoblots from D283Med 
cells exposed to vehicle (0.01% DMSO), 10 nM 17β-E2, or 10 nM DPN for either 24 or 
48 hours, respectively. Immunoblots were performed once for each of three samples (n=3) 
which were treated and collected on separate days.  
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Figure 19 
Quantification of immunoblots for IGF1 pathway proteins by densitometry. A. 
Relative IGF1R protein expression normalized to β-actin. B. Relative IGF1R 
phosphorylation normalized to β-actin. C. Relative ERK phosphorylation after 24 hours of 
exposure normalized to total ERK. D. Relative ERK phosphorylation after 48 hours of 
exposure normalized to total ERK. E. Relative AKT phosphorylation normalized to total 
AKT. F. Relative BCL2 protein expression normalized to β-actin. For all measurements, 
n=3. These measurements were performed by a semi-quantitative method and were not 
subjected to statistical analysis.   
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3.8 The effect of IGF1R inhibition, or the inhibition of the downstream pro-survival 
mediators MEK 1/2 and PI3K on estradiol-mediated cytoprotection 
 The mRNA and protein expression data suggested that activation of the IGF1 
pathway may mediate the protective effect of 17β-E2 in D283Med cells subjected to L-
glutamine withdrawal. To further investigate this possibility, the effect of IGF1 pathway 
mediator inhibitors on the protective effect of 17β-E2 was assessed. Increasing 
concentrations of the selective IGF1R inhibitor NVP-AEW541 clearly blocked [F (3, 41) = 
6.08, p = 0.0016] (Figure 20A) the protective effect of 17β-E2. Further examination using 
Dunnett’s multiple comparisons test confirmed that the 10 µM concentration of NVP-
AEW541 significantly (p < 0.05) blocked the protective effect of 17β-E2. Similarly, the 
selective mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor U0126 blocked [F 
(3, 37) = 3.07, p = 0.0398] (Figure 20B) the protective effect of 17β-E2 in a concentration-
dependent manner. Dunnett’s multiple comparisons test revealed that the 10 µM 
concentration of U0126 significantly (p < 0.05) blocked the protective effect of 17β-E2. In 
contrast, the selective phosphatidylinositol-3-kinase (PI3K) irreversible inhibitor 
wortmannin had no effect [F (3, 43) = 1.41, p = 0.2531] (Figure 20C) on the protective 
effect of 17β-E2. To confirm that the protective effect of 17β-E2 was not dependent on 
PI3K activation; the effect of the competitive PI3K inhibitor LY294002 was also assessed. 
Analysis of caspase-3 activity data in D283Med cells subjected to L-glutamine withdrawal 
and co-treated with 10 µM LY294002/10 nM 17β-E2 revealed no difference [t(18) = 0.25, 
p = 0.8044] when compared to cells treated with 17β-E2 alone (Figure 20D). These data 
confirm that the protective effect of 17β-E2 is dependent on the activation of the IGF1 
pathway as suggested by the mRNA and protein expression data. Furthermore, these 
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data demonstrate that 17β-E2 protects D238Med cells from L-glutamine withdrawal-
induced cell death by an IGF1R and ERK dependent mechanism. 
 
 
Figure 20 
Assessment of the effect of IGF1 pathway inhibition on the cytoprotective effect of 
17β-E2.A-C. Relative caspase-3 activity in D283Med cells subjected to 48 hours of L-
glutamine withdrawal while exposed to 10 nM 17β-E2 and co-exposed to increasing 
concentrations of the indicated inhibitors; NVP-AEW541, U0126 or Wortmannin, 
respectively. D. Relative caspase-3 activity in D283Med cells subjected to 48 hours of L-
glutamine withdrawal while exposed to 10 nM 17β-E2 either with or without 10 µM 
LY294002. Results are expressed as mean ± SEM. Data was analyzed by one-way 
ANOVA and significance between treatment groups was determined by Dunnett’s 
multiple comparisons test and is indicated above the error bars; *. p ≤ 0.05. Groups are 
composed of three or more replicates. The experiment was repeated three times (n=3) 
on separate days with similar results. 
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3.9 Characterization of 17β-E2-mediated protection of metabolic stress in PFSK1 
cells 
 To determine whether the protective effect of 17β-E2 in PNET cells in 
generalizable, the PFSK1 PNET cell line (described in section 2.2) was used. As with the 
D283Med cells, the L-glutamine withdrawal sensitivity of the PFSK1 cell line had to be 
established first. After 96 hours of L-glutamine withdrawal, there was a significant [t(10) 
= 15.67, p < 0.0001] decrease in viable cell numbers, demonstrating that the PFSK1 cell 
line is also sensitive to L-glutamine withdrawal (Figure 21A). After establishing that 
PFSK1 cells were sensitive to L-glutamine withdrawal, the effect of 17β-E2 and selective 
ER agonists on L-glutamine withdrawal-induced cell death was assessed. Analysis of 
viable cell count data by ANOVA revealed that treatment significantly [F (3, 20) = 24.62, 
p < 0.001] affected the results (Figure 21B). Further analysis by Dunnett’s multiple 
comparisons test demonstrated that both 17β-E2 (10 nM) and DPN (10 nM) significantly 
(p < 0.0001) increased viable cell numbers while PPT (10 nM) had no effect. Furthermore, 
analysis of caspase-3 activity data revealed that the treatment groups significantly [F (3, 
43) = 15.81, p < 0.0001] affected the results (Figure 21C). Specifically, Dunnett’s multiple 
comparisons test revealed that both 17β-E2 and DPN significantly (p < 0.001) reduced 
caspase-3 activity in PFSK1 cells subjected to L-glutamine withdrawal for 48 hours, while 
PPT had no effect. These data demonstrate that, similar to observations in D283Med 
cells, PFSK1 cells are sensitive to L-glutamine withdrawal and can be protected from L-
glutamine withdrawal-induced cell death by activation of ERβ. Furthermore, this suggests 
that the protective effect of 17β-E2 in ERβ-positive PNET cells may be generalizable, 
however, analysis of additional cell lines is required.   
 
135 
 
 
Figure 21 
Characterization of the cytoprotective effect of 17β-E2 in the PFSK1 PNET cell line. 
A. Viable PFSK1 cell numbers following 96 hours of culture in MEM supplemented with 
10% CSS either with or without L-glutamine. B. Viable PFSK1 cell numbers following 96 
hours of L-glutamine withdrawal while exposed to the indicated ER agonists. C. Relative 
caspase-3 activity in PFSK1 cells subjected to 48 hours of L-glutamine withdrawal while 
exposed to the indicated ER agonists. Results are expressed as mean ± SEM. Data was 
analyzed by one-way ANOVA or Student’s t-test as appropriate. Significance between 
treatment groups was determined by Dunnett’s multiple comparisons test or Student’s t-
test and is indicated above the error bars; *. p ≤ 0.05. Groups are composed of three or 
more replicates. The experiment was repeated three times (n=3) on separate days with 
similar results. 
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CHAPTER 4 
INVESTIGATING THE EFFECT OF FULVESTRANT TREATMENT IN MOUSE 
MODELS OF MEDULLOBLASTOMA 
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4.1 Survival analysis of Ptch1+/- Trp53-/- mice treated with fulvestrant versus the 
castor oil vehicle 
To further characterize the protective effect of 17β-E2 in MB, the effect of ER 
inhibition on MB growth was examined in vivo. It had been previously observed that 
fulvestrant treatment inhibited D283Med xenograft growth, and to further characterize the 
effect of fulvestrant on MB growth, an in vivo genetic model of MB was utilized (S. M. 
Belcher et al., 2009). The therapeutic efficacy of ER inhibition by fulvestrant was 
determined by assessing MB symptom onset in Ptch1+/- Trp53-/- mice. Median symptom-
free survival for Ptch1+/- Trp53-/- mice treated with the castor oil vehicle control was 35 
days. Fulvestrant treatment significantly (p < 0.0001) delayed MB progression as 
indicated by the median symptom-free survival being increased to 52 days for Ptch+/- 
Trp53-/- mice treated with fulvestrant (Figure 22). The finding that fulvestrant delayed 
symptom onset in Ptch+/- Trp53-/- mice supported the notion that ER function is important 
for MB growth as suggested by the previous D283Med xenograft studies.  
 
Figure 22 
Analysis of symptom-free survival for Ptch1+/- Trp53-/- mice treated with either the 
castor oil vehicle or fulvestrant. Median symptom-free survival was 35 and 52 days for 
the castor oil (n=10) and fulvestrant (n=9) groups respectively and the hazard ratio was 
22.56. The survival curves are significantly different as determined by Kaplan-Meier 
analysis with a p ≤ 0.05. 
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4.2 Histochemical and immunohistochemical assessment of proliferation and 
apoptosis in Ptch1+/- Trp53-/- tumors and D283Med xenografts 
 To assess the impact of ER inhibition by fulvestrant on apoptosis and proliferation, 
tumors from Ptch1+/- Trp53-/- mice and D283Med xenografts were immunostained for 
cleaved caspase 3 and the mitotic index of the tumors was determined. There was no 
observed difference in mitotic index between treatment groups in tumors from Ptch1+/- 
Trp53-/- mice [t(11) = 1.099, p = 0.2952] (Figure 23A-C) or in D283Med xenografts [t(7) = 
0.7932, p = 0.4537] (Figure 23D-F) as determined by counting mitotic figures in 
hematoxylin and eosin stained tumor sections. Furthermore, phosphorylated histone H3, 
a marker of mitosis, immunopositive cell counts were also not affected [t(7) = 0.4971, p = 
0.6343] by fulvestrant treatment in tumors from Ptch1+/- Trp53-/- mice (Figure 24A-D). 
Compared to vehicle control (M = 0.6, SD = 0.4), apoptotic index was significantly 
increased [t(9) = 4.246, p = 0.0022] by fulvestrant treatment (M = 2.0, SD = 0.8) in Ptch1+/- 
Trp53-/- tumors (Figure 25A-C; G) as determined by cleaved caspase-3 immunopositive 
cell counts. In D283Med xenografts, fulvestrant treatment (M = 1.1, SD = 0.1) also 
significantly increased [t(9) = 4.625, p = 0.0021] the apoptotic index as compared to the 
castor oil vehicle control (M = 0.3, SD = 0.1) (Figure 25D-F; H). These results demonstrate 
fulvestrant treatment increases apoptosis in MB tumors from Ptch1+/- Trp53-/- mice and in 
D283Med xenografts, suggesting that ER activity regulates MB growth by limiting 
caspase-dependent cell death in the tumor. These data also support the notion that ER 
activity regulates cell death in MB as suggested by the in vitro studies detailed in chapter 
3. 
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Figure 23 
Analysis of mitotic index in D283Med xenografts and MB tumors from Ptch1+/- 
Trp53-/- mice. Representative images from hematoxylin and eosin stained sections from 
Ptch1+/- Trp53-/- MB tumors and D283Med xenografts and quantification of mitotic index. 
A,D. Representative images from vehicle treated Ptch1+/- Trp53-/- MB tumors and 
D283Med xenografts, respectively. B,E. Representative images from fulvestrant treated 
Ptch1+/- Trp53-/- MB tumors and D283Med xenografts, respectively. C,F. Quantification  
of mitotic index for Ptch1+/- Trp53-/- MB tumors and D283Med xenografts, respectively. All 
results are expressed as mean ± SD. Each group is comprised of at least three samples 
(n≥3). Scale bar for images is 50 μm. 
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Figure 24 
Analysis of phosphorylated histone H3 in MB tumors from Ptch1+/- Trp53-/- mice. 
Representative phosphorylated histone H3 immunostained images and quantification. 
A,B. Representative images from vehicle and fulvestrant treated Ptch1+/- Trp53-/- MB 
tumors, respectively. C. Representative image of the no primary antibody immunostaining 
control from Ptch1+/- Trp53-/- MB tumors. D. Quantification of phosphorylated histone H3 
immunopositive cell numbers normalized to total cell numbers. All results are expressed 
as mean ± SD. Each group is comprised of at least three samples (n≥3). Scale bar for 
images is 50μm. 
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Figure 25 
Analysis of apoptotic index in D283Med xenografts and MB tumors from Ptch1+/- 
Trp53-/- mice. Representative cleaved caspase-3 immunostained images and 
quantification. A,D. Representative images from vehicle treated Ptch1+/- Trp53-/- MB 
tumors and D283Med xenografts, respectively. B,E. Representative images from 
fulvestrant treated Ptch1+/- Trp53-/- MB tumors and D283Med xenografts, respectively. 
C,F. Representative images of the no primary antibody immunostaining control from 
Ptch1+/- Trp53-/- MB tumors and D283Med xenografts, respectively. G,H. Quantification  
of cleaved caspase-3 immunostaining, expressed as apoptotic index, for Ptch1+/- Trp53-/- 
MB tumors and D283Med xenografts, respectively. All results are expressed as mean ± 
SD. A level of significant difference between groups was determined by Student’s t-test 
and is indicated above the error bars; *. p≤0.05. Each group is comprised of at least three 
samples (n≥3). Scale bar for images is 50μm. 
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4.3 Immunohistochemical assessment of the IGF1R in Ptch1+/- Trp53-/- tumors and 
D283Med xenografts 
Due to the involvement of the IGF1 pathway in the protective effect of 17β-E2 
observed in the D283Med cell line, the involvement of the IGF1 pathway in the effect of 
fulvestrant on tumor apoptosis was investigated. Assessment of IGF1R immunostaining 
intensity revealed that ER inhibition by fulvestrant significantly decreased IGF1R 
immunoreactivity, as assessed by the HSCORE method, in MB tumors from Ptch1+/- 
Trp53-/- mice [t(8) = 6.684, p = 0.0002] (Figure 26A-D) and in D283Med xenografts [t(8) = 
8.176, p < 0.0001] (Figure 26E-H). These data indicate that IGF1 pathway activity may 
be involved in the effect of fulvestrant on cell death in MB tumors as suggested by the in 
vitro studies in the D283Med cell line. 
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Figure 26 
Analysis of IGF1R immunostaining in D283Med xenografts and MB tumors from 
Ptch1+/- Trp53-/- mice. Representative IGF1R immunostained images and quantification 
by the HSCORE method. A,D. Representative images from vehicle treated Ptch1+/- Trp53-
/- MB tumors and D283Med xenografts, respectively. B,E. Representative images from 
fulvestrant treated Ptch1+/- Trp53-/- MB tumors and D283Med xenografts, respectively. 
C,F. Representative images of the no primary antibody immunostaining control from 
Ptch1+/- Trp53-/- MB tumors and D283Med xenografts, respectively. G,H. Quantification 
of IGF1R immunostaining by the HSCORE method for Ptch1+/- Trp53-/- MB tumors and 
D283Med xenografts, respectively. All results are expressed as mean ± SD. A level of 
significant difference between groups was determined by Student’s t-test and is indicated 
above the error bars; *. p≤0.05. Each group is comprised of at least three samples (n≥3). 
Scale bar for images is 50μm. 
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4.4 Immunohistochemical assessment of the downstream mediators of the IGF1 
pathway in Ptch1+/- Trp53-/- tumors and D283Med xenografts 
Activation of ERK and AKT as well as BCL2 expression were assessed due to their 
involvement in pro-survival growth factor pathways and the suggested involvement of the 
IGF1 pathway in the effect of ER activity on cell death in MB. To determine the specificity 
of mitogen activated protein kinase (MAPK) activation by ER activity in MB, the activation 
of p38 MAPK and c-Jun N-terminal kinase (JNK) was also assessed. ER inhibition by 
fulvestrant treatment significantly decreased the number pERK [t(8) = 8.262, p < 0.0001] 
and pAKT [t(6) = 4.321, p = 0.0050] immunopositive cells in MB tumors from Ptch1+/- 
Trp53-/- mice. In contrast, phosphorylation of p38 [t(8) = 0.090, p = 0.9303] and JNK [t(4) 
= 0.553, p = 0.6095] was not affected by fulvestrant treatment (Table 6). Quantitative 
assessment of BCL2 immunopositive cells demonstrated that BCL2 expression was 
significantly [t(4) = 3.223, p = 0.0322] decreased in fulvestrant treated (M = 10, SD = 2.0) 
versus castor oil treated (M = 4, SD = 2.1) MB tumors from Ptch1+/- Trp53-/- mice (Figure 
27A-D). Furthermore, BCL2 immunopositive cell counts were also significantly [t(7) = 
4.701, p = 0.0022] decreased in fulvestrant treated (M = 40, SD = 5.6) versus castor oil 
treated (M = 95, SD = 25.4) D283Med xenografts (Figure 27E-H). Together, these data 
demonstrate that ER inhibition by fulvestrant inhibits MB tumor growth. This likely occurs 
due to a disruption of the balance between tumor proliferation and cell death, as observed 
by the increased cell death in MB tumors from fulvestrant treated mice. The increased 
cell death is likely caused by a down-regulation of the IGF1 pathway activity, and this 
conclusion is further supported by the in vitro studies detailed in Chapter 3.  
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Table 6 - Quantification of Immunostaining for Growth Factor Pathway Proteins in 
Ptch1+/- Trp53-/- MB tumors 
 
 
Figure 27 
Analysis of BCL2 immunostaining in D283Med xenografts and MB tumors from 
Ptch1+/- Trp53-/- mice. Representative BCL2 immunostained images and quantification 
of immunopositive cells. A,D. Representative images from vehicle treated Ptch1+/- Trp53-
/- MB tumors and D283Med xenografts, respectively. B,E. Representative images from 
fulvestrant treated Ptch1+/- Trp53-/- MB tumors and D283Med xenografts, respectively. 
C,F. Representative images of the no primary antibody immunostaining control from 
Ptch1+/- Trp53-/- MB tumors and D283Med xenografts, respectively. G,H. Quantification 
of BCL2 immunostaining for Ptch1+/- Trp53-/- MB tumors and D283Med xenografts, 
respectively. All results are expressed as mean ± SD. A level of significant difference 
between groups was determined by Student’s t-test and is indicated above the error bars; 
*. p≤0.05. Each group is comprised of at least three samples (n≥3). Scale bar for images 
is 50μm. 
 Control Fulvestrant 
Phospho-ERK 23.8 ± 5.1 (n=6) 6.5 ± 1.0* (n=4) 
Phospho-p38 10.3 ± 3.5 (n=3) 10.0 ± 2.0 (n=3) 
Phospho-JNK 3.0 ± 1.0 (n=6) 3.33± 0.6 (n=4) 
Phospho-AKT 31.0 ± 12.6 (n=4) 7.3 ± 4.6* (n=4) 
Values are means of immunopositive cells per 1000 cells ±SD 
* Significantly different from control by Students t-test (p <0.05) 
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CHAPTER 5 
CHARACTERIZATION OF THE Esr2-/- Ptch1C/C Atoh1-cre MOUSE MODEL OF 
MEDULLOBLASTOMA
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5.1 Tumor weight analysis of medulloblastoma from Esr2-/- Ptch1C/C Atoh1-cre 
versus Esr2+/+ Ptch1C/C Atoh1-cre mice 
The role of ERβ in MB tumor growth was examined by determining differences in 
tumor wet weight for Esr2+/+ and Esr2-/- Ptch1C/C Atoh1-cre mice at PND45. Analysis of 
MB tumor weight data by 2-way ANOVA revealed no significant main effect of gender [F 
(1, 25) = 2.76, p = 0.1089]; however, there was a significant main effect of genotype on 
tumor weight [F (1, 25) = 21.33, p = 0.0001]. The tumor weight for the Esr2-/- (M = 413.9 
mg, SD = 79.4 mg) mice was significantly reduced [t(27) = 4.37, p = 0.0002] compared to 
Esr2+/+ (M = 551.9 mg, SD = 84.3 mg) mice (Figure 28A). Furthermore, the lack of ERβ 
expression in MB tumors form the Esr2-/- mice was confirmed through IHC using an 
antibody specific for ERβ1/ERβ2 (Figure 28B,C). The observation that deletion of Esr2 
decreased tumor growth rate is consistent with the in vitro findings in Chapter 3 and 
support the conclusion that estrogen increases MB tumor growth through ERβ-mediated 
mechanisms. 
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Figure 28 
Analysis of MB tumor weight and ERβ immunostaining in Esr2+/+ and Esr2-/- 
Ptch1C/C Atoh1-cre mice. A. Analysis of MB tumor weight collected from Esr2+/+ and 
Esr2-/- Ptch1C/C Atoh1-cre mice at PND45. Tumor weight decreased from 549.1 mg in 
Esr2+/+ mice (n=18) to 425.3 mg in Esr2-/- mice (n=11). B,C. Representative images of 
MB tumor sections immunostained for ERβ1/ERβ2 from Esr2+/+ and Esr2-/- Ptch1C/C 
Atoh1-cre mice, respectively. D. Representative image of the no primary antibody 
immunostaining control from Ptch1C/C Atoh1-cre MB tumors. All results are expressed as 
mean ± SD. A level of significant difference between groups was determined by Student’s 
t-test and is indicated above the error bars; *. p≤0.05. Scale bar for images is 50μm. 
 
5.2 Histochemical and immunohistochemical assessment of proliferation and 
apoptosis in tumors from Ptch1C/C Atoh1-cre mice  
To determine the role of ERβ in MB proliferation and cell death, mitotic figure counts, 
Ki67 immunostaining and cleaved caspase-3 immunostaining was performed in MB 
tumors from Esr2+/+ and Esr2-/- Ptch1C/C Atoh1-cre mice. Mitotic index was assessed by 
counting mitotic figures in hematoxylin and eosin stained MB tumor sections. Analysis of 
mitotic index revealed that genetic ablation of ERβ in Ptch1C/C Atoh1-cre mice had no 
effect [t(25) = 1.465, p = 0.1555] (Figure 29). Proliferation was also assessed by 
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immunostaining MB tumor section for Ki67, which is a marker of proliferation. Analysis of 
proliferation by Ki67 immunostaining revealed that genetic ablation of ERβ in Ptch1C/C 
Atoh1-cre mice had no effect [t(10) = 1.598, p = 0.1410] (Figure 30). Immunostaining for 
cleaved caspase-3 revealed that apoptotic index was significantly increased in MB tumors 
from Esr2-/- Ptch1C/C Atoh1-cre mice (M = 2.1, SD = 0.3) versus Esr2+/+ Ptch1C/C Atoh1-
cre mice (M = 0.8, SD = 0.2) [t(25) = 11.25, p < 0.0001] (Figure 31). These data 
demonstrate that loss of ERβ affects the balance between tumor proliferation and 
apoptosis by increasing MB tumor apoptosis.   
 
 
 
 
 
Figure 29 
Analysis of mitotic index in MB tumors from Ptch1C/C Atoh1-cre mice. 
Representative images of hematoxylin and eosin stained MB tumor sections from 
Ptch1C/C Atoh1-cre mice and quantification of mitotic index. A,B. Representative images 
of MB tumor sections from Esr2+/+ and Esr2-/- Ptch1C/C Atoh1-cre mice, respectively. C. 
Quantification of mitotic index for Ptch1C/C Atoh1-cre MB tumors. All results are expressed 
as mean ± SD. A level of significant difference between groups was determined by 
Student’s t-test and is indicated above the error bars; *. p≤0.05. Each group is comprised 
of at least three samples (n≥3). Scale bar for images is 50μm.  
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Figure 30 
Analysis of Ki-67 immunostaining in MB tumors from Ptch1C/C Atoh1-cre mice. 
Representative Ki67 immunostained images and quantification. A,B. Representative 
images of Esr2+/+ and Esr2-/- Ptch1C/C Atoh1-cre MB tumor sections, respectively. C. 
Representative image of the no primary antibody immunostaining control from Ptch1C/C 
Atoh1-cre MB tumor D. Quantification of Ki67 immunostaining, expressed as apoptotic 
index, for Ptch1C/C Atoh1-cre MB tumors. All results are expressed as mean ± SD. Each 
group is comprised of at least three samples (n≥3). Scale bar for images is 50μm.  
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Figure 31 
Analysis of apoptotic index in MB tumors from Ptch1C/C Atoh1-cre mice. 
Representative images of Ptch1C/C Atoh1-cre MB tumor sections immunostained for 
cleaved caspase 3 and quantification of immunopositive cell numbers. A,B. 
Representative images of Esr2+/+ and Esr2-/- Ptch1C/C Atoh1-cre MB tumor sections, 
respectively. C. Representative image of the no primary antibody immunostaining control 
from Ptch1C/C Atoh1-cre MB tumor D. Quantification of cleaved caspase-3 
immunostaining, expressed as apoptotic index, for Ptch1C/C Atoh1-cre MB tumors. All 
results are expressed as mean ± SD. Each group is comprised of at least three samples 
(n≥3). Scale bar for images is 50μm. 
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5.3 Immunohistochemical assessment of the IGF1R in tumors from Ptch1C/C Atoh1-
cre mice 
Due to the involvement of the IGF1 pathway in the protective effect of 17β-E2 
observed in the D283Med cell line, and in the effect of fulvestrant treatment in the in vivo 
studies detailed in Chapter 4, the involvement of the IGF1 pathway in the effect of Esr2 
ablation on tumor apoptosis was investigated. Assessment of IGF1R immunostaining 
intensity revealed that genetic ablation of Esr2 significantly decreased IGF1R 
immunoreactivity, as assessed by the HSCORE method, in MB tumors from Ptch1C/C 
Atoh1-cre mice [t(10) = 8.212, p < 0.0001] (Figure 32). These data indicate that IGF1 
pathway activity may be involved in the effect of Esr2 ablation on cell death in MB tumors 
as suggested by the in vitro and in vivo studies as detailed in chapters 3 and 4. 
 
Figure 32 
Analysis of IGF1R immunostaining in MB tumors from Ptch1C/C Atoh1-cre mice. 
Representative IGF1R immunostained images and quantification by the HSCORE 
method. A,B. Representative images of Esr2+/+ and Esr2-/- Ptch1C/C Atoh1-cre MB tumor 
sections, respectively. C. Representative image of the no primary antibody 
immunostaining control from Ptch1C/C Atoh1-cre MB tumor. D. Quantification of IGF1R 
immunostaining by the HSCORE method for Ptch1C/C Atoh1-cre MB tumors. All results 
are expressed as mean ± SD. A level of significant difference between groups was 
determined by Student’s t-test and is indicated above the error bars; *. p≤0.05. Each 
group is comprised of at least three samples (n≥3). Scale bar for images is 50μm. 
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5.4 Immunohistochemical assessment of the downstream mediators of the IGF1 
pathway in tumors from Ptch1C/C Atoh1-cre mice 
Activation of ERK and AKT as well as BCL2 expression were assessed due to their 
involvement in pro-survival growth factor pathways and the suggested involvement of the 
IGF1 pathway in the effect of ER activity on cell death in MB. To determine the specificity 
of MAPK activation by ER activity in MB, the activation of p38 and JNK was also assessed. 
Loss of ERβ activity by genetic ablation of Esr2 significantly decreased the number pERK 
[t(10) = 7.210 p < 0.0001] and pAKT [t(9) = 4.307 p = 0.0020] immunopositive cells in MB 
tumors from Ptch1C/C Atoh1-cre mice. In contrast, phosphorylation of p38 [t(10) = 0.371 
p = 0.7184] or JNK [t(10) = 0.461 p = 0.6547] was not affected by loss of ERβ (Table 7). 
Quantitative assessment of BCL2 immunopositive cells demonstrated that BCL2 
expression was significantly [t(10) = 4.415 p = 0.0013] decreased in Esr2-/- (M = 10 SD = 
3.5) versus Esr2+/+ (M = 22 SD = 5.5) MB tumors from Ptch1C/C Atoh1-cre mice (Figure 
33). Together, these data demonstrate that loss of ERβ activity by genetic ablation of 
Esr2 inhibits MB tumor growth. This likely occurs due to a disruption of the balance 
between tumor proliferation and cell death, as observed by the increased cell death in 
MB tumors from Esr2-/- mice. The increased cell death is likely caused by a down-
regulation of the IGF1 pathway activity, and this conclusion is further supported by the in 
vitro and in vivo studies detailed in Chapters 3 and 4. 
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Table 7 - Quantification of Immunostaining for Growth Factor Pathway Proteins in 
Ptch1C/C Atoh1-cre MB tumors 
 
 
 
Figure 33 
Analysis of BCL2 immunostaining in MB tumors from Ptch1C/C Atoh1-cre mice. 
Representative BCL2 immunostained images and quantification of immunopositive cells. 
A,B. Representative images from Esr2+/+ and Esr2-/- Ptch1C/C Atoh1-cre MB tumors, 
respectively. C. Representative image of the no primary antibody immunostaining control 
from Ptch1C/C Atoh1-cre MB tumors. D. Quantification of BCL2 immunostaining for 
Ptch1C/C Atoh1-cre MB tumors. All results are expressed as mean ± SD. A level of 
significant difference between groups was determined by Student’s t-test and is indicated 
above the error bars; *. p≤0.05. Each group is comprised of at least three samples (n≥3). 
Scale bar for images is 50μm. 
 Esr2+/+ Esr2-/- 
Phospho-ERK 16.3 ± 2.8 (n=6) 8.3 ± 1.0* (n=6) 
Phospho-p38 5.0 ± 2.8 (n=6) 5.7 ± 3.5 (n=6) 
Phospho-JNK 2.2 ± 0.8 (n=6) 2.5 ± 1.2 (n=6) 
Phospho-AKT 18.8 ± 5.6 (n=5) 7.0 ± 3.4* (n=6) 
Values are means of immunopositive cells per 1000 cells ±SD  
* Significantly different from control by Students t-test (p <0.05) 
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CHAPTER 6 
INVESTIGATING THE EFFECT OF ESTROGEN ON THE CHEMOSENSITIVITY OF 
PNET CELL LINES
156 
 
6.1 Concentration response analysis of chemotherapeutic agent cytotoxicity in the 
D283Med cell line 
 To determine the sensitivity of D283Med cells to the cytotoxic effect of cisplatin, 
vincristine and lomustine, concentration response analysis was performed using a colony 
forming assay. These chemotherapeutic compounds were chosen due to their use in 
medulloblastoma treatment according to the current standard of care (De Braganca & 
Packer, 2013; Martin et al., 2014). The surviving fraction plotted against cisplatin 
concentration clearly demonstrates a cytotoxic effect of cisplatin at concentrations above 
10 µM and nonlinear regression analysis utilizing the variable slope model calculated the 
IC50 of cisplatin to be 48.41 µM (Figure 34A). However, the fact that the solvent, DMSO, 
reduces the potency of cisplatin by approximately 25-fold in D283Med cells (Figure 5) 
should be kept in mind when considering this data. Similarly, vincristine clearly decreased 
colony formation at concentrations above 1 nM and nonlinear regression analysis 
calculated the IC50 of vincristine to be 2.120 nM (Figure 34B). Increasing concentrations 
of lomustine were also clearly cytotoxic in the colony forming assay at concentrations 
above 10 µM and the calculated IC50 for lomustine by nonlinear regression analysis was 
12.08 µM (Figure 34C). These studies were important in determining what range of 
concentrations should be used when studying the effect of 17β-E2 on chemotherapeutic-
induced cell death.   
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Figure 34 
Kill curve analysis of chemotherapeutic compounds in D283Med cells. A-C. 
D283Med colony formation following treatment with increasing concentrations of cisplatin, 
vincristine and lomustine, respectively. Preliminary analysis which is consistent with 
reported IC50 values (n=1 per data point). 
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6.2 The effect of 17β-E2 and selective ER agonists on the cytotoxicity of 
chemotherapeutic agents in the D283Med cell line  
A MTT assay was utilized to further characterize the sensitivity of D283Med cells 
to cisplatin exposure and the effect of 17β-E2 on D283Med chemosensitivity. Two-way 
ANOVA analysis revealed a significant main effect of increasing concentrations of 
cisplatin [F (5, 36) = 83.48, p < 0.0001] and a significant main effect of 10 nM 17β-E2 [F 
(1, 36) = 26.06, p < 0.0001]. Post-test analysis revealed that compared to D283Med cells 
exposed to 300 µM cisplatin alone, MTT viability was significantly increased in cells that 
were co-exposed to 300 µM cisplatin and 10 nM 17β-E2 (p < 0.001) (Figure 35). 
 
 
Figure 35 
The effect of 17β-E2 on the cytotoxicity of cisplatin as assessed by MTT assay in 
D283Med cells. MTT viability of D283Med cells following treatment with increasing 
concentrations of cisplatin both with and without 10 nM 17β-E2. Each data point is 
composed of 6 replicates and the experiment was repeated three times (n=3) on separate 
days with similar results.   
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Further investigation was performed to determine if 17β-E2 affected the clonogenic 
potential of D283Med cells that were co-exposed to varying concentrations of 
chemotherapeutic drugs. Two-way ANOVA analysis revealed a significant main effect of 
increasing concentrations of cisplatin [F (2, 18) = 30.77, p < 0.0001] and a significant 
main effect of 10 nM 17β-E2 [F (1, 18) = 234.45, p < 0.0001]. Post-test analysis revealed 
that exposure to E2 significantly protected the clonogenic potential of D283Med cells from 
all tested concentrations of cisplatin (p < 0.001) (Figure 36). Similarly, two-way ANOVA 
analysis revealed a significant main effect of increasing concentrations of vincristine [F 
(2, 18) = 75.85, p < 0.0001] and a significant main effect of 10 nM 17β-E2 [F (1, 18) = 
196.19, p < 0.0001]. Post-test analysis revealed that exposure to 17β-E2 significantly 
protected D283Med cells from the cytotoxic effect of vincristine at all tested 
concentrations (p < 0.001) (Figure 37A). Furthermore, two-way ANOVA analysis revealed 
a significant main effect of increasing concentrations of lomustine [F (2, 30) = 31.18, p < 
0.0001] and a significant main effect of 10 nM 17β-E2 [F (1, 30) = 57.56, p < 0.0001]. 
Post-test analysis revealed that 17β-E2 significantly blocked the cytotoxic effect of 
lomustine on colony formation in D283Med cells at all tested lomustine concentrations (p 
< 0.001) (Figure 37B). 
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Figure 36 
The effect of 17β-E2 on the cytotoxicity of cisplatin as assessed by colony forming 
assay in D283Med cells. Representative images of D283Med colony formation assays 
and quantification of colony forming potential. A. Representative image of D283Med 
colony formation following treatment with 50 µM cisplatin. B. Representative image of 
D283Med colony formation following co-treatment with 50 µM cisplatin and 10 nM 17β-
E2. C. Quantification of colony counts for D283Med cells exposed to increasing 
concentration of cisplatin with and without 10 nM 17β-E2 normalized based on the plating 
efficiency of D283Med cells. Groups were composed of at least 4 replicates. The 
experiment was repeated three times (n=3) on separate days with similar results. 
Significance was determined by two-way ANOVA followed by post-test analysis and is 
indicated above the error bars; *. p≤0.05.    
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Figure 37 
The effect of 17β-E2 on the cytotoxicity of vincristine and lomustine as assessed 
by colony forming assay in D283Med cells. A. Quantification of colony counts for 
D283Med cells exposed to increasing concentration of vincristine with and without 10 nM 
17β-E2 normalized based on the plating efficiency of D283Med cells. B. Quantification of 
colony counts for D283Med cells exposed to increasing concentration of lomustine with 
and without 10 nM 17β-E2 normalized based on the plating efficiency of D283Med cells. 
Groups were composed of at least 4 replicates. The experiment was repeated three times 
(n=3) on separate days with similar results. Significance was determined by two-way 
ANOVA followed by post-test analysis and is indicated above the error bars; *. p≤0.05.    
 
Studies were also conducted using selective ER agonists to determine which 
receptor was responsible for the chemoprotective effect of 17β-E2. Analysis of surviving 
fraction data revealed that the ERβ-selective agonist, DPN, significantly [t(6) = 3.817 p = 
0.0088] (Figure 38B) protected the colony forming potential of D283Med cells co-exposed 
to 100 µM cisplatin while the ERα-selective agonist, PPT, had no effect [t(6) = 0.617 p = 
0.5598] (Figure 38C). Furthermore, treatment with the ERβ-selective phytoestrogens 
daidzein, genistein and (s)-equol significantly [F (3, 20) = 34.69, p < 0.0001] affected 
colony formation of D283Med cells co-exposed to 100 µM cisplatin. Further analysis 
utilizing Dunnett’s multiple comparisons test revealed that daidzein (p < 0.001), genistein 
(p < 0.01), and (s)-equol (p < 0.001) all significantly protected D283Med cells from the 
cytotoxic effect of cisplatin (Figure 39). These data demonstrate that ERβ activation, but 
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not ERα activation, is chemoprotective and suggests that 17β-E2 mediates MB 
chemoprotection through the activation of ERβ.  
 
 
 
 
Figure 38 
The effect of selective ER agonists on the cytotoxicity of cisplatin in D283Med cells. 
Representative images of D283Med colony formation assays and quantification of colony 
forming potential. A1-3. Representative images of D283Med colony formation following 
treatment with 100 µM cisplatin and 0.01% DMSO (Vehicle), 10 nM DPN, or 10 nM PPT, 
respectively. B. Quantification of colony counts for D283Med cells exposed to 100 µM 
cisplatin with and without 10 nM DPN normalized based on the plating efficiency of 
D283Med cells. C. Quantification of colony counts for D283Med cells exposed to 100 µM 
cisplatin with and without 10 nM PPT normalized based on the plating efficiency of 
D283Med cells. Groups were composed of at least 4 replicates. The experiment was 
repeated three times (n=3) on separate days with similar results. Significance was 
determined by Student’s t-test and is indicated above the error bars; *. p≤0.05.    
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Figure 39 
The effect of phytoestrogens on the cytotoxicity of cisplatin in D283Med cells. 
Representative images of D283Med colony formation assays and quantification of colony 
forming potential. A1-4. Representative images of D283Med colony formation following 
treatment with 100 µM cisplatin and 0.01% DMSO (Vehicle), 10 nM genistein, 10 nM 
daidzein, or 10 nM (s)-equol, respectively. B. Quantification of colony counts for D283Med 
cells exposed to 100 µM cisplatin and co-exposed to the indicated phytoestrogen 
compounds, normalized based on the plating efficiency of D283Med cells. Groups were 
composed of at least 4 replicates. The experiment was repeated three times (n=3) on 
separate days with similar results. Significant differences from control were determined 
by Dunnett’s multiple comparisons test and is indicated above the error bars; *. p≤0.05.    
164 
 
6.3 The effect of 4-OHT, fulvestrant and the ERβ-selective antagonist PHTTP on the 
chemoprotective effect of 17β-E2 in the D283Med cell line 
 To further characterize the mechanism underlying the chemoprotective effect of 
17β-E2 in D283Med cells, selective and non-selective inhibitors of ERs were utilized. To 
determine whether the ER inhibitors could block the chemoprotective effect of 17β-E2, 
D283Med cells were co-exposed to 100 µM cisplatin and various combinations of 17β-
E2, 4-OHT, fulvestrant, or PHTPP. Analysis of colony formation demonstrated that 
exposure to the SERM, 4-OHT, had no effect [t(6) = 1.868 p = 0.1110] by itself, but 
significantly [t(5) = 4.616 p = 0.0058] blocked the protective effect of 17β-E2 when cells 
were co-exposed (Figure 40A). Similarly, the non-selective ER inhibitor fulvestrant 
significantly [t(6) = 4.292 p = 0.0051] blocked the chemoprotective effect of 17β-E2 but 
did not affect [t(6) = 0.100 p = 0.9235] colony formation in the absence of 17β-E2 (Figure 
40B). These data demonstrated that 17β-E2 protected D283Med cells from the cytotoxic 
effect of cisplatin through ER activation while the above ER agonist studies suggested 
that 17β-E2-mediated D283Med chemoprotection through ERβ activation. To confirm that 
17β-E2 protects D283Med cells through ERβ activation, the ERβ-selective antagonist, 
PHTPP, was utilized. Analysis of D283Med colony formation demonstrated that PHTPP 
significantly [t(6) = 4.737 p = 0.0032] blocked the protective effect of 17β-E2 while having 
no effect [t(6) = 0.962 p = 0.3734] on its own (Figure 40C). These data demonstrate that 
the chemoprotective effect of 17β-E2 is mediated by ERβ activation.   
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Figure 40 
The effect of ER inhibitors on the chemoprotective effect of 17β-E2. A. Quantification 
of colony counts for D283Med cells exposed to 100 µM cisplatin and co-exposed to 17β-
E2 and/or 4-OHT as indicated, normalized based on the plating efficiency of D283Med 
cells. B. Quantification of colony counts for D283Med cells exposed to 100 µM cisplatin 
and co-exposed to 17β-E2 and/or fulvestrant as indicated. C. Quantification of colony 
counts for D283Med cells exposed to 100 µM cisplatin and co-exposed to 17β-E2 and/or 
PHTPP as indicated. All colony counts were normalized based on the plating efficiency 
of D283Med cells. Groups were composed of at least 4 replicates. The experiment was 
repeated three times (n=3) on separate days with similar results. Significance differences 
from the vehicle control was determined by Dunnett’s multiple comparisons test and is 
indicated above the error bars; *. p≤0.05. 
166 
 
6.4 Characterization of 17β-E2-mediated chemoprotection in the PFSK1 cell line 
To determine whether the chemoprotective effect of 17β-E2 was generalizable to 
other PNET cell lines, the PFSK1 cell line was utilized. The colony forming potential of 
PFSK1 cells was assessed following treatment with increasing concentrations of cisplatin 
with and without 17β-E2. Two-way ANOVA analysis revealed a significant main effect of 
increasing concentrations of cisplatin [F (2, 18) = 32.63, p = 0.0005] and a significant 
main effect of 10 nM 17β-E2 [F (1, 18) = 42.31, p < 0.0001]. Post-test analysis 
demonstrated that 17β-E2 significantly protected PFSK1 from the cytotoxic effect of 
cisplatin at all tested concentrations (p < 0.05) (Figure 41A). Furthermore, to confirm that 
17β-E2 mediates chemoprotection through the activation of ERs, the effect of the non-
selective ER inhibitor fulvestrant was investigated in the presence of 5 µM cisplatin. 
Analysis of the surviving fraction from a colony formation assay revealed that while 
fulvestrant had no effect [t(6) = 0.594 p = 0.5742] on its own, the protective effect of 17β-
E2 was significantly [t(6) = 3.400 p = 0.0145] blocked by co-treatment with fulvestrant 
(Figure 41B). These data demonstrate that 17β-E2 protects PFSK1 cells from the 
cytotoxic effect of cisplatin through ER activation. Taken together, the above data 
demonstrate that 17β-E2 protects PNET cells from the cytotoxic effect of 
chemotherapeutic compounds through the activation of ERβ.  
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Figure 41 
Characterization of the chemoprotective effect of 17β-E2 in PFSK1 cells. A. 
Quantification of colony counts for PFSK1 cells exposed to increasing concentrations of 
cisplatin with and without 10 nM 17β-E2. B. Quantification of colony counts for PFSK1 
cells exposed to 100 µM cisplatin and co-exposed to 17β-E2 and/or fulvestrant as 
indicated. All colony counts were normalized based on the plating efficiency of the PFSK1 
cell line. Groups were composed of at least 4 replicates. The experiment was repeated 
three times (n=3) on separate days with similar results. Significance was determined by 
two-way ANOVA followed by post-test analysis or Dunnett’s multiple comparisons test as 
appropriate and is indicated above the error bars; *. p≤0.05.  
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CHAPTER 7 
DISCUSSION 
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7.1 The identity of the receptor involved in the 17β-E2-mediated protection of MB 
cells from caspase-dependent cell death 
 The results presented here demonstrate that 17β-E2 is cytoprotective in MB 
through the utilization of caspase-3 activity assays and the assessment of viable cell 
numbers with and without a selective caspase-3 inhibitor. The identity of the receptor 
responsible for this effect was of great interest due to conflicting reports regarding the 
role of ERβ, the ER expressed in MB, in cancer as described in detail in section 1.8 (S. 
M. Belcher et al., 2009; Thomas & Gustafsson, 2011). Therefore, several experiments 
with selective agonists and antagonists of ERα and ERβ were conducted to determine 
which receptor was responsible for the effect of 17β-E2 on cell survival. The results 
demonstrated that while ERβ activation increased viable cell numbers and decreased 
caspase-3 activity in D283Med cells, ERα activation had no effect. Furthermore, inhibition 
of ERβ, but not ERα, blocked the cytoprotective effect of 17β-E2. These data demonstrate 
that ERβ is the receptor that is responsible for the 17β-E2-mediated protection of MB cells 
from caspase-dependent cell death. In addition to the in vitro findings, it was also 
demonstrated that blockade of ERβ activity by fulvestrant or genetic loss of ERβ function 
in in vivo mouse models of MB resulted in decreased growth and increased apoptosis. 
These data suggested that ERβ also regulates MB cell death in vivo and that this 
regulation likely affects tumor growth. These observations are significant in the context of 
the conflicting reports regarding whether ERβ is a tumor suppressor or oncogene in 
cancer (Caiazza et al., 2015; Haring, Schuler, et al., 2012; Leygue & Murphy, 2013; 
Nelson et al., 2014; Siegfried & Stabile, 2014; Thomas & Gustafsson, 2011). The studies 
presented here support that proposal that in ERα-negative cancers, ERβ can promote 
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tumor growth which is consistent with several observations in lung, endometrial and 
breast cancer (see section 1.8) (S. M. Belcher et al., 2009; Leygue & Murphy, 2013; 
Siegfried & Stabile, 2014). While the studies presented here are the first to define a pro-
survival role of ERβ in MB, other studies have investigated the role of ERβ in MB, primarily 
with regard to MB carcinogenesis. In these studies, the irradiated Ptch1+/- murine model 
of MB was utilized. In this MB model, Ptch1+/- mice receive neonatal irradiation which 
increases the incidence of MB from approximately 10% to 50% (Goodrich et al., 1997; 
Pazzaglia et al., 2002). The incidence of preneoplastic lesions (PNLs) in irradiated 
Ptch1+/- mice was increased in OVX mice compared to intact females while 17β-E2 
treatment reduced the incidence of PNLs in OVX mice. To investigate the contribution of 
the individual ERs, selective ER agonists were utilized. Treatment of OVX mice with the 
ERβ-selective agonist, DPN, also reduced the incidence of PNLs while the ERα-selective 
agonist, PPT, had no effect on PNL incidence in OVX mice (Mancuso et al., 2010; 
Mancuso et al., 2011). The effect of ERβ activation on the proliferation of cerebellar GCPs 
in PNLs was also assessed in order to determine if the suppression of proliferation may 
be involved in the effect of ERβ activation on PNL incidence. It was demonstrated that 
both 17β-E2 and DPN inhibited proliferation in the PNLs while PPT had no effect 
(Mancuso et al., 2010; Mancuso et al., 2011). Lastly, in studies utilizing the in vivo 
D283Med xenograft model it was observed that the xenografts grew faster in males, as 
observed previously (Ciucci, Meco, et al., 2014; S. M. Belcher et al., 2009), but it was 
also demonstrated that proliferation was decreased in xenografts from females versus 
males. This result was interpreted to indicate that increased ERβ activation in females 
due to serum 17β-E2 was suppressing tumor growth (Ciucci, Meco, et al., 2014). However, 
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an alternative hypothesis, that is consistent with the studies presented here as well as the 
observation that fulvestrant inhibits D283Med xenograft growth, is that serum 
testosterone in males is being converted to 17β-E2 in the tumor by aromatase and 
promoting growth (S. M. Belcher et al., 2009; Ciucci, Meco, et al., 2014; Mancuso et al., 
2010; Mancuso et al., 2011). One suggested implication of these studies was that the 
effect of ERβ activation on PNL incidence in the irradiated Ptch1+/- murine model of MB 
may help to explain epidemiological data that demonstrates a higher incidence and worse 
prognosis of MB in males (Ciucci, Meco, et al., 2014; Mancuso et al., 2010; Mancuso et 
al., 2011; Ries et al., 1999). It is also possible that the observations with regard to PNL 
incidence are due to the neuroprotective role of estrogen that may have protected the 
cerebellar GCPs from the damaging effects of irradiation that causes the increased 
incidence of MB in the irradiated Ptch1+/- model of MB (Mancuso et al., 2010; Mancuso 
et al., 2011; J. K. Wong et al., 2003; Zorrilla Zubilete et al., 2011). Furthermore, MB 
incidence in the Ptch1+/- and Ptch1+/- Sufu+/- mouse models of MB is greater in females 
than males, which is the opposite of what is observed in humans. The observation that 
current mouse models do not recapitulate the differential incidence in humans between 
males and females suggests that these models are not appropriate for investigating the 
effect of sex on MB incidence (Ries et al., 1999; Svard et al., 2009). Another implication 
of these studies is that ERβ may suppress MB carcinogenesis and then switch roles once 
the tumor is established and promote tumor progression as demonstrated in the studies 
presented here. This possibility is not entirely unprecedented as it has been suggested 
that ERβ is a tumor suppressor during prostate carcinogenesis but promotes tumor 
progression in hormone naïve and castration resistant prostate cancer as discussed in 
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detail in section 1.8.1.3 (Mancuso et al., 2010; Mancuso et al., 2011; Nelson et al., 2014). 
Further support for this hypothesis is found in the observation that chronic 17β-E2 
exposure inhibits the proliferation of cerebellar GCPs which is consistent with the 
observation that 17β-E2 inhibits proliferation in PNLs, which are composed of cerebellar 
GCPs. The inhibition of proliferation would presumably decrease MB incidence by 
preventing the accumulation of additional mutations required for neoplastic 
transformation. Importantly, it should be noted that the studies presented here 
demonstrate that in MB tumors, 17β-E2 no longer has any effect on proliferation. However, 
the pro-survival effect of 17β-E2, which is also observed in cerebellar GCPs, is retained 
in MB cells (Mancuso et al., 2010; Mancuso et al., 2011; J. K. Wong et al., 2003). Taken 
together, these studies and the results presented here suggest that ERβ may play 
differential roles during MB carcinogenesis and progression but exactly how or if this 
switch occurs is unclear. It is, however, clear that ERβ activation enhances the survival 
of MB cells.   
7.2 Significance of IGF1R up-regulation in medulloblastoma by 17β-E2 
 As discussed in section 1.7, the IGF1 and estrogen signaling pathways are known 
to interact to promote survival in a variety of tissues including the CNS and cancers 
(Alonso & Gonzalez, 2012; Deroo & Korach, 2006; L M Garcia-Segura et al., 2010). For 
this reason, the potential involvement of the IGF1 in the protective effect of ERβ activation 
was investigated. It was demonstrated in cultured D283Med cells that both 17β-E2 and 
DPN increase the mRNA expression of IGF1 and IGF1R in addition to a downstream 
mediator of the IGF1 pathway, BCL2. The effect on BCL2 expression is particularly 
important due to its well-characterized role as an anti-apoptotic regulator (Delbridge & 
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Strasser, 2015). Protein expression of IGF1R and BCL2 were also increased by 17β-E2 
or DPN as were the phosphorylation of the IGF1R and the downstream mediators of the 
IGF1 pathway, ERK 1/2 and AKT. In the Ptch1+/- Trp53-/- and D283Med xenograft mouse 
models of MB, fulvestrant treatment decreased IGF1R and BCL2 protein expression as 
well as the phosphorylation of the downstream IGF1 pathway mediators, AKT and ERK 
1/2. Lastly, the genetic loss of Esr2 in the Ptch1C/C Atoh1-cre murine model of MB had a 
similar effect as fulvestrant treatment with decreased IGF1R and BCL2 protein expression 
and decreased AKT/ERK 1/2 activation being observed in Esr2-/- versus Esr2+/+ MB 
tumors. In addition to the up-regulation of the IGF1R pathway, the blockade of IGF1 
pathway activity through the use of a selective IGF1R inhibitor or the inhibition of ERK 
1/2, which is downstream of the IGF1R, prevented the cytoprotective effect of ERβ 
activation in D283Med cells in vitro. These results demonstrate that ERβ increases MB 
survival through the up-regulation of the pro-survival IGF1 pathway. A similar modulation 
of the IGF1 pathway is also observed in A549 NSCLC cells, which are ERα-negative/ERβ-
positive. Exposure to 17β-E2 increased the protein expression of IGF1 as well as the 
phosphorylation of the IGF1R in A549 cells. Additionally, biomarker analysis in human 
NSCLC samples revealed that expression of ERβ is positively correlated with IGF1 and 
IGF1R expression (Tang et al., 2012). Taken together, these results suggest that in the 
absence of ERα, ERβ is capable of increasing the activity of the IGF1 pathway, which is 
known to promote tumor progression through increased tumor cell survival and 
proliferation. Furthermore, these studies suggest that targeting of ERβ, with or without 
IGF1R inhibition, may decrease tumor growth and allow for better clinical outcomes.   
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7.3 The significance of medulloblastoma growth inhibition by fulvestrant or genetic 
loss of ERβ 
 Due to the success of endocrine therapy in breast cancer, and the demonstration 
that MB is an estrogen-responsive tumor, the efficacy of fulvestrant treatment in mouse 
models of MB was investigated. Additionally, due to the observation that ERβ was 
expressed in MB and responsible for the protective effects of 17β-E2 in D283Med cells 
in vitro, the role of ERβ in MB progression was further characterized through the genetic 
loss of ERβ in a mouse model of MB (Bauerschlag et al., 2014; S. M. Belcher et al., 2009; 
B. Huang et al., 2014). Symptom-free survival was increased while tumor growth was 
decreased by fulvestrant treatment in Ptch1+/- Trp53-/- MB tumors and D283Med 
xenografts, respectively (S. M. Belcher et al., 2009). As discussed in more detail above, 
the modulation of tumor growth in these models by fulvestrant is likely due to the inhibition 
of ERβ and subsequent decreases in IGF1 pathway activity as well as increased cell 
death. Similarly, the loss of Esr2 in Ptch1C/C Atoh1-cre mice resulted in MB tumors that 
lacked ERβ expression and had a smaller mass at PND45. The decreased tumor growth 
due to the loss of ERβ expression is likely due to decreased IGF1 pathway activity and 
increased cell death as discussed in more detail above. These results are of interest 
because they are the first to demonstrate that ERβ promotes MB tumor growth in pre-
clinical mouse models of the disease. These studies also suggest that fulvestrant, or 
preferably ERβ-selective antagonists to avoid the potential developmental side effects of 
ERα inhibition, may be useful as an adjuvant treatment for MB to improve outcomes 
(Burns & Korach, 2012; Deroo & Korach, 2006). 
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7.4 The potential for future medulloblastoma treatment incorporating ERβ 
inhibition to decrease tumor growth and increase chemosensitivity 
 It has long been known that multi-modal therapies that target cancer growth 
through multiple mechanisms are typically more effective than single agent therapies. In 
medulloblastoma treatment, this has led to the incorporation of chemotherapy into the 
standard of care for MB. This is due to the improved outcomes observed when 
chemotherapy is given in addition to surgery and radiation, and the fact that 
chemotherapy allows for lower doses of radiation to be used while maintaining disease 
management which is important due to the debilitating side-effects that radiation 
treatment can cause (Aapro, 2001; Davis & Carbone, 1978; DeVita, Young, & Canellos, 
1975; Frange et al., 2009; Fu, 1985; Hoang et al., 2014; Lee et al., 2014; Mueller & Chang, 
2009; Muggia, Cortes-Funes, & Wasserman, 1978; Mulhern et al., 2005; Packer et al., 
1999; R. E. Taylor et al., 2003; Uday et al., 2015). Because of the need to develop 
adjuvant treatments that can improve outcomes and potentially reduce the need for 
radiation therapy and the resulting side-effects, the effect of ERβ activation on the 
chemosensitivity of MB cell lines was investigated. Activation of ERβ by DPN or 17β-E2 
protected D283Med cells from the cytotoxic effects of cisplatin, vincristine, and lomustine 
which are commonly used to treat medulloblastoma (De Braganca & Packer, 2013; Martin 
et al., 2014; Mueller & Chang, 2009). Importantly, the chemoprotective effect of 17β-E2 
could be blocked by tamoxifen, fulvestrant and the ERβ-selective inhibitor, PHTPP. 
Similarly, the PFSK1 PNET cell line was protected from cisplatin cytotoxicity by 17β-E2 
and this chemoprotective effect of 17β-E2 was blocked by co-exposure to fulvestrant. 
When considered with the results from the in vivo studies presented here, these data 
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suggest that ERβ inhibition may be an effective adjuvant treatment for MB. Inhibition of 
ERβ may be capable of improving MB outcomes not only through the suppression of 
tumor growth but also by sensitizing the MB tumor cells to the cytotoxic actions of 
chemotherapeutic compounds that are commonly used in MB treatment.     
7.5 Limitations and Future Studies 
There are many potential future directions for the studies presented here in order 
to further examine the role of ERβ in MB, evaluate the clinical efficacy of ERβ inhibition 
in MB treatment and address limitations of the presented studies. One important limitation 
of the chemotherapeutic studies regards the use of DMSO as the solvent for cisplatin. As 
discussed in section 2.4.5, the use of DMSO as the solvent for cisplatin reduces the 
potency of cisplatin. Because of this, the results of the studies performed here should be 
confirmed using cisplatin in a more clinically relevant solution, such as dissolved in saline 
(Hall et al., 2014). One limitation of the in vivo studies is that the genetic models of MB 
that were utilized both have 100% incidence of MB. These models therefore only allow 
the assessment of tumor progression and conclusions about tumor carcinogenesis are 
not possible. Due to this limitation, one possible future direction would be to investigate 
the potentially differential role of ERβ in MB carcinogenesis versus tumor progression. 
This could be accomplished using any of several MB mouse models that do not have 100% 
incidence of the disease such as the Ptch1+/- murine model of MB (Goodrich et al., 1997). 
Ideally, these mice would be crossed with the Esr2-/- model to generate Ptch1+/- mice that 
lack ERβ expression and then the incidence of MB would be compared between Esr2-/- 
Ptch1+/-  and Esr2+/+ Ptch1+/- mice. This type of study would give definitive evidence either 
supporting or refuting the notion that ERβ is a tumor suppressor during MB 
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carcinogenesis. This knowledge, combined with the results presented here which clearly 
demonstrate that ERβ promotes MB progression, would increase our understanding of 
ERβ in cancer, and in particular, the role of ERβ in MB. Additionally, this knowledge may 
inform on a potential therapeutic strategy to reduce the risk of MB in high-risk individuals 
such as those that have NBCCS. The MB mouse models also only represent the SHH-
MB subtype (see section 1.10.1.1). SHH-MB arise from cerebellar GCPs that escape 
terminal differentiation and it was hypothesized that they would express ERβ and respond 
to estrogen treatment in a similar manner as developing cerebellar GCPs. Aside from 
WNT-MB tumors, which do not originate from cerebellar GCPs like SHH-MB, the 
developmental origins of the other MB subtypes are not known. Due to the potentially 
different origins of the subtypes of MB, it is possible that ERβ, if expressed, may not play 
the same role in all MB subtypes. Because of this possibility, the expression and potential 
role of ERβ in the other subtypes of MB should be evaluated. The knowledge gained from 
such studies could potentially guide the therapeutic use of ERβ inhibition in MB treatment 
so that only patients with MB subtypes that are vulnerable to ERβ inhibition would receive 
the treatment.  
Another limitation of the studies presented here is the extent to which the 
interaction between the ERβ and IGF1 signaling is investigated. There are many 
questions about the underlying mechanism of this interaction and its importance in MB 
progression that are left unanswered. For instance, the in vitro data suggests that ERβ 
activation increases the activity of the IGF1 pathway through transcriptional up-regulation 
of IGF1, IGF1R and IRS1. However, it is unclear how ERβ increases the expression of 
the genes and further studies would be required to elucidate the mechanism. To this end, 
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chromatin immunoprecipitation experiments could be performed to determine if ERβ 
localizes to the promoters of these genes when activated. Additionally, since rapid effects 
of ERβ activation were observed with regard to ERK 1/2 activation in D283Med cells, it is 
also possible that ERβ affects the expression of IGF1 pathway genes through indirect 
mechanisms that should also be investigated. Furthermore, the in vivo studies focused 
on the potential therapeutic importance of ERβ in MB rather than the importance of the 
interaction between ERβ and IGF1 signaling. It is possible that IGF1R inhibition would be 
just as effective as or more effective than ERβ inhibition with regard to MB growth 
inhibition. Furthermore, the potential for additive or synergistic MB growth inhibition by 
inhibiting both ERβ and the IGF1R should be considered. To this end, further in vivo 
studies could be conducted to compare the potential clinical efficacy of ERβ inhibition and 
IGF1R inhibition both alone and in combination.  
7.5.1 Clinical significance and future directions 
 The studies presented here highlight the importance of ERβ and IGF1 signaling, 
as well as the potential crosstalk between these pathways, in medulloblastoma 
progression. It is clear from the in vivo studies that the non-selective ER antagonist, 
fulvestrant, delays the progression of MB. A similar effect on tumor progression was also 
observed when ERβ expression was lost by crossing the Ptch1C/C Atoh1-cre mouse 
model of MB with the Esr2-/- mouse model. These results, combined with the fact that MB 
tumors only express ERβ, suggest that the effect of fulvestrant on MB progression is likely 
due to ERβ inhibition (S. M. Belcher et al., 2009; Mancuso et al., 2010; Mancuso et al., 
2011). It is also clear from the in vitro studies that ERβ signaling is involved in 
chemoprotection. Specifically, inhibition of ERβ could block the chemoprotective effect of 
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17β-E2, suggesting that inhibiting ERβ may improve the response of patients to 
chemotherapeutic regimens utilized in MB treatment.  
 However, further research is needed to understand the clinical implications of ERβ 
in medulloblastoma and potentially develop new treatments for MB, which was the 
ultimate goal of the studies presented here. To this end, another direction to take these 
studies would be towards human trials. To begin with, it would be of interest to investigate 
the prognostic value of ERβ in MB. The studies presented here would suggest that ERβ 
is a negative prognostic factor in MB. If this was confirmed, then there would be a solid 
rationale for investigating the therapeutic potential of ERβ inhibition in MB patients, 
especially when taking into consideration the results of the studies presented here. 
7.6 Summary 
The results presented here have furthered the characterization of 
medulloblastoma as an estrogen-responsive tumor. It was demonstrated through the use 
of the human D283Med cell line of MB that ERβ activation increases cell numbers through 
the up-regulation of pro-survival signaling. Specifically, ERβ activation increased the 
expression of several IGF1 pathway proteins and increased the overall activity of the pro-
survival IGF1 pathway. Importantly, the cytoprotective effect of 17β-E2 was blocked by 
the inhibition of the IGF1 pathway, demonstrating that the cytoprotective effect of 17β-E2 
is dependent on the activation of the IGF1R and the downstream mediator ERK 1/2. Not 
only was this pro-survival mechanism of ERβ activation observed in vitro using cultured 
D283Med cells, but it was also observed in pre-clinical murine models of MB. Specifically, 
fulvestrant treatment increased symptom-free survival in the Ptch1+/- Trp53-/- murine 
model of MB and the genetic ablation of Esr2 inhibited the growth of MB tumors in the 
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Ptch1C/C Atoh1-cre murine model of MB. In addition to affecting MB tumor growth, 
fulvestrant treatment and the loss of ERβ expression also increased apoptosis in these 
MB tumors and decreased the expression and phosphorylation of multiple proteins in the 
IGF1 pathway. Importantly, these in vivo results are completely consistent with the in vitro 
mechanistic studies, suggesting ERβ affects tumor growth in vivo through the modulation 
of IGF1 pathway activation and subsequently, MB cell survival. Lastly, it was 
demonstrated that ERβ activation decreases the chemosensitivity of both MB and PNET 
cell lines. Furthermore, this chemoprotective effect of ERβ activation could be blocked by 
co-treatment with tamoxifen, fulvestrant or PHTPP, suggesting that the inhibition of ERβ 
may be able to improve outcomes in MB patients by not only decreasing tumor growth 
but also by sensitizing the MB cells to chemotherapeutic agents. Taken together, the 
presented studies demonstrate that ERβ promotes MB progression through a mechanism 
that involves the up-regulation of the pro-survival IGF1-pathway as summarized in Figure 
42.  
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Figure 42 
ERβ-mediated survival of MB cells and crosstalk with the IGF1 pathway. As 
demonstrated in the studies presented in Chapters 3-6, ERβ activation results in the up-
regulation of IGF1 and IGF1R mRNA as well as the pro-survival protein BCL2, at the 
mRNA and protein level. The up-regulation of IGF1 and IGF1R mRNA likely results in 
increased IGF1 pathway activity which is mediated downstream by the activation of AKT 
and ERK, although the pro-survival effect of ERβ activation is only dependent on 
downstream activation of ERK. 
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